ORIGINAL_ARTICLE
MicroRNA-96: A therapeutic and diagnostic tumor marker
Cancer has been always considered as one of the main human health challenges worldwide. One of the main causes of cancer-related mortality is late diagnosis in the advanced stages of the disease, which reduces the therapeutic efficiency. Therefore, novel non-invasive diagnostic methods are required for the early detection of tumors and improving the quality of life and survival in cancer patients. MicroRNAs (miRNAs) have pivotal roles in various cellular processes such as cell proliferation, motility, and neoplastic transformation. Since circulating miRNAs have high stability in body fluids, they can be suggested as efficient noninvasive tumor markers. MiR-96 belongs to the miR-183-96-182 cluster that regulates cell migration and tumor progression as an oncogene or tumor suppressor by targeting various genes in solid tumors. In the present review, we have summarized all of the studies that assessed the role of miR-96 during tumor progression. This review clarifies the molecular mechanisms and target genes recruited by miR-96 to regulate tumor progression and metastasis. It was observed that miR-96 mainly affects tumorigenesis by targeting the structural proteins and FOXO transcription factors.
https://ijbms.mums.ac.ir/article_19434_ff7fa24f14ea56f74a3406f162818d35.pdf
2022-01-01
3
13
10.22038/ijbms.2021.59604.13226
Cancer
Diagnosis
MicroRNA
miR-96
Prognosis
Hamid Reza
Rahimi
rahimihr@mums.ac.ir
1
Department of Medical Genetics and Molecular Medicine, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
AUTHOR
Majid
Mojarad
mojaradm@mums.ac.ir
2
Department of Medical Genetics and Molecular Medicine, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
AUTHOR
Meysam
Moghbeli
moghbelim@mums.ac.ir
3
Department of Medical Genetics and Molecular Medicine, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
LEAD_AUTHOR
1. Chen J, Zhang K, Xu Y, Gao Y, Li C, Wang R, et al. The role of microRNA-26a in human cancer progression and clinical application. Tumour Biol 2016; 37:7095-7108.
1
2. Croce CM. Causes and consequences of microRNA dysregulation in cancer. Nat Rev Genet 2009; 10:704-714.
2
3. Cheng G. Circulating miRNAs: Roles in cancer diagnosis, prognosis and therapy. Adv Drug Deliv Rev 2015; 81:75-93.
3
4. Berindan-Neagoe I, Monroig Pdel C, Pasculli B, Calin GA. MicroRNAome genome: A treasure for cancer diagnosis and therapy. CA Cancer J Clin 2014; 64:311-336.
4
5. Cuk K, Zucknick M, Heil J, Madhavan D, Schott S, Turchinovich A, et al. Circulating microRNAs in plasma as early detection markers for breast cancer. Int J Cancer 2013; 132:1602-1612.
5
6. Gorur A, Balci Fidanci S, Dogruer Unal N, Ayaz L, Akbayir S, Yildirim Yaroglu H, et al. Determination of plasma microRNA for early detection of gastric cancer. Mol Biol Rep 2013; 40:2091-2096.
6
7. Guo Y, Liu H, Zhang H, Shang C, Song Y. miR-96 regulates FOXO1-mediated cell apoptosis in bladder cancer. Oncol Lett 2012; 4:561-565.
7
8. Li Z, Wang Y. miR-96 targets SOX6 and promotes proliferation, migration, and invasion of hepatocellular carcinoma. Biochem Cell Biol 2018; 96:365-371.
8
9. Li XL, Hara T, Choi Y, Subramanian M, Francis P, Bilke S, et al. A p21-ZEB1 complex inhibits epithelial-mesenchymal transition through the microRNA 183-96-182 cluster. Mol Cell Biol 2014; 34:533-550.
9
10. Tang X, Zheng D, Hu P, Zeng Z, Li M, Tucker L, et al. Glycogen synthase kinase 3 beta inhibits microRNA-183-96-182 cluster via the beta-Catenin/TCF/LEF-1 pathway in gastric cancer cells. Nucleic Acids Res 2014; 42:2988-2998.
10
11. Tsai YC, Chen WY, Siu MK, Tsai HY, Yin JJ, Huang J, et al. Epidermal growth factor receptor signaling promotes metastatic prostate cancer through microRNA-96-mediated downregulation of the tumor suppressor ETV6. Cancer Lett 2017; 384:1-8.
11
12. Hunter KW. Ezrin, a key component in tumor metastasis. Trends Mol Med 2004; 10:201-204.
12
13. Yao Q, Pei Y, Zhang X, Xie B. microRNA-96 acts as a tumor suppressor gene in human osteosarcoma via target regulation of EZRIN. Life Sci 2018; 203:1-11.
13
14. Yu N, Fu S, Liu Y, Xu Z, Liu Y, Hao J, et al. miR-96 suppresses renal cell carcinoma invasion via downregulation of Ezrin expression. J Exp Clin Cancer Res 2015; 34:107.
14
15. Tanaka-Okamoto M, Hori K, Ishizaki H, Hosoi A, Itoh Y, Wei M, et al. Increased susceptibility to spontaneous lung cancer in mice lacking LIM-domain only 7. Cancer Sci 2009; 100:608-616.
15
16. Kang S, Xu H, Duan X, Liu JJ, He Z, Yu F, et al. PCD1, a novel gene containing PDZ and LIM domains, is overexpressed in several human cancers. Cancer Res 2000; 60:5296-5302.
16
17. Wu H, Zhou J, Mei S, Wu D, Mu Z, Chen B, et al. Circulating exosomal microRNA-96 promotes cell proliferation, migration and drug resistance by targeting LMO7. J Cell Mol Med 2017; 21:1228-1236.
17
18. Gao XH, Zhang YL, Zhang ZY, Guo SS, Chen XB, Guo YZ. MicroRNA-96-5p represses breast cancer proliferation and invasion through Wnt/beta-catenin signaling via targeting CTNND1. Sci Rep 2020; 10:44.
18
19. Xie F, Ye L, Ta M, Zhang L, Jiang WG. MTSS1: a multifunctional protein and its role in cancer invasion and metastasis. Front Biosci (Schol Ed) 2011; 3:621-631.
19
20. Huang XY, Huang ZL, Xu B, Chen Z, Re TJ, Zheng Q, et al. Elevated MTSS1 expression associated with metastasis and poor prognosis of residual hepatitis B-related hepatocellular carcinoma. J Exp Clin Cancer Res 2016; 35:85.
20
21. Li XD, Zhang JX, Jiang LJ, Wang FW, Liu LL, Liao YJ, et al. Overexpression of maelstrom promotes bladder urothelial carcinoma cell aggressiveness by epigenetically downregulating MTSS1 through DNMT3B. Oncogene 2016; 35:6281-6292.
21
22. Yin X, Chai Z, Sun X, Chen J, Wu X, Yang L, et al. Overexpression of microRNA-96 is associated with poor prognosis and promotes proliferation, migration and invasion in cholangiocarcinoma cells via MTSS1. Exp Ther Med 2020; 19:2757-2765.
22
23. Xie W, Sun F, Chen L, Cao X. miR-96 promotes breast cancer metastasis by suppressing MTSS1. Oncol Lett 2018; 15:3464-3471.
23
24. Xu L, Zhong J, Guo B, Zhu Q, Liang H, Wen N, et al. miR-96 promotes the growth of prostate carcinoma cells by suppressing MTSS1. Tumour Biol 2016; 37:12023-12032.
24
25. Fatica A, Bozzoni I. Long non-coding RNAs: new players in cell differentiation and development. Nat Rev Genet 2014; 15:7-21.
25
26. Gordon FE, Nutt CL, Cheunsuchon P, Nakayama Y, Provencher KA, Rice KA, et al. Increased expression of angiogenic genes in the brains of mouse meg3-null embryos. Endocrinology 2010; 151:2443-2452.
26
27. Kruer TL, Dougherty SM, Reynolds L, Long E, de Silva T, Lockwood WW, et al. Expression of the lncRNA maternally expressed gene 3 (MEG3) contributes to the control of lung cancer cell proliferation by the Rb pathway. PLoS One 2016; 11:e0166363.
27
28. Zhang S, Guo W. Long noncoding RNA MEG3 suppresses the growth of glioma cells by regulating the miR965p/MTSS1 signaling pathway. Mol Med Rep 2019; 20:4215-4225.
28
29. Lu KH, Li W, Liu XH, Sun M, Zhang ML, Wu WQ, et al. Long non-coding RNA MEG3 inhibits NSCLC cells proliferation and induces apoptosis by affecting p53 expression. BMC Cancer 2013; 13:461.
29
30. Zhou Y, Zhong Y, Wang Y, Zhang X, Batista DL, Gejman R, et al. Activation of p53 by MEG3 non-coding RNA. J Biol Chem 2007; 282:24731-24742.
30
31. Qi L, Bart J, Tan LP, Platteel I, Sluis T, Huitema S, et al. Expression of miR-21 and its targets (PTEN, PDCD4, TM1) in flat epithelial atypia of the breast in relation to ductal carcinoma in situ and invasive carcinoma. BMC Cancer 2009; 9:163.
31
32. Nijak A, Alaerts M, Kuiperi C, Corveleyn A, Suys B, Paelinck B, et al. Left ventricular non-compaction with Ebstein anomaly attributed to a TPM1 mutation. Eur J Med Genet 2018; 61:8-10.
32
33. Liu G, Zhao X, Zhou J, Cheng X, Ye Z, Ji Z. Long non-coding RNA MEG3 suppresses the development of bladder urothelial carcinoma by regulating miR-96 and TPM1. Cancer Biol Ther 2018; 19:1039-1056.
33
34. Ge T, Xiang P, Mao H, Tang S, Zhou J, Zhang Y. Inhibition of miR-96 enhances the sensitivity of colorectal cancer cells to oxaliplatin by targeting TPM1. Exp Ther Med 2020; 20:2134-2140.
34
35. Wang S, Qiu Y, Bai B. The expression, regulation, and biomarker potential of glypican-1 in cancer. Front Oncol 2019; 9:614.
35
36. Li C, Du X, Tai S, Zhong X, Wang Z, Hu Z, et al. GPC1 regulated by miR-96-5p, rather than miR-182-5p, in inhibition of pancreatic carcinoma cell proliferation. Int J Mol Sci 2014; 15:6314-6327.
36
37. Bernfield M, Gotte M, Park PW, Reizes O, Fitzgerald ML, Lincecum J, et al. Functions of cell surface heparan sulfate proteoglycans. Annu Rev Biochem 1999; 68:729-777.
37
38. Cai Z, Grobe K, Zhang X. Role of heparan sulfate proteoglycans in optic disc and stalk morphogenesis. Dev Dyn 2014; 243:1310-1316.
38
39. Fei X, Zhang J, Zhao Y, Sun M, Zhao H, Li S. miR-96 promotes invasion and metastasis by targeting GPC3 in non-small cell lung cancer cells. Oncol Lett 2018; 15:9081-9086.
39
40. Chidlow JH, Jr., Sessa WC. Caveolae, caveolins, and cavins: complex control of cellular signalling and inflammation. Cardiovasc Res 2010; 86:219-225.
40
41. Cohen AW, Hnasko R, Schubert W, Lisanti MP. Role of caveolae and caveolins in health and disease. Physiol Rev 2004; 84:1341-1379.
41
42. Ayala G, Morello M, Frolov A, You S, Li R, Rosati F, et al. Loss of caveolin-1 in prostate cancer stroma correlates with reduced relapse-free survival and is functionally relevant to tumour progression. J Pathol 2013; 231:77-87.
42
43. Kannan A, Krishnan A, Ali M, Subramaniam S, Halagowder D, Sivasithamparam ND. Caveolin-1 promotes gastric cancer progression by up-regulating epithelial to mesenchymal transition by crosstalk of signalling mechanisms under hypoxic condition. Eur J Cancer 2014; 50:204-215.
43
44. Liu B, Zhang J, Yang D. miR-96-5p promotes the proliferation and migration of ovarian cancer cells by suppressing Caveolae1. J Ovarian Res 2019; 12:57.
44
45. Fraser SP, Diss JK, Chioni AM, Mycielska ME, Pan H, Yamaci RF, et al. Voltage-gated sodium channel expression and potentiation of human breast cancer metastasis. Clin Cancer Res 2005; 11:5381-5389.
45
46. Kunzelmann K. Ion channels and cancer. J Membr Biol 2005; 205:159-173.
46
47. Afrasiabi E, Hietamaki M, Viitanen T, Sukumaran P, Bergelin N, Tornquist K. Expression and significance of HERG (KCNH2) potassium channels in the regulation of MDA-MB-435S melanoma cell proliferation and migration. Cell Signal 2010; 22:57-64.
47
48. Shao XD, Wu KC, Guo XZ, Xie MJ, Zhang J, Fan DM. Expression and significance of HERG protein in gastric cancer. Cancer Biol Ther 2008; 7:45-50.
48
49. Lastraioli E, Guasti L, Crociani O, Polvani S, Hofmann G, Witchel H, et al. herg1 gene and HERG1 protein are overexpressed in colorectal cancers and regulate cell invasion of tumor cells. Cancer Res 2004; 64:606-611.
49
50. Pillozzi S, Brizzi MF, Bernabei PA, Bartolozzi B, Caporale R, Basile V, et al. VEGFR-1 (FLT-1), beta1 integrin, and hERG K+ channel for a macromolecular signaling complex in acute myeloid leukemia: role in cell migration and clinical outcome. Blood 2007; 110:1238-1250.
50
51. Feng J, Yu J, Pan X, Li Z, Chen Z, Zhang W, et al. HERG1 functions as an oncogene in pancreatic cancer and is downregulated by miR-96. Oncotarget 2014; 5:5832-5844.
51
52. Kikkert M, Doolman R, Dai M, Avner R, Hassink G, van Voorden S, et al. Human HRD1 is an E3 ubiquitin ligase involved in degradation of proteins from the endoplasmic reticulum. J Biol Chem 2004; 279:3525-3534.
52
53. Gao Z, Wang H, Li H, Li M, Wang J, Zhang W, et al. Long non-coding RNA CASC2 inhibits breast cancer cell growth and metastasis through the regulation of the miR-96-5p/SYVN1 pathway. Int J Oncol 2018; 53:2081-2090.
53
54. Gao J, Huo L, Sun X, Liu M, Li D, Dong JT, et al. The tumor suppressor CYLD regulates microtubule dynamics and plays a role in cell migration. J Biol Chem 2008; 283:8802-8809.
54
55. Gao J, Sun L, Huo L, Liu M, Li D, Zhou J. CYLD regulates angiogenesis by mediating vascular endothelial cell migration. Blood 2010; 115:4130-4137.
55
56. Wickstrom SA, Masoumi KC, Khochbin S, Fassler R, Massoumi R. CYLD negatively regulates cell-cycle progression by inactivating HDAC6 and increasing the levels of acetylated tubulin. EMBO J 2010; 29:131-144.
56
57. Zhao M, Xin XF, Zhang JY, Dai W, Lv TF, Song Y. LncRNA GMDS-AS1 inhibits lung adenocarcinoma development by regulating miR-96-5p/CYLD signaling. Cancer Med 2020; 9:1196-1208.
57
58. Wei S, Zheng Y, Jiang Y, Li X, Geng J, Shen Y, et al. The circRNA circPTPRA suppresses epithelial-mesenchymal transitioning and metastasis of NSCLC cells by sponging miR-96-5p. EBioMedicine 2019; 44:182-193.
58
59. Liu ZM, Wu ZY, Li WH, Wang LQ, Wan JN, Zhong Y. MiR-96-5p promotes the proliferation, invasion and metastasis of papillary thyroid carcinoma through down-regulating CCDC67. Eur Rev Med Pharmacol Sci 2019; 23:3421-3430.
59
60. Kaufmann E, Knochel W. Five years on the wings of fork head. Mech Dev 1996; 57:3-20.
60
61. Myatt SS, Lam EW. The emerging roles of forkhead box (Fox) proteins in cancer. Nat Rev Cancer 2007; 7:847-859.
61
62. Kousteni S. FoxO1: a molecule for all seasons. J Bone Miner Res 2011; 26:912-917.
62
63. Kops GJ, Medema RH, Glassford J, Essers MA, Dijkers PF, Coffer PJ, et al. Control of cell cycle exit and entry by protein kinase B-regulated forkhead transcription factors. Mol Cell Biol 2002; 22:2025-2036.
63
64. Schmidt M, Fernandez de Mattos S, van der Horst A, Klompmaker R, Kops GJ, Lam EW, et al. Cell cycle inhibition by FoxO forkhead transcription factors involves downregulation of cyclin D. Mol Cell Biol 2002; 22:7842-7852.
64
65. Dijkers PF, Medema RH, Lammers JW, Koenderman L, Coffer PJ. Expression of the pro-apoptotic Bcl-2 family member Bim is regulated by the forkhead transcription factor FKHR-L1. Curr Biol 2000; 10:1201-1204.
65
66. Modur V, Nagarajan R, Evers BM, Milbrandt J. FOXO proteins regulate tumor necrosis factor-related apoptosis inducing ligand expression. Implications for PTEN mutation in prostate cancer. J Biol Chem 2002; 277:47928-47937.
66
67. Brunet A, Kanai F, Stehn J, Xu J, Sarbassova D, Frangioni JV, et al. 14-3-3 transits to the nucleus and participates in dynamic nucleocytoplasmic transport. J Cell Biol 2002; 156:817-828.
67
68. Kim SJ, Winter K, Nian C, Tsuneoka M, Koda Y, McIntosh CH. Glucose-dependent insulinotropic polypeptide (GIP) stimulation of pancreatic beta-cell survival is dependent upon phosphatidylinositol 3-kinase (PI3K)/protein kinase B (PKB) signaling, inactivation of the forkhead transcription factor Foxo1, and down-regulation of bax expression. J Biol Chem 2005; 280:22297-22307.
68
69. Machida S, Spangenburg EE, Booth FW. Forkhead transcription factor FoxO1 transduces insulin-like growth factor’s signal to p27Kip1 in primary skeletal muscle satellite cells. J Cell Physiol 2003; 196:523-531.
69
70. Hou T, Ou J, Zhao X, Huang X, Huang Y, Zhang Y. MicroRNA-196a promotes cervical cancer proliferation through the regulation of FOXO1 and p27Kip1. Br J Cancer 2014; 110:1260-1268.
70
71. Zaballos MA, Santisteban P. FOXO1 controls thyroid cell proliferation in response to TSH and IGF-I and is involved in thyroid tumorigenesis. Mol Endocrinol 2013; 27:50-62.
71
72. Song HM, Luo Y, Li DF, Wei CK, Hua KY, Song JL, et al. MicroRNA-96 plays an oncogenic role by targeting FOXO1 and regulating AKT/FOXO1/Bim pathway in papillary thyroid carcinoma cells. Int J Clin Exp Pathol 2015; 8:9889-9900.
72
73. Yang N, Zhou J, Li Q, Han F, Yu Z. miR-96 exerts carcinogenic effect by activating AKT/GSK-3beta/beta-catenin signaling pathway through targeting inhibition of FOXO1 in hepatocellular carcinoma. Cancer Cell Int 2019; 19:38.
73
74. Fendler A, Jung M, Stephan C, Erbersdobler A, Jung K, Yousef GM. The antiapoptotic function of miR-96 in prostate cancer by inhibition of FOXO1. PLoS One 2013; 8:e80807.
74
75. Yang L, Liu L, Zhang X, Zhu Y, Li L, Wang B, et al. miR-96 enhances the proliferation of cervical cancer cells by targeting FOXO1. Pathol Res Pract 2020; 216:152854.
75
76. Lang C, Xu M, Zhao Z, Chen J, Zhang L. MicroRNA-96 expression induced by low-dose cisplatin or doxorubicin regulates chemosensitivity, cell death and proliferation in gastric cancer SGC7901 cells by targeting FOXO1. Oncol Lett 2018; 16:4020-4026.
76
77. Yu JJ, Wu YX, Zhao FJ, Xia SJ. miR-96 promotes cell proliferation and clonogenicity by down-regulating of FOXO1 in prostate cancer cells. Med Oncol 2014; 31:910.
77
78. Huang H, Tindall DJ. Dynamic FoxO transcription factors. J Cell Sci 2007; 120:2479-2487.
78
79. Lin H, Dai T, Xiong H, Zhao X, Chen X, Yu C, et al. Unregulated miR-96 induces cell proliferation in human breast cancer by downregulating transcriptional factor FOXO3a. PLoS One 2010; 5:e15797.
79
80. Zhou Y, Chen Y, Ding W, Hua Z, Wang L, Zhu Y, et al. LncRNA UCA1 impacts cell proliferation, invasion, and migration of pancreatic cancer through regulating miR-96/FOXO3. IUBMB Life 2018; 70:276-290.
80
81. Li J, Li P, Chen T, Gao G, Chen X, Du Y, et al. Expression of microRNA-96 and its potential functions by targeting FOXO3 in non-small cell lung cancer. Tumour Biol 2015; 36:685-692.
81
82. Yin Z, Wang W, Qu G, Wang L, Wang X, Pan Q. MiRNA-96-5p impacts the progression of breast cancer through targeting FOXO3. Thorac Cancer 2020; 11:956-963.
82
83. Gao F, Wang W. MicroRNA-96 promotes the proliferation of colorectal cancer cells and targets tumor protein p53 inducible nuclear protein 1, forkhead box protein O1 (FOXO1) and FOXO3a. Mol Med Rep 2015; 11:1200-1206.
83
84. Cai J, Tian AX, Wang QS, Kong PZ, Du X, Li XQ, et al. FOXF2 suppresses the FOXC2-mediated epithelial-mesenchymal transition and multidrug resistance of basal-like breast cancer. Cancer Lett 2015; 367:129-137.
84
85. Higashimori A, Dong Y, Zhang Y, Kang W, Nakatsu G, Ng SSM, et al. Forkhead box F2 suppresses gastric cancer through a novel FOXF2-IRF2BPL-beta-catenin signaling axis. Cancer Res 2018; 78:1643-1656.
85
86. Zhang Y, Wang X, Wang Z, Tang H, Fan H, Guo Q. miR-182 promotes cell growth and invasion by targeting forkhead box F2 transcription factor in colorectal cancer. Oncol Rep 2015; 33:2592-2598.
86
87. Simpson-Haidaris PJ, Rybarczyk B. Tumors and fibrinogen. The role of fibrinogen as an extracellular matrix protein. Ann N Y Acad Sci 2001; 936:406-425.
87
88. Vihinen P, Kahari VM. Matrix metalloproteinases in cancer: prognostic markers and therapeutic targets. Int J Cancer 2002; 99:157-166.
88
89. Wang H, Ma N, Li W, Wang Z. MicroRNA-96-5p promotes proliferation, invasion and EMT of oral carcinoma cells by directly targeting FOXF2. Biol Open 2020; 9.
89
90. Wei WR, Zeng GJ, Liu C, Zou BW, Li L. Overexpression of miR-96 promotes cell proliferation by targeting FOXF2 in prostate cancer. Int J Clin Exp Pathol 2017; 10:7596-7602.
90
91. Abbaszadegan MR, Riahi A, Forghanifard MM, Moghbeli M. WNT and NOTCH signaling pathways as activators for epidermal growth factor receptor in esophageal squamous cell carcinoma. Cell Mol Biol Lett 2018; 23:42.
91
92. Moghbeli M, Abbaszadegan MR, Golmakani E, Forghanifard MM. Correlation of Wnt and NOTCH pathways in esophageal squamous cell carcinoma. J Cell Commun Signal 2016; 10:129-135.
92
93. Yan Z, Wang J, Wang C, Jiao Y, Qi W, Che S. miR-96/HBP1/Wnt/beta-catenin regulatory circuitry promotes glioma growth. FEBS Lett 2014; 588:3038-3046.
93
94. Bafico A, Gazit A, Pramila T, Finch PW, Yaniv A, Aaronson SA. Interaction of frizzled related protein (FRP) with Wnt ligands and the frizzled receptor suggests alternative mechanisms for FRP inhibition of Wnt signaling. J Biol Chem 1999; 274:16180-16187.
94
95. Zhang H, Chen R, Shao J. MicroRNA-96-5p facilitates the viability, migration, and invasion and suppresses the apoptosis of cervical cancer cells bynegatively modulating SFRP4. Technol Cancer Res Treat 2020; 19:1533033820934132.
95
96. Moghbeli M, Rad A, Farshchian M, Taghehchian N, Gholamin M, Abbaszadegan MR. Correlation between meis1 and msi1 in esophageal squamous cell carcinoma. J Gastrointest Cancer 2016; 47:273-277.
96
97. Moghbeli M, Sadrizadeh A, Forghanifard MM, Mozaffari HM, Golmakani E, Abbaszadegan MR. Role of Msi1 and PYGO2 in esophageal squamous cell carcinoma depth of invasion. J Cell Commun Signal 2016; 10:49-53.
97
98. Rankin EB, Giaccia AJ. Hypoxic control of metastasis. Science 2016; 352:175-180.
98
99. Lu X, Kang Y. Hypoxia and hypoxia-inducible factors: master regulators of metastasis. Clin Cancer Res 2010; 16:5928-5935.
99
100. Shih JW, Chiang WF, Wu ATH, Wu MH, Wang LY, Yu YL, et al. Long noncoding RNA LncHIFCAR/MIR31HG is a HIF-1alpha co-activator driving oral cancer progression. Nat Commun 2017; 8:15874.
100
101. Guo Z, Wang X, Yang Y, Chen W, Zhang K, Teng B, et al. Hypoxic tumor-derived exosomal long noncoding RNA UCA1 promotes angiogenesis via miR-96-5p/AMOTL2 in pancreatic cancer. Mol Ther Nucleic Acids 2020; 22:179-195.
101
102. Thiery JP. Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer 2002; 2:442-454.
102
103. Karhadkar SS, Bova GS, Abdallah N, Dhara S, Gardner D, Maitra A, et al. Hedgehog signalling in prostate regeneration, neoplasia and metastasis. Nature 2004; 431:707-712.
103
104. Shin SY, Rath O, Zebisch A, Choo SM, Kolch W, Cho KH. Functional roles of multiple feedback loops in extracellular signal-regulated kinase and Wnt signaling pathways that regulate epithelial-mesenchymal transition. Cancer Res 2010; 70:6715-6724.
104
105. Valcourt U, Kowanetz M, Niimi H, Heldin CH, Moustakas A. TGF-beta and the Smad signaling pathway support transcriptomic reprogramming during epithelial-mesenchymal cell transition. Mol Biol Cell 2005; 16:1987-2002.
105
106. Yoo BK, Chen D, Su ZZ, Gredler R, Yoo J, Shah K, et al. Molecular mechanism of chemoresistance by astrocyte elevated gene-1. Cancer Res 2010; 70:3249-3258.
106
107. Robertson CL, Srivastava J, Rajasekaran D, Gredler R, Akiel MA, Jariwala N, et al. The role of AEG-1 in the development of liver cancer. Hepat Oncol 2015; 2:303-312.
107
108. Feng S, Yao J, Zhang Z, Zhang Y, Zhang Z, Liu J, et al. miR96 inhibits EMT by targeting AEG1 in glioblastoma cancer cells. Mol Med Rep 2018; 17:2964-2972.
108
109. Chang S, Bok P, Tsai CY, Sun CP, Liu H, Deussing JM, et al. NPTX2 is a key component in the regulation of anxiety. Neuropsychopharmacology 2018; 43:1943-1953.
109
110. Xu C, Tian G, Jiang C, Xue H, Kuerbanjiang M, Sun L, et al. NPTX2 promotes colorectal cancer growth and liver metastasis by the activation of the canonical Wnt/beta-catenin pathway via FZD6. Cell Death Dis 2019; 10:217.
110
111. Xiang W, Han L, Mo G, Lin L, Yu X, Chen S, et al. MicroRNA-96 is a potential tumor repressor by inhibiting NPTX2 in renal cell carcinoma. J Cell Biochem 2020; 121:1504-1513.
111
112. Shao S, Wang C, Wang S, Zhang H, Zhang Y. LncRNA STXBP5-AS1 suppressed cervical cancer progression via targeting miR-96-5p/PTEN axis. Biomed Pharmacother 2019; 117:109082.
112
113. Vahabi M, Pulito C, Sacconi A, Donzelli S, D’Andrea M, Manciocco V, et al. miR-96-5p targets PTEN expression affecting radio-chemosensitivity of HNSCC cells. J Exp Clin Cancer Res 2019; 38:141.
113
114. Iwashita H, Okudela K, Matsumura M, Yamanaka S, Sawazumi T, Enaka M, et al. Succinate dehydrogenase B-deficient renal cell carcinoma: A case report with novel germline mutation. Pathol Int 2017; 67:585-589.
114
115. Miettinen M, Lasota J. Succinate dehydrogenase deficient gastrointestinal stromal tumors (GISTs) - a review. Int J Biochem Cell Biol 2014; 53:514-519.
115
116. Fuhrmann DC, Wittig I, Brune B. TMEM126B deficiency reduces mitochondrial SDH oxidation by LPS, attenuating HIF-1alpha stabilization and IL-1beta expression. Redox Biol 2019; 20:204-216.
116
117. Loriot C, Domingues M, Berger A, Menara M, Ruel M, Morin A, et al. Deciphering the molecular basis of invasiveness in Sdhb-deficient cells. Oncotarget 2015; 6:32955-32965.
117
118. Zhao X, Li Y, Zhou Y. MicroRNA-96-3p promotes metastasis of papillary thyroid cancer through targeting SDHB. Cancer Cell Int 2019; 19:287.
118
119. van Horssen R, Ten Hagen TL, Eggermont AM. TNF-alpha in cancer treatment: molecular insights, antitumor effects, and clinical utility. Oncologist 2006; 11:397-408.
119
120. Wu L, Pu X, Wang Q, Cao J, Xu F, Xu LI, et al. miR-96 induces cisplatin chemoresistance in non-small cell lung cancer cells by downregulating SAMD9. Oncol Lett 2016; 11:945-952.
120
121. Hall A. The cellular functions of small GTP-binding proteins. Science 1990; 249:635-640.
121
122. Campbell PM, Groehler AL, Lee KM, Ouellette MM, Khazak V, Der CJ. K-Ras promotes growth transformation and invasion of immortalized human pancreatic cells by Raf and phosphatidylinositol 3-kinase signaling. Cancer Res 2007; 67:2098-2106.
122
123. Kallifatidis G, Rausch V, Baumann B, Apel A, Beckermann BM, Groth A, et al. Sulforaphane targets pancreatic tumour-initiating cells by NF-kappaB-induced antiapoptotic signalling. Gut 2009; 58:949-963.
123
124. McCubrey JA, Steelman LS, Chappell WH, Abrams SL, Wong EW, Chang F, et al. Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biochim Biophys Acta 2007; 1773:1263-1284.
124
125. Zhang W, Liu HT. MAPK signal pathways in the regulation of cell proliferation in mammalian cells. Cell Res 2002; 12:9-18.
125
126. Yu S, Lu Z, Liu C, Meng Y, Ma Y, Zhao W, et al. miRNA-96 suppresses KRAS and functions as a tumor suppressor gene in pancreatic cancer. Cancer Res 2010; 70:6015-6025.
126
127. He RJ, Yu ZH, Zhang RY, Zhang ZY. Protein tyrosine phosphatases as potential therapeutic targets. Acta Pharmacol Sin 2014; 35:1227-1246.
127
128. Su F, Ren F, Rong Y, Wang Y, Geng Y, Wang Y, et al. Protein tyrosine phosphatase Meg2 dephosphorylates signal transducer and activator of transcription 3 and suppresses tumor growth in breast cancer. Breast Cancer Res 2012; 14:R38.
128
129. Yuan T, Wang Y, Zhao ZJ, Gu H. Protein-tyrosine phosphatase PTPN9 negatively regulates ErbB2 and epidermal growth factor receptor signaling in breast cancer cells. J Biol Chem 2010; 285:14861-14870.
129
130. Gritsko T, Williams A, Turkson J, Kaneko S, Bowman T, Huang M, et al. Persistent activation of stat3 signaling induces survivin gene expression and confers resistance to apoptosis in human breast cancer cells. Clin Cancer Res 2006; 12:11-19.
130
131. Turkson J, Jove R. STAT proteins: novel molecular targets for cancer drug discovery. Oncogene 2000; 19:6613-6626.
131
132. Hong Y, Liang H, Uzair Ur R, Wang Y, Zhang W, Zhou Y, et al. miR-96 promotes cell proliferation, migration and invasion by targeting PTPN9 in breast cancer. Sci Rep 2016; 6:37421.
132
133. Ma X, Shi W, Peng L, Qin X, Hui Y. MiR-96 enhances cellular proliferation and tumorigenicity of human cervical carcinoma cells through PTPN9. Saudi J Biol Sci 2018; 25:863-867.
133
134. Suzuki A, Kusakai G, Kishimoto A, Lu J, Ogura T, Lavin MF, et al. Identification of a novel protein kinase mediating Akt survival signaling to the ATM protein. J Biol Chem 2003; 278:48-53.
134
135. Suzuki A, Kusakai G, Kishimoto A, Lu J, Ogura T, Esumi H. ARK5 suppresses the cell death induced by nutrient starvation and death receptors via inhibition of caspase 8 activation, but not by chemotherapeutic agents or UV irradiation. Oncogene 2003; 22:6177-6182.
135
136. Suzuki A, Kusakai G, Kishimoto A, Shimojo Y, Miyamoto S, Ogura T, et al. Regulation of caspase-6 and FLIP by the AMPK family member ARK5. Oncogene 2004; 23:7067-7075.
136
137. Huang X, Lv W, Zhang JH, Lu DL. miR96 functions as a tumor suppressor gene by targeting NUAK1 in pancreatic cancer. Int J Mol Med 2014; 34:1599-1605.
137
138. Ren R. Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia. Nat Rev Cancer 2005; 5:172-183.
138
139. Huang T, Fu Y, Wang S, Xu M, Yin X, Zhou M, et al. miR-96 acts as a tumor suppressor via targeting the BCR-ABL1 oncogene in chronic myeloid leukemia blastic transformation. Biomed Pharmacother 2019; 119:109413.
139
140. Ciardiello F, Tortora G. EGFR antagonists in cancer treatment. N Engl J Med 2008; 358:1160-1174.
140
141. Tsai YC, Zeng T, Abou-Kheir W, Yeh HL, Yin JJ, Lee YC, et al. Disruption of ETV6 leads to TWIST1-dependent progression and resistance to epidermal growth factor receptor tyrosine kinase inhibitors in prostate cancer. Mol Cancer 2018; 17:42.
141
142. Li JJ, Liu DP, Liu GT, Xie D. EphrinA5 acts as a tumor suppressor in glioma by negative regulation of epidermal growth factor receptor. Oncogene 2009; 28:1759-1768.
142
143. Wang TH, Yeh CT, Ho JY, Ng KF, Chen TC. OncomiR miR-96 and miR-182 promote cell proliferation and invasion through targeting ephrinA5 in hepatocellular carcinoma. Mol Carcinog 2016; 55:366-375.
143
144. Chiang CH, Hou MF, Hung WC. Up-regulation of miR-182 by beta-catenin in breast cancer increases tumorigenicity and invasiveness by targeting the matrix metalloproteinase inhibitor RECK. Biochim Biophys Acta 2013; 1830:3067-3076.
144
145. Hirata H, Ueno K, Shahryari V, Tanaka Y, Tabatabai ZL, Hinoda Y, et al. Oncogenic miRNA-182-5p targets Smad4 and RECK in human bladder cancer. PLoS One 2012; 7:e51056.
145
146. Zhao H, Wang Y, Yang L, Jiang R, Li W. MiR-25 promotes gastric cancer cells growth and motility by targeting RECK. Mol Cell Biochem 2014; 385:207-213.
146
147. Xia H, Chen S, Chen K, Huang H, Ma H. MiR-96 promotes proliferation and chemo- or radioresistance by down-regulating RECK in esophageal cancer. Biomed Pharmacother 2014; 68:951-958.
147
148. Zhang J, Kong X, Li J, Luo Q, Li X, Shen L, et al. miR-96 promotes tumor proliferation and invasion by targeting RECK in breast cancer. Oncol Rep 2014; 31:1357-1363.
148
149. Guo H, Li Q, Li W, Zheng T, Zhao S, Liu Z. MiR-96 downregulates RECK to promote growth and motility of non-small cell lung cancer cells. Mol Cell Biochem 2014; 390:155-160.
149
150. Iwai N, Yasui K, Tomie A, Gen Y, Terasaki K, Kitaichi T, et al. Oncogenic miR-96-5p inhibits apoptosis by targeting the caspase-9 gene in hepatocellular carcinoma. Int J Oncol 2018; 53:237-245.
150
151. Matsuhashi S, Manirujjaman M, Hamajima H, Ozaki I. Control Mechanisms of the Tumor Suppressor PDCD4: Expression and Functions. Int J Mol Sci 2019; 20.
151
152. Guo P, Yu Y, Tian Z, Lin Y, Qiu Y, Yao W, et al. Upregulation of miR-96 promotes radioresistance in glioblastoma cells via targeting PDCD4. Int J Oncol 2018; 53:1591-1600.
152
153. Colhado Rodrigues BL, Lallo MA, Perez EC. The controversial role of autophagy in tumor development: A systematic review. Immunol Invest 2020; 49:386-396.
153
154. Guo F, Liu X, Cai H, Le W. Autophagy in neurodegenerative diseases: pathogenesis and therapy. Brain Pathol 2018; 28:3-13.
154
155. Han J, Hou W, Goldstein LA, Stolz DB, Watkins SC, Rabinowich H. A Complex between Atg7 and Caspase-9: A Novel mechanism of cross-regulation between autophagy and apoptosis. J Biol Chem 2014; 289:6485-6497.
155
156. Zheng W, Xie W, Yin D, Luo R, Liu M, Guo F. ATG5 and ATG7 induced autophagy interplays with UPR via PERK signaling. Cell Commun Signal 2019; 17:42.
156
157. Li JJ, Chen XF, Wang M, Zhang PP, Zhang F, Zhang JJ. Long non-coding RNA UCA1 promotes autophagy by targeting miR-96-5p in acute myeloid leukaemia. Clin Exp Pharmacol Physiol 2020; 47:877-885.
157
158. Bianco S, Jangal M, Garneau D, Gevry N. LRH-1 controls proliferation in breast tumor cells by regulating CDKN1A gene expression. Oncogene 2015; 34:4509-4518.
158
159. Wu Z, Liu K, Wang Y, Xu Z, Meng J, Gu S. Upregulation of microRNA-96 and its oncogenic functions by targeting CDKN1A in bladder cancer. Cancer Cell Int 2015; 15:107.
159
ORIGINAL_ARTICLE
An overview of pharmacological activities of baicalin and its aglycone baicalein: New insights into molecular mechanisms and signaling pathways
The flavonoids, baicalin, and its aglycone baicalein possess multi-fold therapeutic properties and are mainly found in the roots of Oroxylum indicum (L.) Kurz and Scutellaria baicalensis Georgi. These flavonoids have been reported to possess various pharmacological properties, including antibacterial, antiviral, anticancer, anticonvulsant, anti-oxidant, hepatoprotective, and neuroprotective effects. The pharmacological properties of baicalin and baicalein are due to their abilities to scavenge reactive oxygen species (ROS) and interaction with various signaling molecules associated with apoptosis, inflammation, autophagy, cell cycle, mitochondrial dynamics, and cytoprotection. In this review, we summarized the molecular mechanisms underlying the chemopreventive and chemotherapeutic applications of baicalin and baicalein in the treatment of cancer and inflammatory diseases. In addition, the preventive effects of baicalin and baicalein on mitochondrial dynamics and functions were highlighted with a particular emphasis on their anti-oxidative and cytoprotective properties. The current review highlights could be useful for future prospective studies to further improve the pharmacological applications of baicalein and baicalin. These studies should define the threshold for optimal drug exposure, dose optimization and focus on therapeutic drug monitoring, objective disease markers, and baicalin/baicalein drug levels.
https://ijbms.mums.ac.ir/article_19489_2ad0459f107121aff4b93a0478ef9dd6.pdf
2022-01-01
14
26
10.22038/ijbms.2022.60380.13381
Baicalein
Baicalin
Cancer
Inflammatory diseases
Mitochondrial functions
Zhihua
Hu
huzhihua@hgnu.edu.cn
1
College of Computer Science, Huanggang Normal University, Huanggang 438000, China
AUTHOR
Yurong
Guan
jsjgyr@hgnu.edu.cn
2
College of Computer Science, Huanggang Normal University, Huanggang 438000, China
AUTHOR
Wanying
Hu
872944979@qq.com
3
College of Veterinary Medicine, Northeast Agricultural University, 600 Changjiang Road, Xiangfang District, Harbin 150030, P. R. China
AUTHOR
Zhiyong
Xu
997987115@qq.com
4
Hubei Zhiying Medical Imaging Center, Radiology Department of Huanggang Hospital of Traditional Chinese Medicine, China
LEAD_AUTHOR
Muhammad
Ishfaq
muhammad@hgnu.edu.cn
5
College of Computer Science, Huanggang Normal University, Huanggang 438000, China
LEAD_AUTHOR
1. Chen LJ, Games DE, Jones J. Isolation and identification of four flavonoid constituents from the seeds of Oroxylum indicum by high-speed counter-current chromatography. J Chromatogr A 2003; 988:95-105.
1
2. Cui X, Shen YM, Jiang S, Qian DW, Shang EX, Zhu ZH, et al. Comparative analysis of the main active components and hypoglycemic effects after the compatibility of Scutellariae radix and Coptidis rhizoma. J Sep Sci 2019; 42:1520-1527.
2
3. Dinda B, Mohanta BC, Arima S, Sato N, Harigaya Y. Flavonoids from the stem-bark of Oroxylum indicum. Natural Product Sciences 2007; 13:190-194.
3
4. Li HB, Jiang Y, Chen F. Separation methods used for Scutellaria baicalensis active components. J Chromatogr B Analyt Technol Biomed Life Sci 2004; 812:277-290.
4
5. Lin CC, Shieh DE. The anti-inflammatory activity of Scutellaria rivularis extracts and its active components, baicalin, baicalein and wogonin. Am J Chin Med 1996; 24:31-36.
5
6. Xie LH, Wang X, Basnet P, Matsunaga N, Yamaji S, Yang DY, et al. Evaluation of variation of acteoside and three major flavonoids in wild and cultivated Scutellaria baicalensis roots by micellar electrokinetic chromatography. Chem Pharm Bull (Tokyo) 2002; 50:896-899.
6
7. Biswas K, Ghosh SE. Bharater bonoushodi; 1994 vol 3: 858.
7
8. Bhandari M, Bhandari A, Prakash R, Bhandari A. Scutellaria baicalensis Georgi : A Rising Paradigm of Herbal Remedies. Webmed Central PHARMACEUTICAL SCIENCES 2010; 1:11.
8
9. Kirtikar KR, Basu BD. Indian Medicinal Plants. New Delhi: International Book Distribution; 1996.
9
10. Cheng CS, Chen J, Tan HY, Wang N, Chen Z, Feng Y. Scutellaria baicalensis and cancer treatment: Recent progress and perspectives in biomedical and clinical studies. Am J Chin Med 2018; 46:25-54.
10
11. Dinda B, Dinda S, DasSharma S, Banik R, Chakraborty A, Dinda M. Therapeutic potentials of baicalin and its aglycone, baicalein against inflammatory disorders. Eur J Med Chem 2017; 131:68-80.
11
12. Gasiorowski K, Lamer-Zarawska E, Leszek J, Parvathaneni K, Yendluri BB, Blach-Olszewska Z, et al. Flavones from root of Scutellaria baicalensis Georgi: drugs of the future in neurodegeneration? CNS Neurol Disord Drug Targets 2011; 10:184-191.
12
13. Chen H, Gao Y, Wu J, Chen Y, Chen B, Hu J, et al. Exploring therapeutic potentials of baicalin and its aglycone baicalein for hematological malignancies. Cancer Lett 2014; 354:5-11.
13
14. Wang CZ, Calway TD, Wen XD, Smith J, Yu C, Wang Y, et al. Hydrophobic flavonoids from Scutellaria baicalensis induce colorectal cancer cell apoptosis through a mitochondrial-mediated pathway. Int J Oncol 2013; 42:1018-1026.
14
15. Wu CC, Chen YR, Lu DH, Hsu LH, Yang KC, Sumi S. Evaluation of the post-treatment anti-inflammatory capacity of osteoarthritic chondrocytes: An in vitro study using baicalein. Regen Ther 2020; 14:177-183.
15
16. Zhao Q, Chen XY, Martin C. Scutellaria baicalensis, the golden herb from the garden of Chinese medicinal plants. Sci Bull (Beijing) 2016; 61:1391-1398.
16
17. Ungvari Z, Tarantini S, Donato AJ, Galvan V, Csiszar A. Mechanisms of vascular aging. Circ Res 2018; 123:849-867.
17
18. Dalgleish AG, O’Byrne KJ. Chronic immune activation and inflammation in the pathogenesis of AIDS and cancer. Adv Cancer Res 2002; 84:231-276.
18
19. Rani A, Dasgupta P, Murphy JJ. Prostate Cancer: The role of inflammation and chemokines. Am J Pathol 2019; 189:2119-2137.
19
20. Saltiel AR, Olefsky JM. Inflammatory mechanisms linking obesity and metabolic disease. J Clin Invest 2017; 127:1-4.
20
21. Moffatt MF, Kabesch M, Liang L, Dixon AL, Strachan D, Heath S, et al. Genetic variants regulating ORMDL3 expression contribute to the risk of childhood asthma. Nature 2007; 448:470-473.
21
22. Study C, Houlston RS, Webb E, Broderick P, Pittman AM, Di Bernardo MC, et al. Meta-analysis of genome-wide association data identifies four new susceptibility loci for colorectal cancer. Nat Genet 2008; 40:1426-1435.
22
23. Zeggini E, Scott LJ, Saxena R, Voight BF, Marchini JL, Hu T, et al. Meta-analysis of genome-wide association data and large-scale replication identifies additional susceptibility loci for type 2 diabetes. Nat Genet 2008; 40:638-645.
23
24. Kondylis V, Kumari S, Vlantis K, Pasparakis M. The interplay of IKK, NF-kappaB and RIPK1 signaling in the regulation of cell death, tissue homeostasis and inflammation. Immunol Rev 2017; 277:113-127.
24
25. Gao Y, Lu J, Zhang Y, Chen Y, Gu Z, Jiang X. Baicalein attenuates bleomycin-induced pulmonary fibrosis in rats through inhibition of miR-21. Pulm Pharmacol Ther 2013; 26:649-654.
25
26. Huang X, He Y, Chen Y, Wu P, Gui D, Cai H, et al. Baicalin attenuates bleomycin-induced pulmonary fibrosis via adenosine A2a receptor related TGF-beta1-induced ERK1/2 signaling pathway. BMC Pulm Med 2016; 16:132.
26
27. Koroskenyi K, Kiss B, Szondy Z. Adenosine A2A receptor signaling attenuates LPS-induced pro-inflammatory cytokine formation of mouse macrophages by inducing the expression of DUSP1. Biochim Biophys Acta 2016; 1863:1461-1471.
27
28. Yan S, Wang Y, Liu P, Chen A, Chen M, Yao D, et al. Baicalin Attenuates Hypoxia-Induced Pulmonary Arterial Hypertension to improve hypoxic cor pulmonale by reducing the activity of the p38 mapk signaling pathway and MMP-9. Evid Based Complement Alternat Med 2016; 2016:2546402.
28
29. Bourgeois A, Lambert C, Habbout K, Ranchoux B, Paquet-Marceau S, Trinh I, et al. FOXM1 promotes pulmonary artery smooth muscle cell expansion in pulmonary arterial hypertension. J Mol Med (Berl) 2018; 96:223-235.
29
30. Zhang L, Pu Z, Wang J, Zhang Z, Hu D, Wang J. Baicalin inhibits hypoxia-induced pulmonary artery smooth muscle cell proliferation via the AKT/HIF-1alpha/p27-associated pathway. Int J Mol Sci 2014; 15:8153-8168.
30
31. Bradding P, Arthur G. Mast cells in asthma--state of the art. Clin Exp Allergy 2016; 46:194-263.
31
32. Lin W, Su F, Gautam R, Wang N, Zhang Y, Wang X. Raf kinase inhibitor protein negatively regulates FcepsilonRI-mediated mast cell activation and allergic response. Proc Natl Acad Sci U S A 2018; 115:E9859-E9868.
32
33. Cannon JG, Evans WJ, Hughes VA, Meredith CN, Dinarello CA. Physiological mechanisms contributing to increased interleukin-1 secretion. J Appl Physiol (1985) 1986; 61:1869-1874.
33
34. Hsieh CJ, Hall K, Ha T, Li C, Krishnaswamy G, Chi DS. Baicalein inhibits IL-1beta- and TNF-alpha-induced inflammatory cytokine production from human mast cells via regulation of the NF-kappaB pathway. Clin Mol Allergy 2007; 5:5.
34
35. Rheumatoid arthritis. Nat Rev Dis Primers 2018; 4:18002.
35
36. Yang X, Yang J, Zou H. Baicalin inhibits IL-17-mediated joint inflammation in murine adjuvant-induced arthritis. Clin Dev Immunol 2013; 2013:268065.
36
37. Bae MJ, Shin HS, See HJ, Jung SY, Kwon DA, Shon DH. Baicalein induces CD4(+)Foxp3(+) T cells and enhances intestinal barrier function in a mouse model of food allergy. Sci Rep 2016; 6:32225.
37
38. Zhu W, Jin Z, Yu J, Liang J, Yang Q, Li F, et al. Baicalin ameliorates experimental inflammatory bowel disease through polarization of macrophages to an M2 phenotype. Int Immunopharmacol 2016; 35:119-126.
38
39. Hang Y, Qin X, Ren T, Cao J. Baicalin reduces blood lipids and inflammation in patients with coronary artery disease and rheumatoid arthritis: a randomized, double-blind, placebo-controlled trial. Lipids Health Dis 2018; 17:146.
39
40. Isola G, Matarese M, Ramaglia L, Iorio-Siciliano V, Cordasco G, Matarese G. Efficacy of a drug composed of herbal extracts on postoperative discomfort after surgical removal of impacted mandibular third molar: A randomized, triple-blind, controlled clinical trial. Clin Oral Investig 2019; 23:2443-2453.
40
41. Guo HX, Liu DH, Ma Y, Liu JF, Wang Y, Du ZY, et al. Long-term baicalin administration ameliorates metabolic disorders and hepatic steatosis in rats given a high-fat diet. Acta Pharmacol Sin 2009; 30:1505-1512.
41
42. Fu Y, Luo J, Jia Z, Zhen W, Zhou K, Gilbert E, et al. Baicalein Protects against Type 2 Diabetes via Promoting Islet beta-Cell Function in Obese Diabetic Mice. Int J Endocrinol 2014; 2014:846742.
42
43. Zhang X, Du L, Zhang W, Yang Y, Zhou Q, Du G. Therapeutic effects of baicalein on rotenone-induced Parkinson’s disease through protecting mitochondrial function and biogenesis. Sci Rep 2017; 7:9968.
43
44. Pu P, Wang XA, Salim M, Zhu LH, Wang L, Chen KJ, et al. Baicalein, a natural product, selectively activating AMPKalpha(2) and ameliorates metabolic disorder in diet-induced mice. Mol Cell Endocrinol 2012; 362:128-138.
44
45. Winder WW, Hardie DG. AMP-activated protein kinase, a metabolic master switch: possible roles in type 2 diabetes. Am J Physiol 1999; 277:E1-10.
45
46. Kong EK, Yu S, Sanderson JE, Chen KB, Huang Y, Yu CM. A novel anti-fibrotic agent, baicalein, for the treatment of myocardial fibrosis in spontaneously hypertensive rats. Eur J Pharmacol 2011; 658:175-181.
46
47. Kasikara C, Doran AC, Cai B, Tabas I. The role of non-resolving inflammation in atherosclerosis. J Clin Invest 2018; 128:2713-2723.
47
48. Wolf D, Ley K. Immunity and Inflammation in Atherosclerosis. Circ Res 2019; 124:315-327.
48
49. Ku SK, Bae JS. Baicalin, baicalein and wogonin inhibits high glucose-induced vascular inflammation in vitro and in vivo. BMB Rep 2015; 48:519-524.
49
50. Dong LH, Wen JK, Miao SB, Jia Z, Hu HJ, Sun RH, et al. Baicalin inhibits PDGF-BB-stimulated vascular smooth muscle cell proliferation through suppressing PDGFRbeta-ERK signaling and increase in p27 accumulation and prevents injury-induced neointimal hyperplasia. Cell Res 2010; 20:1252-1262.
50
51. Cheng PY, Lee YM, Wu YS, Chang TW, Jin JS, Yen MH. Protective effect of baicalein against endotoxic shock in rats in vivo and in vitro. Biochem Pharmacol 2007; 73:793-804.
51
52. Patwardhan RS, Sharma D, Thoh M, Checker R, Sandur SK. Baicalein exhibits anti-inflammatory effects via inhibition of NF-kappaB transactivation. Biochem Pharmacol 2016; 108:75-89.
52
53. Lee YM, Cheng PY, Chim LS, Kung CW, Ka SM, Chung MT, et al. Baicalein, an active component of Scutellaria baicalensis Georgi, improves cardiac contractile function in endotoxaemic rats via induction of heme oxygenase-1 and suppression of inflammatory responses. J Ethnopharmacol 2011; 135:179-185.
53
54. Shao ZH, Vanden Hoek TL, Qin Y, Becker LB, Schumacker PT, Li CQ, et al. Baicalein attenuates oxidant stress in cardiomyocytes. Am J Physiol Heart Circ Physiol 2002; 282:H999-H1006.
54
55. Zeng Y, Song C, Ding X, Ji X, Yi L, Zhu K. Baicalin reduces the severity of experimental autoimmune encephalomyelitis. Braz J Med Biol Res 2007; 40:1003-1010.
55
56. Zhang Y, Li X, Ciric B, Ma CG, Gran B, Rostami A, et al. Therapeutic effect of baicalin on experimental autoimmune encephalomyelitis is mediated by SOCS3 regulatory pathway. Sci Rep 2015; 5:17407.
56
57. Staff PO. Correction: baicalein selectively induces apoptosis in activated lymphocytes and ameliorates concanavalin a-induced hepatitis in mice. PLoS One 2015; 10:e0117635.
57
58. Sun H, Che QM, Zhao X, Pu XP. Antifibrotic effects of chronic baicalein administration in a CCl4 liver fibrosis model in rats. Eur J Pharmacol 2010; 631:53-60.
58
59. Huang HL, Wang YJ, Zhang QY, Liu B, Wang FY, Li JJ, et al. Hepatoprotective effects of baicalein against CCl4-induced acute liver injury in mice. World J Gastroenterol 2012; 18:6605-6613.
59
60. Peng XD, Dai LL, Huang CQ, He CM, Chen LJ. Correlation between anti-fibrotic effect of baicalin and serum cytokines in rat hepatic fibrosis. World J Gastroenterol 2009; 15:4720-4725.
60
61. Sowndhararajan K, Deepa P, Kim M, Park SJ, Kim S. Baicalein as a potent neuroprotective agent: A review. Biomed Pharmacother. 95:1021-1032.
61
62. Cheng Y, He G, Mu X, Zhang T, Li X, Hu J, et al. Neuroprotective effect of baicalein against MPTP neurotoxicity: behavioral, biochemical and immunohistochemical profile. Neurosci Lett 2008; 441:16-20.
62
63. Song JX, Choi MY, Wong KC, Chung WW, Sze SC, Ng TB, et al. Baicalein antagonizes rotenone-induced apoptosis in dopaminergic SH-SY5Y cells related to Parkinsonism. Chin Med 2012; 7:1.
63
64. Mu X, He G, Cheng Y, Li X, Xu B, Du G. Baicalein exerts neuroprotective effects in 6-hydroxydopamine-induced experimental parkinsonism in vivo and in vitro. Pharmacol Biochem Behav 2009; 92:642-648.
64
65. Wang W, Zhou PH, Xu CG, Zhou XJ, Hu W, Zhang J. Baicalein attenuates renal fibrosis by inhibiting inflammation via down-regulating NF-kappaB and MAPK signal pathways. J Mol Histol 2015; 46:283-290.
65
66. Ishfaq M, Zhang W, Hu W, Waqas Ali Shah S, Liu Y, Wang J, et al. Antagonistic Effects of baicalin on Mycoplasma gallisepticum-induced inflammation and apoptosis by restoring energy metabolism in the chicken lungs. Infect Drug Resist 2019; 12:3075-3089.
66
67. Bao J, Wu Z, Ishfaq M, Miao Y, Li R, Clifton AC, et al. Comparison of Experimental Infection of Normal and Immunosuppressed Chickens with Mycoplasma gallisepticum. J Comp Pathol 2020; 175:5-12.
67
68. Cheng P, Wang T, Li W, Muhammad I, Wang H, Sun X, et al. Baicalin alleviates lipopolysaccharide-induced liver inflammation in chicken by suppressing TLR4-mediated NF-kappaB pathway. Front Pharmacol 2017; 8:547.
68
69. Li J, Qiao Z, Hu W, Zhang W, Shah SWA, Ishfaq M. Baicalin mitigated Mycoplasma gallisepticum-induced structural damage and attenuated oxidative stress and apoptosis in chicken thymus through the Nrf2/HO-1 defence pathway. Vet Res 2019; 50:83.
69
70. Chen C, Li J, Zhang W, Shah SWA, Ishfaq M. Mycoplasma gallisepticum triggers immune damage in the chicken thymus by activating the TLR-2/MyD88/NF-kappaB signaling pathway and NLRP3 inflammasome. Vet Res 2020; 51:52.
70
71. Wu Z, Chen C, Miao Y, Liu Y, Zhang Q, Li R, et al. Baicalin Attenuates Mycoplasma gallisepticum-Induced Inflammation via Inhibition of the TLR2-NF-kappaB Pathway in Chicken and DF-1 Cells. Infect Drug Resist 2019; 12:3911-3923.
71
72. Huang T, Liu Y, Zhang C. Pharmacokinetics and Bioavailability Enhancement of Baicalin: A Review. Eur J Drug Metab Pharmacokinet 2019; 44:159-168.
72
73. Luo J, Kong H, Zhang M, Cheng J, Sun Z, Xiong W, et al. Novel Carbon Dots-Derived from Radix Puerariae Carbonisata Significantly Improve the Solubility and Bioavailability of Baicalin. J Biomed Nanotechnol 2019; 15:151-161.
73
74. Cavalcante GC, Schaan AP, Cabral GF, Santana-da-Silva MN, Pinto P, Vidal AF, et al. A Cell’s fate: An overview of the molecular biology and genetics of apoptosis. Int J Mol Sci 2019; 20.
74
75. Kiraz Y, Adan A, Kartal Yandim M, Baran Y. Major apoptotic mechanisms and genes involved in apoptosis. Tumour Biol 2016; 37:8471-8486.
75
76. Liu G, Pei F, Yang F, Li L, Amin AD, Liu S, et al. Role of autophagy and apoptosis in non-small-cell lung cancer. Int J Mol Sci 2017; 18.
76
77. Gong WY, Zhao ZX, Liu BJ, Lu LW, Dong JC. Exploring the chemopreventive properties and perspectives of baicalin and its aglycone baicalein in solid tumors. Eur J Med Chem 2017; 126:844-852.
77
78. Chang HT, Chou CT, Kuo DH, Shieh P, Jan CR, Liang WZ. The mechanism of Ca2+ movement in the involvement of baicalein-induced cytotoxicity in ZR-75-1 human breast cancer cells. J Nat Prod 2015; 78:1624-1634.
78
79. Lin YT, Yang JS, Lin HJ, Tan TW, Tang NY, Chaing JH, et al. Baicalein induces apoptosis in SCC-4 human tongue cancer cells via a Ca2+-dependent mitochondrial pathway. In Vivo 2007; 21:1053-1058.
79
80. Lee JH, Li YC, Ip SW, Hsu SC, Chang NW, Tang NY, et al. The role of Ca2+ in baicalein-induced apoptosis in human breast MDA-MB-231 cancer cells through mitochondria- and caspase-3-dependent pathway. Anticancer Res 2008; 28:1701-1711.
80
81. Mu J, Liu T, Jiang L, Wu X, Cao Y, Li M, et al. The traditional chinese medicine baicalein potently inhibits gastric cancer cells. J Cancer 2016; 7:453-461.
81
82. Wang CZ, Zhang CF, Chen L, Anderson S, Lu F, Yuan CS. Colon cancer chemopreventive effects of baicalein, an active enteric microbiome metabolite from baicalin. Int J Oncol 2015; 47:1749-1758.
82
83. Takahashi H, Chen MC, Pham H, Angst E, King JC, Park J, et al. Baicalein, a component of Scutellaria baicalensis, induces apoptosis by Mcl-1 down-regulation in human pancreatic cancer cells. Biochim Biophys Acta 2011; 1813:1465-1474.
83
84. Li X, Zou K, Gou J, Du Q, Li D, He X, et al. Effect of baicalin-copper on the induction of apoptosis in human hepatoblastoma cancer HepG2 cells. Med Oncol 2015; 32:72.
84
85. Zhou QM, Wang S, Zhang H, Lu YY, Wang XF, Motoo Y, et al. The combination of baicalin and baicalein enhances apoptosis via the ERK/p38 MAPK pathway in human breast cancer cells. Acta Pharmacol Sin 2009; 30:1648-1658.
85
86. Liang RR, Zhang S, Qi JA, Wang ZD, Li J, Liu PJ, et al. Preferential inhibition of hepatocellular carcinoma by the flavonoid Baicalein through blocking MEK-ERK signaling. Int J Oncol 2012; 41:969-978.
86
87. Xu XM, Yuan GJ, Deng JJ, Guo HT, Xiang M, Yang F, et al. Inhibition of 12-lipoxygenase reduces proliferation and induces apoptosis of hepatocellular carcinoma cells in vitro and in vivo. Hepatobiliary Pancreat Dis Int 2012; 11:193-202.
87
88. Taniguchi H, Yoshida T, Horinaka M, Yasuda T, Goda AE, Konishi M, et al. Baicalein overcomes tumor necrosis factor-related apoptosis-inducing ligand resistance via two different cell-specific pathways in cancer cells but not in normal cells. Cancer Res 2008; 68:8918-8927.
88
89. Ren X, Zhang Z, Tian J, Wang H, Song G, Guo Q, et al. The down-regulation of c-Myc and its target gene hTERT is associated with the antiproliferative effects of baicalin on HL-60 cells. Oncol Lett 2017; 14:6833-6840.
89
90. Lambert AW, Pattabiraman DR, Weinberg RA. Emerging biological principles of metastasis. Cell 2017; 168:670-691.
90
91. Massague J, Batlle E, Gomis RR. Understanding the molecular mechanisms driving metastasis. Mol Oncol 2017; 11:3-4.
91
92. Chung H, Choi HS, Seo EK, Kang DH, Oh ES. Baicalin and baicalein inhibit transforming growth factor-beta1-mediated epithelial-mesenchymal transition in human breast epithelial cells. Biochem Biophys Res Commun 2015; 458:707-713.
92
93. Chen F, Zhuang M, Peng J, Wang X, Huang T, Li S, et al. Baicalein inhibits migration and invasion of gastric cancer cells through suppression of the TGF-beta signaling pathway. Mol Med Rep 2014; 10:1999-2003.
93
94. Ma X, Yan W, Dai Z, Gao X, Ma Y, Xu Q, et al. Baicalein suppresses metastasis of breast cancer cells by inhibiting EMT via down-regulation of SATB1 and Wnt/beta-catenin pathway. Drug Des Devel Ther 2016; 10:1419-1441.
94
95. Gao XY, Xue XH, Ma YN, Zhang SQ. Effect of baicalein on the expression of SATB1 in human breast cancer cells. Exp Ther Med 2015; 9:1665-1669.
95
96. Chen K, Zhang S, Ji Y, Li J, An P, Ren H, et al. Baicalein inhibits the invasion and metastatic capabilities of hepatocellular carcinoma cells via down-regulation of the ERK pathway. PLoS One 2013; 8:e72927.
96
97. Chiu YW, Lin TH, Huang WS, Teng CY, Liou YS, Kuo WH, et al. Baicalein inhibits the migration and invasive properties of human hepatoma cells. Toxicol Appl Pharmacol 2011; 255:316-326.
97
98. Gong WY, Wu JF, Liu BJ, Zhang HY, Cao YX, Sun J, et al. Flavonoid components in Scutellaria baicalensis inhibit nicotine-induced proliferation, metastasis and lung cancer-associated inflammation in vitro. Int J Oncol 2014; 44:1561-1570.
98
99. Rui X, Yan XI, Zhang K. Baicalein inhibits the migration and invasion of colorectal cancer cells via suppression of the AKT signaling pathway. Oncol Lett 2016; 11:685-688.
99
100. Wang L, Ling Y, Chen Y, Li CL, Feng F, You QD, et al. Flavonoid baicalein suppresses adhesion, migration and invasion of MDA-MB-231 human breast cancer cells. Cancer Lett 2010; 297:42-48.
100
101. Wang XF, Zhou QM, Du J, Zhang H, Lu YY, Su SB. Baicalin suppresses migration, invasion and metastasis of breast cancer via p38MAPK signaling pathway. Anticancer Agents Med Chem 2013; 13:923-931.
101
102. Yan H, Xin S, Wang H, Ma J, Zhang H, Wei H. Baicalein inhibits MMP-2 expression in human ovarian cancer cells by suppressing the p38 MAPK-dependent NF-kappaB signaling pathway. Anticancer Drugs 2015; 26:649-656.
102
103. Yan X, Rui X, Zhang K. Baicalein inhibits the invasion of gastric cancer cells by suppressing the activity of the p38 signaling pathway. Oncol Rep 2015; 33:737-743.
103
104. Guo Z, Hu X, Xing Z, Xing R, Lv R, Cheng X, et al. Baicalein inhibits prostate cancer cell growth and metastasis via the caveolin-1/AKT/mTOR pathway. Mol Cell Biochem 2015; 406:111-119.
104
105. Shang D, Li Z, Zhu Z, Chen H, Zhao L, Wang X, et al. Baicalein suppresses 17-beta-estradiol-induced migration, adhesion and invasion of breast cancer cells via the G protein-coupled receptor 30 signaling pathway. Oncol Rep 2015; 33:2077-2085.
105
106. Wu B, Li J, Huang D, Wang W, Chen Y, Liao Y, et al. Baicalein mediates inhibition of migration and invasiveness of skin carcinoma through Ezrin in A431 cells. BMC Cancer 2011; 11:527.
106
107. Liu TY, Gong W, Tan ZJ, Lu W, Wu XS, Weng H, et al. Baicalein inhibits progression of gallbladder cancer cells by down-regulating ZFX. PLoS One 2015; 10:e0114851.
107
108. Kim SD, Lee YJ, Baik JS, Han JY, Lee CG, Heo K, et al. Baicalein inhibits agonist- and tumor cell-induced platelet aggregation while suppressing pulmonary tumor metastasis via cAMP-mediated VASP phosphorylation along with impaired MAPKs and PI3K-Akt activation. Biochem Pharmacol 2014; 92:251-265.
108
109. Liu JJ, Huang TS, Cheng WF, Lu FJ. Baicalein and baicalin are potent inhibitors of angiogenesis: Inhibition of endothelial cell proliferation, migration and differentiation. Int J Cancer 2003; 106:559-565.
109
110. Miocinovic R, McCabe NP, Keck RW, Jankun J, Hampton JA, Selman SH. In vivo and in vitro effect of baicalein on human prostate cancer cells. Int J Oncol 2005; 26:241-246.
110
111. Nie D, Krishnamoorthy S, Jin R, Tang K, Chen Y, Qiao Y, et al. Mechanisms regulating tumor angiogenesis by 12-lipoxygenase in prostate cancer cells. J Biol Chem 2006; 281:18601-18609.
111
112. Du G, Han G, Zhang S, Lin H, Wu X, Wang M, et al. Baicalin suppresses lung carcinoma and lung metastasis by SOD mimic and HIF-1alpha inhibition. Eur J Pharmacol 2010; 630:121-130.
112
113. Gade S, Gandhi NM. Baicalein inhibits MCF-7 cell proliferation in vitro, induces radiosensitivity, and inhibits hypoxia inducible factor. J Environ Pathol Toxicol Oncol 2015; 34:299-308.
113
114. Agarwal S, Achari C, Praveen D, Roy KR, Reddy GV, Reddanna P. Inhibition of 12-LOX and COX-2 reduces the proliferation of human epidermoid carcinoma cells (A431) by modulating the ERK and PI3K-Akt signalling pathways. Exp Dermatol 2009; 18:939-946.
114
115. Bednar W, Holzmann K, Marian B. Assessing 12(S)-lipoxygenase inhibitory activity using colorectal cancer cells overexpressing the enzyme. Food Chem Toxicol 2007; 45:508-514.
115
116. Cathcart MC, Useckaite Z, Drakeford C, Semik V, Lysaght J, Gately K, et al. Anti-cancer effects of baicalein in non-small cell lung cancer in-vitro and in-vivo. BMC Cancer 2016; 16:707.
116
117. Leung HW, Yang WH, Lai MY, Lin CJ, Lee HZ. Inhibition of 12-lipoxygenase during baicalein-induced human lung nonsmall carcinoma H460 cell apoptosis. Food Chem Toxicol 2007; 45:403-411.
117
118. Li YJ, Lei YH, Yao N, Wang CR, Hu N, Ye WC, et al. Autophagy and multidrug resistance in cancer. Chin J Cancer 2017; 36:52.
118
119. Yu L, Chen Y, Tooze SA. Autophagy pathway: Cellular and molecular mechanisms. Autophagy 2018; 14:207-215.
119
120. Amaravadi R, Kimmelman AC, White E. Recent insights into the function of autophagy in cancer. Genes Dev 2016; 30:1913-1930.
120
121. Poillet-Perez L, White E. Role of tumor and host autophagy in cancer metabolism. Genes Dev 2019; 33:610-619.
121
122. Zhang X, Tang X, Liu H, Li L, Hou Q, Gao J. Autophagy induced by baicalin involves down-regulation of CD147 in SMMC-7721 cells in vitro. Oncol Rep 2012; 27:1128-1134.
122
123. Aryal P, Kim K, Park PH, Ham S, Cho J, Song K. Baicalein induces autophagic cell death through AMPK/ULK1 activation and down-regulation of mTORC1 complex components in human cancer cells. FEBS J 2014; 281:4644-4658.
123
124. Deng X, Liu J, Liu L, Sun X, Huang J, Dong J. Drp1-mediated mitochondrial fission contributes to baicalein-induced apoptosis and autophagy in lung cancer via activation of AMPK signaling pathway. Int J Biol Sci 2020; 16:1403-1416.
124
125. Lin C, Tsai SC, Tseng MT, Peng SF, Kuo SC, Lin MW, et al. AKT serine/threonine protein kinase modulates baicalin-triggered autophagy in human bladder cancer T24 cells. Int J Oncol 2013; 42:993-1000.
125
126. Tan HY, Wang N, Man K, Tsao SW, Che CM, Feng Y. Autophagy-induced RelB/p52 activation mediates tumour-associated macrophage repolarisation and suppression of hepatocellular carcinoma by natural compound baicalin. Cell Death Dis 2015; 6:e1942.
126
127. Wang YF, Li T, Tang ZH, Chang LL, Zhu H, Chen XP, et al. Baicalein triggers autophagy and inhibits the protein kinase B/mammalian target of rapamycin pathway in hepatocellular carcinoma HepG2 cells. Phytother Res 2015; 29:674-679.
127
128. Wang Z, Jiang C, Chen W, Zhang G, Luo D, Cao Y, et al. Baicalein induces apoptosis and autophagy via endoplasmic reticulum stress in hepatocellular carcinoma cells. Biomed Res Int 2014; 2014:732516.
128
129. Gao J, Morgan WA, Sanchez-Medina A, Corcoran O. The ethanol extract of Scutellaria baicalensis and the active compounds induce cell cycle arrest and apoptosis including up-regulation of p53 and Bax in human lung cancer cells. Toxicol Appl Pharmacol 2011; 254:221-228.
129
130. Lee HZ, Leung HW, Lai MY, Wu CH. Baicalein induced cell cycle arrest and apoptosis in human lung squamous carcinoma CH27 cells. Anticancer Res 2005; 25:959-964.
130
131. Chen CH, Huang TS, Wong CH, Hong CL, Tsai YH, Liang CC, et al. Synergistic anti-cancer effect of baicalein and silymarin on human hepatoma HepG2 Cells. Food Chem Toxicol 2009; 47:638-644.
131
132. Chang WH, Chen CH, Lu FJ. Different effects of baicalein, baicalin and wogonin on mitochondrial function, glutathione content and cell cycle progression in human hepatoma cell lines. Planta Med 2002; 68:128-132.
132
133. Wang N, Ren D, Deng S, Yang X. Differential effects of baicalein and its sulfated derivatives in inhibiting proliferation of human breast cancer MCF-7 cells. Chem Biol Interact 2014; 221:99-108.
133
134. Zheng YH, Yin LH, Grahn TH, Ye AF, Zhao YR, Zhang QY. Anticancer effects of baicalein on hepatocellular carcinoma cells. Phytother Res 2014; 28:1342-1348.
134
135. Cheng YH, Li LA, Lin P, Cheng LC, Hung CH, Chang NW, et al. Baicalein induces G1 arrest in oral cancer cells by enhancing the degradation of cyclin D1 and activating AhR to decrease Rb phosphorylation. Toxicol Appl Pharmacol 2012; 263:360-367.
135
136. Cogliati S, Lorenzi I, Rigoni G, Caicci F, Soriano ME. Regulation of Mitochondrial Electron Transport Chain Assembly. J Mol Biol 2018; 430:4849-4873.
136
137. Paradies G, Paradies V, Ruggiero FM, Petrosillo G. Role of cardiolipin in mitochondrial function and dynamics in health and disease: Molecular and Pharmacological Aspects. Cells 2019; 8.
137
138. Signes A, Fernandez-Vizarra E. Assembly of mammalian oxidative phosphorylation complexes I-V and supercomplexes. Essays Biochem 2018; 62:255-270.
138
139. Angelova PR, Abramov AY. Functional role of mitochondrial reactive oxygen species in physiology. Free Radic Biol Med 2016; 100:81-85.
139
140. Berry BJ, Trewin AJ, Amitrano AM, Kim M, Wojtovich AP. Use the protonmotive force: mitochondrial uncoupling and reactive oxygen species. J Mol Biol 2018; 430:3873-3891.
140
141. Grivennikova VG, Vinogradov AD. Generation of superoxide by the mitochondrial Complex I. Biochim Biophys Acta 2006; 1757:553-561.
141
142. Raimondi V, Ciccarese F, Ciminale V. Oncogenic pathways and the electron transport chain: a dangeROS liaison. Br J Cancer 2020; 122:168-181.
142
143. Halliwell B. Oxidative stress and neurodegeneration: Where are we now? J Neurochem 2006; 97:1634-1658.
143
144. Singh R, Karakoti AS, Self W, Seal S, Singh S. Redox-sensitive cerium oxide nanoparticles protect human keratinocytes from oxidative stress induced by glutathione depletion. Langmuir 2016; 32:12202-12211.
144
145. Green DR, Galluzzi L, Kroemer G. Cell biology. Metabolic control of cell death. Science 2014; 345:1250256.
145
146. Vakifahmetoglu-Norberg H, Ouchida AT, Norberg E. The role of mitochondria in metabolism and cell death. Biochem Biophys Res Commun 2017; 482:426-431.
146
147. Lee HJ, Noh YH, Lee DY, Kim YS, Kim KY, Chung YH, et al. Baicalein attenuates 6-hydroxydopamine-induced neurotoxicity in SH-SY5Y cells. Eur J Cell Biol 2005; 84:897-905.
147
148. Zhang S, Ye J, Dong G. Neuroprotective effect of baicalein on hydrogen peroxide-mediated oxidative stress and mitochondrial dysfunction in PC12 cells. J Mol Neurosci 2010; 40:311-320.
148
149. Liu B, Jian Z, Li Q, Li K, Wang Z, Liu L, et al. Baicalein protects human melanocytes from H2O2-induced apoptosis via inhibiting mitochondria-dependent caspase activation and the p38 MAPK pathway. Free Radic Biol Med 2012; 53:183-193.
149
150. Li XX, He GR, Mu X, Xu B, Tian S, Yu X, et al. Protective effects of baicalein against rotenone-induced neurotoxicity in PC12 cells and isolated rat brain mitochondria. Eur J Pharmacol 2012; 674:227-233.
150
151. Naveenkumar C, Raghunandhakumar S, Asokkumar S, Devaki T. Baicalein abrogates reactive oxygen species (ROS)-mediated mitochondrial dysfunction during experimental pulmonary carcinogenesis in vivo. Basic Clin Pharmacol Toxicol 2013; 112:270-281.
151
152. Waisundara VY, Hsu A, Tan BK, Huang D. Baicalin reduces mitochondrial damage in streptozotocin-induced diabetic Wistar rats. Diabetes Metab Res Rev 2009; 25:671-677.
152
153. Kim SJ, Moon YJ, Lee SM. Protective effects of baicalin against ischemia/reperfusion injury in rat liver. J Nat Prod 2010; 73:2003-2008.
153
154. Lin M, Li L, Li L, Pokhrel G, Qi G, Rong R, et al. The protective effect of baicalin against renal ischemia-reperfusion injury through inhibition of inflammation and apoptosis. BMC Complement Altern Med 2014; 14:19.
154
155. Ventura-Clapier R, Garnier A, Veksler V. Transcriptional control of mitochondrial biogenesis: the central role of PGC-1alpha. Cardiovasc Res 2008; 79:208-217.
155
156. Yan W, Liu J. Effects of Chinese herbal monomers on oxidative phosphorylation and membrane potential in cerebral mitochondria isolated from hypoxia-exposed rats in vitro. Neural Regen Res 2012; 7:2099-2106.
156
157. Cui L, Zhang X, Yang R, Liu L, Wang L, Li M, et al. Baicalein is neuroprotective in rat MCAO model: role of 12/15-lipoxygenase, mitogen-activated protein kinase and cytosolic phospholipase A2. Pharmacol Biochem Behav 2010; 96:469-475.
157
158. de Oliveira MR, Nabavi SF, Habtemariam S, Erdogan Orhan I, Daglia M, Nabavi SM. The effects of baicalein and baicalin on mitochondrial function and dynamics: A review. Pharmacol Res 2015; 100:296-308.
158
159. Liang W, Huang X, Chen W. The effects of baicalin and baicalein on cerebral ischemia: A review. Aging Dis 2017; 8:850-867.
159
160. Liu C, Wu J, Xu K, Cai F, Gu J, Ma L, et al. Neuroprotection by baicalein in ischemic brain injury involves PTEN/AKT pathway. J Neurochem 2010; 112:1500-1512.
160
161. Pallast S, Arai K, Pekcec A, Yigitkanli K, Yu Z, Wang X, et al. Increased nuclear apoptosis-inducing factor after transient focal ischemia: a 12/15-lipoxygenase-dependent organelle damage pathway. J Cereb Blood Flow Metab 2010; 30:1157-1167.
161
162. Qi Z, Xu Y, Liang Z, Li S, Wang J, Wei Y, et al. Baicalein alters PI3K/Akt/GSK3beta signaling pathway in rats with diabetes-associated cognitive deficits. Int J Clin Exp Med 2015; 8:1993-2000.
162
163. Zhang Z, Cui W, Li G, Yuan S, Xu D, Hoi MP, et al. Baicalein protects against 6-OHDA-induced neurotoxicity through activation of Keap1/Nrf2/HO-1 and involving PKCalpha and PI3K/AKT signaling pathways. J Agric Food Chem 2012; 60:8171-8182.
163
164. Lai MY, Hsiu SL, Chen CC, Hou YC, Chao PD. Urinary pharmacokinetics of baicalein, wogonin and their glycosides after oral administration of Scutellariae rdix in humans. Biol Pharm Bull 2003; 26:79-83.
164
165. Srinivas NR. Baicalin, an emerging multi-therapeutic agent: pharmacodynamics, pharmacokinetics, and considerations from drug development perspectives. Xenobiotica 2010; 40:357-367.
165
166. Morisaki T, Hou XL, Takahashi K, Takahashi K. Baicalin pharmacokinetic profile of absorption process using novel in-vitro model: Cytochrome P450 3A4-induced Caco-2 cell monolayers combined with rat intestinal rinse fluids. J Pharm Pharmacol 2013; 65:1526-1535.
166
167. Liu L, Deng YX, Liang Y, Pang XY, Liu XD, Liu YW, et al. Increased oral AUC of baicalin in streptozotocin-induced diabetic rats due to the increased activity of intestinal beta-glucuronidase. Planta Med 2010; 76:70-75.
167
168. Fan L, Wang JC, Jiang F, Tan ZR, Chen Y, Li Q, et al. Induction of cytochrome P450 2B6 activity by the herbal medicine baicalin as measured by bupropion hydroxylation. Eur J Clin Pharmacol 2009; 65:403-409.
168
169. Jang SI, Kim HJ, Hwang KM, Jekal SJ, Pae HO, Choi BM, et al. Hepatoprotective effect of baicalin, a major flavone from Scutellaria radix, on acetaminophen-induced liver injury in mice. Immunopharmacol Immunotoxicol 2003; 25:585-594.
169
170. Ernstgard L, Johanson G, Karlsson AS, Warholm M. Phenotyping of cytochrome P450 2E1 in vitro and in vivo. Curr Drug Metab 2007; 8:493-498.
170
171. Mo SL, Liu WF, Chen Y, Luo HB, Sun LB, Chen XW, et al. Ligand- and protein-based modeling studies of the inhibitors of human cytochrome P450 2D6 and a virtual screening for potential inhibitors from the Chinese herbal medicine, Scutellaria baicalensis (Huangqin,Baikal Skullcap). Comb Chem High Throughput Screen 2012; 15:36-80.
171
172. Tian X, Cheng ZY, He J, Jia LJ, Qiao HL. Concentration-dependent inhibitory effects of baicalin on the metabolism of dextromethorphan, a dual probe of CYP2D and CYP3A, in rats. Chem Biol Interact 2013; 203:522-529.
172
173. Ming J, Zhuoneng L, Guangxun Z. Protective role of flavonoid baicalin from Scutellaria baicalensis in periodontal disease pathogenesis: A literature review. Complement Ther Med 2018; 38:11-18.
173
174. Yan WJ, Ma XC, Gao XY, Xue XH, Zhang SQ. Latest research progress in the correlation between baicalein and breast cancer invasion and metastasis. Mol Clin Oncol 2016; 4:472-476.
174
ORIGINAL_ARTICLE
In vivo solid tumor targeting with recombinant VEGF-diphtheria immunotoxin
Objective(s): A variety of signaling molecules have been identified that play a role in angiogenesis, of prime importance, vascular endothelial growth factor (VEGF) and its resceptor (VEGFR), which is highly expressed in most human solid tumors. Targeting VEGF or/and VEGFR with immunotoxin may be a promising approach to directly affect cancer cells. Immunotoxins are for targeted treatment comprising two functional moieties, an antibody that binds to target cells along with toxin that kills molecules. Materials and Methods: In this study, an immunotoxin comprising domain of diphtheria toxin subunit A (DT386) genetically fused to mouse VEGF (mVEGF-DT) was developed. The second construct, which contains the DT386 domain, was made to investigate the action of the DT386 domain on tumor cells. Both gene constructs were cloned, expressed, and were further purified. The biological activity of mVEGF-DT and DT386 proteins was assessed on the TC1 cell line bearing mouse model. Proteins were injected intra-tumoral in mice, in separate groups. Results: Tumors in the mVEGF-DT group started to dwindle after six injections, but tumor size in both control groups (DT386 and PBS), continued to grow. Conclusion: Successful targeting of solid tumor cells by mVEGF-DT immunotoxin demonstrates the therapeutic potential utility of these conjugates for tumor targeting.
https://ijbms.mums.ac.ir/article_19108_6007af86ddcf194520f441d519302e32.pdf
2022-01-01
27
31
10.22038/ijbms.2021.54293.12195
Angiogenesis
Immunotherapy
Immunotoxin
Tumor
Vascular endothelial growth - factor (VEGF)
Mohammad
Hosseininejad-Chafi
hoseininejad62@gmail.com
1
Biotechnology Research Center, Venom & Biotherapeutics Molecules Lab, Pasteur Institute of Iran, Tehran, Iran
AUTHOR
Ehsan
Alirahimi
ehsan.ali70@gmail.com
2
Biotechnology Research Center, Venom & Biotherapeutics Molecules Lab, Pasteur Institute of Iran, Tehran, Iran
AUTHOR
Behzad
Ramezani
behzad126@gmail.com
3
Biotechnology Research Center, Venom & Biotherapeutics Molecules Lab, Pasteur Institute of Iran, Tehran, Iran
AUTHOR
Akbar
Oghalaei
aoghalaie@gmail.com
4
Biotechnology Research Center, Venom & Biotherapeutics Molecules Lab, Pasteur Institute of Iran, Tehran, Iran
AUTHOR
Nazli
Sotoudeh
nazli_sotoudeh@yahoo.com
5
Biotechnology Research Center, Venom & Biotherapeutics Molecules Lab, Pasteur Institute of Iran, Tehran, Iran
AUTHOR
Hajarsadat
Ghaderi
hajar.ghadery@gmail.com
6
Biotechnology Research Center, Venom & Biotherapeutics Molecules Lab, Pasteur Institute of Iran, Tehran, Iran
AUTHOR
Fatemeh
Kazemi-Lomedasht
fa_kazemi@pasteur.ac.ir
7
Biotechnology Research Center, Venom & Biotherapeutics Molecules Lab, Pasteur Institute of Iran, Tehran, Iran
AUTHOR
Mahdi
Habibi-Anbouhi
habibi.mha@gmail.com
8
National Cell Bank, Pasteur Institute of Iran, Tehran, Iran
AUTHOR
Reza
Moazzami
r.moazzami@gmail.com
9
Human Genetics Research Center, Baqiyatallah University of Medical Sciences, Tehran, Iran
AUTHOR
Mahdi
Behdani
behdani@pasteur.ac.ir
10
Biotechnology Research Center, Venom & Biotherapeutics Molecules Lab, Pasteur Institute of Iran, Tehran, Iran
LEAD_AUTHOR
1. Sitohy B, Nagy JA, Dvorak HF. Anti-VEGF/VEGFR therapy for cancer: reassessing the target. Cancer Res 2012; 72:1909-1914.
1
2. Neufeld G, Cohen T, Gengrinovitch S, Poltorak Z. Vascular endothelial growth factor (VEGF) and its receptors. FASEB J 1999; 13:9-22.
2
3. Folkman J, Hanahan D, editors. Switch to the angiogenic phenotype during tumorigenesis. Princess Takamatsu Symp 1991; 22:339-347.
3
4. Folkman J. What is the evidence that tumors are angiogenesis dependent?. J Natl Cancer Inst 1990; 82:4-6.
4
5. Eichmann A, Simons M. VEGF signaling inside vascular endothelial cells and beyond. Curr Opin Cell Biol 2012; 24:188-193.
5
6. Carmeliet P, Jain RK. Molecular mechanisms and clinical applications of angiogenesis. Nature 2011; 473:298-307.
6
7. Mohseni N, Jahanian-Najafabadi A, Kazemi-Lomedasht F, Arezomand R, Habibi-Anbouhi M, Shahbazzadeh D, et al. Recombinant expression and purification of functional vascular endothelial growth factor-121 in the baculovirus expression system. Asian Pac J Trop Med 2016; 9:1195-1199.
7
8. Kazemi-Lomedasht F, Pooshang-Bagheri K, Habibi-Anbouhi M, Hajizadeh-Safar E, Shahbazzadeh D, Mirzahosseini H, et al. In vivo immunotherapy of lung cancer using cross-species reactive vascular endothelial growth factor nanobodies. Iran J Basic Med Sci 2017; 20:489-496.
8
9. Alirahimi E, Ashkiyan A, Kazemi-Lomedasht F, Azadmanesh K, Hosseininejad-Chafi M, Habibi-Anbouhi M, et al. Intrabody targeting vascular endothelial growth factor receptor-2 mediates downregulation of surface localization. Cancer Gene Ther 2017; 24:33-37.
9
10. Moolten FL, Cooperband SR. Selective destruction of target cells by diphtheria toxin conjugated to antibody directed against antigens on the cells. Science 1970; 169:68-70.
10
11. Krolick K, Villemez C, Isakson P, Uhr J, Vitetta E. Selective killing of normal or neoplastic B cells by antibodies coupled to the A chain of ricin. PNAS USA 1980; 77:5419.
11
12. Cawley DB, Herschman HR, Gilliland DG, Collier RJ. Epidermal growth factor-toxin A chain conjugates: EGF-ricin A is a potent toxin while EGF-diphtheria fragment A is nontoxic. Cell 1980; 22:563-570.
12
13. Kreitman RJ. Immunotoxins for targeted cancer therapy. AAPS J 2006; 8:E532-E551.
13
14. Borthakur G, Rosenblum MG, Talpaz M, Daver N, Ravandi F, Faderl S, et al. Phase 1 study of an anti-CD33 immunotoxin, humanized monoclonal antibody M195 conjugated to recombinant gelonin (HUM-195/rGEL), in patients with advanced myeloid malignancies. Haematologica 2013; 98:217-221.
14
15. Hassan R, Sharon E, Thomas A, Zhang J, Ling A, Miettinen M, et al. Phase 1 study of the antimesothelin immunotoxin SS1P in combination with pemetrexed and cisplatin for front‐line therapy of pleural mesothelioma and correlation of tumor response with serum mesothelin, megakaryocyte potentiating factor, and cancer antigen 125. Cancer 2014; 120:3311-3319.
15
16. Zhang Y, Schulte W, Pink D, Phipps K, Zijlstra A, Lewis JD, et al. Sensitivity of cancer cells to truncated diphtheria toxin. PLoS One 2010; 5:e10498.
16
17. Shafiee F, Rabbani M, Behdani M, Jahanian-Najafabadi A. Expression and purification of truncated diphtheria toxin, DT386, in Escherichia coli: An attempt for production of a new vaccine against diphtheria. Res Pharm Sci 2016; 11:428-434.
17
18. Ramakrishnan S, Olson T, Bautch VL, Mohanraj D. Vascular endothelial growth factor-toxin conjugate specifically inhibits KDR/flk-1-positive endothelial cell proliferation in vitro and angiogenesis in vivo. Cancer Res 1996; 56:1324-1330.
18
19. Shafiee F, Rabbani M, Jahanian-Najafabadi A. Production and evaluation of cytotoxic effects of DT386-BR2 fusion protein as a novel anti-cancer agent. J Microbiol Methods 2016; 130:100-105.
19
20. Maruyama D, Tobinai K, Ando K, Ohmachi K, Ogura M, Uchida T, et al. Phase I study of E7777, a diphtheria toxin fragment-interleukin-2 fusion protein, in japanese patients with relapsed or refractory peripheral and cutaneous t-cell lymphoma. Blood 2015; 126:2724-2724.
20
21. Urieto JO, Liu T, Black JH, Cohen KA, Hall PD, Willingham MC, et al. Expression and purification of the recombinant diphtheria fusion toxin DT 388 IL3 for phase I clinical trials. Protein Expr Purif 2004; 33:123-133.
21
22. Hogge DE, Yalcintepe L, Wong S-H, Gerhard B, Frankel AE. Variant diphtheria toxin-interleukin-3 fusion proteins with increased receptor affinity have enhanced cytotoxicity against acute myeloid leukemia progenitors. Clin Cancer Res 2006; 12:1284-1291.
22
23. Xanthopoulos J, Romano A, Majumdar SK. Response of mouse breast cancer cells to anastrozole, tamoxifen, and the combination. Biomed Res Int 2005; 2005:10-19.
23
24. Pastan I, Hassan R, FitzGerald DJ, Kreitman RJ. Immunotoxin treatment of cancer. Annu Rev Med 2007; 58:221-237.
24
25. Spiess K, Jeppesen MG, Malmgaard-Clausen M, Krzywkowski K, Kledal TN, Rosenkilde MM. Novel Chemokine-Based Immunotoxins for Potent and Selective Targeting of Cytomegalovirus Infected Cells. J Immunol Res 2017; 2017:4069260.
25
26. Yamaizumi M, Mekada E, Uchida T, Okada Y. One molecule of diphtheria toxin fragment A introduced into a cell can kill the cell. Cell 1978; 15:245-250.
26
27. Thorpe P, Ross W, Cumber A, Hinson C, Edwards D, Davies A. Toxicity of diphtheria toxin for lymphoblastoid cells is increased by conjugation to antilymphocytic globulin. Nature 1978; 23;271.
27
28. Bennett MJ, Eisenberg D. Refined structure of monomeric diphtheria toxin at 2.3 A resolution. Protein Sci 1994; 3:1464-1475.
28
29. Olsen E, Duvic M, Frankel A, Kim Y, Martin A, Vonderheid E, et al. Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma. J Clin Oncol 2001; 19:376-388.
29
30. Lin AY, Dinner SN. Moxetumomab pasudotox for hairy cell leukemia: preclinical development to FDA approval. Blood Adv 2019; 3:2905-2910.
30
31. Wang C, Gao W, Feng M, Pastan I, Ho M. Construction of an immunotoxin, HN3-mPE24, targeting glypican-3 for liver cancer therapy. Oncotarget 2016.
31
32. Hollevoet K, Mason-Osann E, Liu X-f, Imhof-Jung S, Niederfellner G, Pastan I. In vitro and in vivo activity of the low-immunogenic antimesothelin immunotoxin RG7787 in pancreatic cancer. Mol Cancer Ther 2014; 13:2040-2049.
32
33. Stepanov A, Belyy A, Kasheverov I, Rybinets A, Dronina M, Dyachenko I, et al. Development of a recombinant immunotoxin for the immunotherapy of autoreactive lymphocytes expressing MOG-specific BCRs. Biotechnol Lett 2016:1-8.
33
34. Robinson CJ, Stringer SE. The splice variants of vascular endothelial growth factor (VEGF) and their receptors. J Cell Sci 2001; 114:853-865.
34
35. Shojaei F. Anti-angiogenesis therapy in cancer: Current challenges and future perspectives. Cancer Lett 2012; 320:130-137.
35
36. Wild R, Dhanabal M, Olson T, Ramakrishnan S. Inhibition of angiogenesis and tumour growth by VEGF121–toxin conjugate: Differential effect on proliferating endothelial cells. Br J Cancer 2000; 83:1077.
36
37. Backer MV, Budker VG, Backer JM. Shiga-like toxin-VEGF fusion proteins are selectively cytotoxic to endothelial cells overexpressing VEGFR-2. J Control Release 2001; 74:349-355.
37
38. Veenendaal LM, Jin H, Ran S, Cheung L, Navone N, Marks JW, et al. In vitro and in vivo studies of a VEGF121/rGelonin chimeric fusion toxin targeting the neovasculature of solid tumors. Proc Natl Acad Sci U S A 2002; 99:7866-7871.
38
39. Hu Cc, Ji Hm, Chen Sl, Zhang Hw, Wang Bq, Zhou Ly, et al. Investigation of a plasmid containing a novel immunotoxin VEGF165‐PE38 gene for antiangiogenic therapy in a malignant glioma model. Int J Cancer 2010; 127:2222-2229.
39
40. Behdani M, Zeinali S, Karimipour M, Khanahmad H, Schoonooghe S, Aslemarz A, et al. Development of VEGFR2-specific Nanobody Pseudomonas exotoxin A conjugated to provide efficient inhibition of tumor cell growth. N Biotechnol 2013; 30:205-209.
40
41. Ramakrishnan S, Olson T, Bautch V, Mohanraj D. Vascular endothelial growth factor-toxin conjugate specifically inhibits KDR/flk-1-positive endothelial cell proliferation in vitro and angiogenesis in vivo. Cancer Res 1996; 56:1324-1330.
41
ORIGINAL_ARTICLE
Decrescent role of recombinant HSP60 antibody against atherosclerosis in high-cholesterol diet immunized rabbits
Objective(s): Atherosclerosis is the main cause of cardiovascular disease (CVD) which has a key role in the development of coronary artery disease (CAD). Based on clinical studies, HSP60 is the only HSP that can cause atherosclerosis. In this paper, the expression level of HSP60 and the pathogenic degree of its cloned part was investigated in atherosclerosis condition.Materials and Methods: After the designation of the specific primers for HSP60, PCR was done by the Pfu enzyme. Subsequently, the PCR products were cloned into a prokaryotic expression vector pET-28a. The resultant recombinant vector was transferred in BL21 and purified. Purification of protein was done by the Nickel affinity column. After confirmation of Western blotting and HSP60 protein purification, purified protein concentration was measured by the Bradford method, and purity was analyzed by SDS PAGE 12%. New Zealand rabbits were tested as an animal model. At the next step, the recombinant protein was injected into the animal model that was on a fatty diet.Results: The prokaryotic expression plasmid pET28a-hps60 was successfully constructed, the HSP60 protein was expressed and purified in Escherichia coli BL21 (DE3). We found that the rabbit that was receiving the recombinant vaccine with the fatty diet showed a lower amount of fat deposition at the media endothelial level than the rabbit which received only the fatty diet. Conclusion: Taking recombinant protein concomitant with a fatty diet, causes betterment of atherosclerosis via decreasing aggregation of cholesterol and thickness of the endothelial media.
https://ijbms.mums.ac.ir/article_19302_fb8baf1f7f078a55a7f44b79af5081cc.pdf
2022-01-01
32
38
10.22038/ijbms.2021.56382.12580
Atherosclerosis
Coronary Artery Disease
Heat- shock proteins
Plasmids
Recombinant protein
Saghar
Zonnar
sagharzonar@yahoo.com
1
Department of Biology, Science and Research Branch, Islamic Azad University, Tehran, Iran
AUTHOR
Said Abdul Ghafour
Saeedy
saeedysaidghafour@yahoo.com
2
Department of Paraclinic, School of Medicine, Herat University, Herat, Afghanistan
AUTHOR
Fahimeh
Nemati
f_nemati@yahoo.com
3
Department of Biotechnology, Faculty of Advanced Science and Technology, Tehran Medical Sciences, Islamic Azad University (IAUPS), Tehran, Iran
AUTHOR
Mohammad Javad
Motamedi
j.motamedi@yahoo.com
4
Department of Plant Bioproducts, Institute of Agricultural Biotechnology, National Institute of Genetic Engineering and Biotechnology (NIGEB), Tehran, Iran
AUTHOR
Hamidreza
Raeespour
hraeespour@yahoo.com
5
Department of Genetics, Islamic Azad University, Varamin Pishva Branch, Tehran, Iran
AUTHOR
Jafar
Amani
jafar.amani@gmail.com
6
Applied Microbiology Research Center, Systems Biology and Poisonings Institute, Baqiyatallah University of Medical Sciences, Tehran, Iran
LEAD_AUTHOR
1. Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation 2002; 105:1135-1143.
1
2. Hansson GK, Libby P. The immune response in atherosclerosis: A double-edged sword. Nat Rev Immunol 2006; 6:508-519.
2
3. Bernhagen J, Krohn R, Lue H, Gregory JL, Zernecke A, Koenen RR, et al. MIF is a noncognate ligand of CXC chemokine receptors in inflammatory and atherogenic cell recruitment. Nat Med 2007; 13:587-596.
3
4. Harvey EJ, Ramji DP. Interferon-γ and atherosclerosis: pro-or anti-atherogenic? Cardiovasc Res 2005; 67:11-20.
4
5. Kleemann R, Zadelaar S, Kooistra T. Cytokines and atherosclerosis:
5
A comprehensive review of studies in mice. Cardiovasc Res 2008; 79:360-376.
6
6. Sepanlou SG, Newson RB, Poustchi H, Malekzadeh MM, Asl PR, Etemadi A, et al. Cardiovascular disease deaths and years of life lost attributable to non-optimal systolic blood pressure and hypertension in Northeastern Iran. Arch Iran Med 2015; 18:144.
7
7. van Puijvelde GH, van Es T, Van Wanrooij E, Habets K, De Vos P, Van Der Zee R, et al. Induction of oral tolerance to HSP60 or an HSP60-peptide activates T cell regulation and reduces atherosclerosis. Arterioscler Thromb Vasc Biol 2007; 27:2677-2683.
8
8. Shatilina ZM, Riss HW, Protopopova MV, Trippe M, Meyer EI, Pavlichenko VV, et al. The role of the heat shock proteins (HSP70 and sHSP) in the thermotolerance of freshwater amphipods from contrasting habitats. J Therm Biol 2011; 36:142-149.
9
9. Lu X, Kakkar V. The role of heat shock protein (HSP) in atherosclerosis: Pathophysiology and clinical opportunities. Curr Med Chem 2010; 17:957-973.
10
10. Kaufman BA, Kolesar JA, Perlman PS, Butow RA. Studies on mitochondrial DNA nucleoids in Saccharomyces cerevisiae: Identification of bifunctional proteins. J Cell Biol 2003; 163:457-461.
11
11. Ghosh JC, Dohi T, Kang BH, Altieri DC. Hsp60 regulation of tumor cell apoptosis. J Biol Chem 2008; 283:5188-5194.
12
12. Zininga T, Ramatsui L, Shonhai A. Heat shock proteins as immunomodulants. Molecules 2018; 23:2846.
13
13. Kim DS, Ko YJ, Lee MW, Park HJ, Park YJ, Kim D-I, et al. Effect of low oxygen tension on the biological characteristics of human bone marrow mesenchymal stem cells. Cell Stress Chaperones 2016; 21:1089-1099.
14
14. Urban-Chmiel R, Dec M, Puchalski A, Wernicki A. Characterization of heat-shock proteins in Escherichia coli strains under thermal stress in vitro. J Med microbiol 2013; 62:1897-1901.
15
15. Wick C. Tolerization against atherosclerosis using heat shock protein 60. Cell Stress Chaperones 2016; 21:201-211.
16
16. Jia C, Ma X, Liu Z, Gu J, Zhang X, Li D, et al. Different Heat Shock Proteins Bind α-Synuclein With Distinct Mechanisms and Synergistically Prevent Its Amyloid Aggregation. Front Neurosci 2019; 13.
17
17. Huang X, Dong H, Ting Z. Cloning, expression of a truncated HSP110 protein that augments the activities of tumor antigen-specific cytotoxic and apoptosis via tHSP110-peptide complex vaccines. Int J Clin Exp Pathol 2017; 10:10304-10314.
18
18. Zhang X, He M, Cheng L, Chen Y, Zhou L, Zeng H, et al. Elevated heat shock protein 60 levels are associated with higher risk of coronary heart disease in Chinese. Circulation 2008; 118:2687-2693.
19
19. Zhang Y, Xiong Q, Hu X, Sun Y, Tan X, Zhang H, et al. A novel atherogenic epitope from Mycobacterium tuberculosis heat shock protein 65 enhances atherosclerosis in rabbit and LDL receptor-deficient mice. Heart Vessels 2012; 27:411-418.
20
20. Ghayour-Mobarhan M, Lamb DJ, Tavallaie S, Ferns GA. Relationship between plasma cholesterol, von Willebrand factor concentrations, extent of atherosclerosis and antibody titres to heat shock proteins-60, -65 and -70 in cholesterol-fed rabbits. Int J Exp Pathol 2007; 88:249-255.
21
21. Khera AV, Cuchel M, De La Llera-Moya M, Rodrigues A, Burke MF, Jafri K, et al. Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis. N Engl J Med 2011; 364:127-135.
22
22. Gaofu Q, Jun L, Xiuyun Z, Wentao L, Jie W, Jingjing L. Antibody against cholesteryl ester transfer protein (CETP) elicited by a recombinant chimeric enzyme vaccine attenuated atherosclerosis in a rabbit model. Life Sci 2005; 77:2690-2702.
23
23. George J, Afek A, Gilburd B, Shoenfeld Y, Harats D. Cellular and humoral immune responses to heat shock protein 65 are both involved in promoting fatty-streak formation in LDL-receptor deficient mice. J Am Coll of Cardiol 2001; 38:900-905.
24
24. Ghayour-Mobarhan M, Rahsepar A, Tavallaie S, Rahsepar S, Ferns G. The potential role of heat shock proteins in cardiovascular disease: evidence from in vitro and in vivo studies. Adv Clin Chem 2009; 48:27-72.
25
25. Lamb DJ, Ferns GA. The magnitude of the immune response to heat shock protein-65 following BCG immunisation is associated with the extent of experimental atherosclerosis. Atherosclerosis 2002; 165:231-240.
26
ORIGINAL_ARTICLE
Chronic treatment with coenzyme Q10 mitigates the behavioral dysfunction of global cerebral ischemia/reperfusion injury in rats
Objective(s): The Ischemia/reperfusion (I/R) phenomenon has a critical role in brain injuries induced by some kinds of stroke. The current study investigates the effects of Coenzyme Q10 (Q10) on global cerebral I/R in rats. Materials and Methods: Fifty male Wistar rats were used in this study. The global cerebral I/R was induced by obstructing both common carotid arteries for 20 min and the animals were treated with Q10 (200 mg/kg; PO.) for 6 weeks. Depressive and anxiety-like behaviors were assessed using the elevated plus-maze and forced swimming test, respectively. Working and spatial learning and memory were assessed by the Y-maze continuous alternation task and Morris water maze. The brain tissues were evaluated for brain edema, brain-derived neurotrophic factor (BDNF) levels, and superoxide dismutase (SOD) activities. Results: Our results indicated that global cerebral I/R increased anxiety and depression-like behavior as well as reduced cognitive performance. Moreover, the levels of BDNF and activities of SOD are reduced in stroke animals. Chronic post-stroke treatment with Q10 decreased brain edema. Furthermore, Q10 administration reduced anxiety and depressive-like behavior as well as cognitive impairments in stroke animals. Q10 also increased the SOD activities and BDNF levels in the brain tissues of stroke animals. Conclusion: Finally, we can conclude that using Q10 supplementation may be beneficial against the global cerebral I/R complications.
https://ijbms.mums.ac.ir/article_19479_633a23e10bdc1197b280a50703e94750.pdf
2022-01-01
39
45
10.22038/ijbms.2022.57630.12865
Brain Injuries
Free radicals
Ischemia/Reperfusion
Q10
Rat
Iman
Fatemi
imanfatemi@gmail.com
1
Research Center of Tropical and Infectious Diseases, Kerman University of Medical Sciences, Kerman, Iran
AUTHOR
Pooya
Saeed Askari
pooyasaeedaskary@gmail.com
2
Student Research Committee, Rafsanjan University of Medical Sciences, Rafsanjan, Iran
AUTHOR
Elham
Hakimizadeh
hakimizadeh_elham@yahoo.com
3
Physiology-Pharmacology Research Center, Research Institute of Basic Medical Sciences, Rafsanjan University of Medical Sciences, Rafsanjan, Iran
AUTHOR
Ayat
Kaeidi
a.kaeidi@rums.ac.ir
4
Physiology-Pharmacology Research Center, Research Institute of Basic Medical Sciences, Rafsanjan University of Medical Sciences, Rafsanjan, Iran
AUTHOR
Sogand
Esmaeil-Moghaddam
esmaeil-moghaddam_s@yahoo.com
5
Student Research Committee, Rafsanjan University of Medical Sciences, Rafsanjan, Iran
AUTHOR
Mohammad
Pak-Hashemi
mohamad.pak.hashemi@gmail.com
6
Student Research Committee, Rafsanjan University of Medical Sciences, Rafsanjan, Iran
AUTHOR
Mohammad
Allahtavakoli
mohammadatir@yahoo.com
7
Physiology-Pharmacology Research Center, Research Institute of Basic Medical Sciences, Rafsanjan University of Medical Sciences, Rafsanjan, Iran
LEAD_AUTHOR
1. Ahad MA, Kumaran KR, Ning T, Mansor NI, Effendy MA, Damodaran T, et al., Insights into the neuropathology of cerebral ischemia and its mechanisms. Rev Neurosci 2020; 31: 521-538.
1
2. Fatemi I, Saeed-Askari P, Hakimizadeh E, Kaeidi A, Esmaeil-Moghaddam S, Pak-Hashemi M, et al., Long-term metformin therapy improves neurobehavioral functions and antioxidative activity after cerebral ischemia/reperfusion injury in rats. Brain Res Bull 2020; 163: 65-71.
2
3. Sharma D, Maslov LN, Singh N, and Jaggi AS, Remote ischemic preconditioning-induced neuroprotection in cerebral ischemia-reperfusion injury: Preclinical evidence and mechanisms. Eur J Pharmacol 2020: 173380.
3
4. Hakimizadeh E, Shamsizadeh A, Roohbakhsh A, Arababadi MK, Hajizadeh MR, Shariati M, et al., TRPV1 receptor-mediated expression of Toll-like receptors 2 and 4 following permanent middle cerebral artery occlusion in rats. Iran J Basic Med Sci 2017; 20: 863-869.
4
5. Lindblom RPF, Tovedal T, Norlin B, Hillered L, Englund E, Thelin S. Mechanical reperfusion following prolonged global cerebral ischemia attenuates brain injury. J Cardiovasc Transl Res 2020.
5
6. Alimohamadi R, Fatemi I, Naderi S, Hakimizadeh E, Rahmani MR, and Allahtavakoli M, Protective effects of Vitex agnus-castus in ovariectomy mice following permanent middle cerebral artery occlusion. Iran J Basic Med Sci 2019; 22: 1097-1101.
6
7. Farhadi Moghadam B and Fereidoni M, Neuroprotective effect of menaquinone-4 (MK-4) on transient global cerebral ischemia/reperfusion injury in rat. PLoS One 2020; 15: e0229769.
7
8. Salehi C, Seiiedy M, Soraya H, Fazli F, and Ghasemnejad-Berenji M, Pretreatment with bisoprolol and vitamin E alone or in combination provides neuroprotection against cerebral ischemia/reperfusion injury in rats. Naunyn Schmiedebergs Arch Pharmacol 2021; 394: 685-695.
8
9. Hassonizadeh Falahieh K, Sarkaki A, Edalatmanesh M, Gharib Naseri MK, and Farbood Y, Ellagic acid attenuates post-cerebral ischemia and reperfusion behavioral deficits by decreasing brain tissue inflammation in rats. Iran J Basic Med Sci 2020; 23: 645-653.
9
10. Turunen M, Olsson J, and Dallner G, Metabolism and function of coenzyme Q. Biochim Biophys Acta 2004; 1660: 171-199.
10
11. Akbari A, Mobini GR, Agah S, Morvaridzadeh M, Omidi A, Potter E, et al., Coenzyme Q10 supplementation and oxidative stress parameters: A systematic review and meta-analysis of clinical trials. Eur J Clin Pharmacol 2020; 76:1483-1499.
11
12. Nagib MM, Tadros MG, Rahmo RM, Sabri NA, Khalifa AE, and Masoud SI, Ameliorative Effects of α-Tocopherol and/or Coenzyme Q10 on Phenytoin-Induced Cognitive Impairment in Rats: Role of VEGF and BDNF-TrkB-CREB Pathway. Neurotox Res 2019; 35: 451-462.
12
13. Attia H, Albuhayri S, Alaraidh S, Alotaibi A, Yacoub H, Mohamad R, et al., Biotin, coenzyme Q10, and their combination ameliorate aluminium chloride-induced Alzheimer’s disease via attenuating neuroinflammation and improving brain insulin signaling. J Biochem Mol Toxicol 2020: e22519.
13
14. Park HW, Park CG, Park M, Lee SH, Park HR, Lim J, et al., Intrastriatal administration of coenzyme Q10 enhances neuroprotection in a Parkinson’s disease rat model. Sci Rep 2020; 10: 1-12.
14
15. Grieb P, Ryba MS, Sawicki J, and Chrapusta SJ, Oral coenzyme Q10 administration prevents the development of ischemic brain lesions in a rabbit model of symptomatic vasospasm. Acta Neuropathol 1997; 94: 363-368.
15
16. Yi YY, Shin HJ, Choi SG, Kang JW, Song HJ, Kim SK, et al., Preventive effects of neuroprotective agents in a neonatal rat of photothrombotic stroke model. Int J Mol Sci 2020; 21.
16
17. Belousova M, Tokareva OG, Gorodetskaya E, Kalenikova EI, and Medvedev OS, Intravenous treatment with coenzyme Q10 improves neurological outcome and reduces infarct volume after transient focal brain ischemia in rats. J Cardiovasc Pharmacol 2016; 67: 103-109.
17
18. Li H, Klein G, Sun P, and Buchan AM, CoQ10 fails to protect brain against focal and global ischemia in rats. Brain Res 2000; 877: 7-11.
18
19. Özalp B, Elbey H, Aydın H, Tekkesin MS, and Uzun H, The effect of coenzyme Q10 on venous ischemia reperfusion injury. J Surg Res 2016; 204: 304-310.
19
20. Erfani S, Khaksari M, Oryan S, Shamsaei N, Aboutaleb N, Nikbakht F, et al., Visfatin reduces hippocampal CA1 cells death and improves learning and memory deficits after transient global ischemia/reperfusion. Neuropeptides 2015; 49: 63-68.
20
21. Fatemi I, Delrobaee F, Bahmani M, Shamsizadeh A, and Allahtavakoli M, The effect of the anti-diabetic drug metformin on behavioral manifestations associated with ovariectomy in mice. Neurosci Lett 2019; 690: 95-98.
21
22. Hakimizadeh E, Kaeidi A, Taghipour Z, Mehrzadi S, Allahtavakoli M, Shamsizadeh A, et al., Ceftriaxone improves senile neurocognition damages induced by D-galactose in mice. Iran J Basic Med Sci 2020; 23: 368-375.
22
23. Rahmati B, Kiasalari Z, Roghani M, Khalili M, and Ansari F, Antidepressant and anxiolytic activity of Lavandula officinalis aerial parts hydroalcoholic extract in scopolamine-treated rats. Pharm Biol 2017; 55: 958-965.
23
24. Hughes RN, The value of spontaneous alternation behavior (SAB) as a test of retention in pharmacological investigations of memory. Neurosci Biobehav Rev 2004; 28: 497-505.
24
25. Mozafari N, Shamsizadeh A, Fatemi I, Allahtavakoli M, Moghadam-Ahmadi A, Kaviani E, et al., CX691 as an AMPA receptor positive modulator, improves the learning and memory in a rat model of Alzheimer’s disease. Iran J Basic Med Sci 2018; 21: 724-730.
25
26. Anisimov VN, Berstein LM, Egormin PA, Piskunova TS, Popovich IG, Zabezhinski MA, et al., Metformin slows down aging and extends life span of female SHR mice. Cell Cycle 2008; 7: 2769-2773.
26
27. Kaviani E, Rahmani M, Kaeidi A, Shamsizadeh A, Allahtavakoli M, Mozafari N, et al., Protective effect of atorvastatin on d-galactose-induced aging model in mice. Behav Brain Res 2017; 334: 55-60.
27
28. Shadman J, Sadeghian N, Moradi A, Bohlooli S, and Panahpour H, Magnesium sulfate protects blood-brain barrier integrity and reduces brain edema after acute ischemic stroke in rats. Metab Brain Dis 2019; 34:1221-1229.
28
29. Fatemi I, Khaluoi A, Kaeidi A, Shamsizadeh A, Heydari S, and Allahtavakoli MA, Protective effect of metformin on D-galactose-induced aging model in mice. Iran J Basic Med Sci 2018; 21: 19-25.
29
30. Fatemi I, Heydari S, Kaeidi A, Shamsizadeh A, Hakimizadeh E, Khaluoi A, et al., Metformin ameliorates the age-related changes of d-galactose administration in ovariectomized mice. Fundam Clin Pharmacol 2018; 32: 392-399.
30
31. Enzmann G, Kargaran S, and Engelhardt B, Ischemia-reperfusion injury in stroke: impact of the brain barriers and brain immune privilege on neutrophil function. Ther Adv Neurol Disord 2018; 11: 1756286418794184.
31
32. Siti HN, Kamisah Y, and Kamsiah J, The role of oxidative stress, anti-oxidants and vascular inflammation in cardiovascular disease (a review). Vascul Pharmacol 2015; 71: 40-56.
32
33. Chang CY, Chen JY, Wu MH, and Hu ML, Therapeutic treatment with vitamin C reduces focal cerebral ischemia-induced brain infarction in rats by attenuating disruptions of blood brain barrier and cerebral neuronal apoptosis. Free Radic Biol Med 2020; 155: 29-36.
33
34. Yang J, Yuan L, Wen Y, Zhou H, Jiang W, Xu D, et al., Protective effects of naringin in cerebral infarction and its molecular mechanism. Med Sci Monit 2020; 26: e918772.
34
35. Ayoobi F, Shamsizadeh A, Fatemi I, Vakilian A, Allahtavakoli M, Hassanshahi G, et al., Bio-effectiveness of the main flavonoids of Achillea millefolium in the pathophysiology of neurodegenerative disorders- a review. Iran J Basic Med Sci 2017; 20: 604-612.
35
36. Onaolapo OJ, Odeniyi AO, Jonathan SO, Samuel MO, Amadiegwu D, Olawale A, et al., An investigation of the anti-Parkinsonism potential of co-enzyme Q10 and co-enzyme Q10 /levodopa-carbidopa combination in mice. Curr Aging Sci 2019; 14:62-75.
36
37. Ibrahim Fouad G. Combination of omega 3 and coenzyme Q10 exerts neuroprotective potential against hypercholesterolemia-induced alzheimer’s-like disease in rats. Neurochem Res 2020; 45: 1142-1155.
37
38. Kumar A, Pareek V, Faiq MA, Kumar P, Raza K, Prasoon P, et al., Regulatory role of NGFs in neurocognitive functions. Rev Neurosci 2017; 28: 649-673.
38
39. Kowianski P, Lietzau G, Czuba E, Waskow M, Steliga A, Morys J. BDNF: A key factor with multipotent impact on brain signaling and synaptic plasticity. Cell Mol Neurobiol 2017; 38:579-593.
39
40. Beeri MS and Sonnen J, Brain BDNF expression as a biomarker for cognitive reserve against Alzheimer disease progression. Neurology 2016; 86: 702-703.
40
41. Abuelezz SA, Hendawy N, and Magdy Y, The potential benefit of combined versus monotherapy of coenzyme Q10 and fluoxetine on depressive-like behaviors and intermediates coupled to Gsk-3β in rats. Toxicol Appl Pharmacol 2018; 340: 39-48.
41
42. Milanlioglu A, Aslan M, Ozkol H, Cilingir V, Nuri Aydin M, and Karadas S, Serum anti-oxidant enzymes activities and oxidative stress levels in patients with acute ischemic stroke: influence on neurological status and outcome. Wien Klin Wochenschr 2016; 128: 169-174.
42
43. Liu Z, Cai Y, Zhang X, Zhu Z, and He J, High serum levels of malondialdehyde and antioxidant enzymes are associated with post-stroke anxiety. Neurol Sci 2018; 39: 999-1007.
43
44. Jiao L, Zhang J, Li Z, Liu H, Chen Y, and Xu S, Edaravone alleviates delayed neuronal death and long-dated cognitive dysfunction of hippocampus after transient focal ischemia in Wistar rat brains. Neuroscience 2011; 182: 177-183.
44
45. Nabavi SF, Habtemariam S, Di Lorenzo A, Sureda A, Khanjani S, Nabavi SM, et al. Post-stroke depression modulation and in vivo antioxidant activity of gallic acid and its synthetic derivatives in a murine model system. Nutrients 2016; 8:1-13.
45
46. Gupta V, Dhull DK, Joshi J, Kaur S, and Kumar A, Neuroprotective potential of azilsartan against cerebral ischemic injury: Possible involvement of mitochondrial mechanisms. Neurochem Int 2020; 132: 104604.
46
47. Yang M, Lian N, Yu Y, Wang Y, Xie K, and Yu Y, Coenzyme Q10 alleviates sevoflurane‑induced neuroinflammation by regulating the levels of apolipoprotein E and phosphorylated tau protein in mouse hippocampal neurons. Mol Med Rep 2020; 22: 445-453.
47
48. Wu HS, Guo PP, Jin Z, Li XY, Yang X, Ke JJ, et al., Effects of lipoxin a4 pretreatment on cognitive function of aged rats after global cerebral ischemia reperfusion. Curr Med Sci 2018; 38: 666-671.
48
49. Salehpour F, Farajdokht F, Mahmoudi J, Erfani M, Farhoudi M, Karimi P, et al., Photobiomodulation and coenzyme Q10 treatments attenuate cognitive impairment associated with model of transient global brain ischemia in artificially aged mice. Front Cell Neurosci 2019; 13: 1-17.
49
50. Soleimani M, Golab F, Alizadeh A, Rigi S, Samani ZN, Vahabzadeh G, et al., Evaluation of the neuroprotective effects of electromagnetic fields and coenzyme Q(10) on hippocampal injury in mouse. J Cell Physiol 2019; 234: 18720-18730.
50
ORIGINAL_ARTICLE
MAGI2-AS3 restrains proliferation, glycolysis, and triggers apoptosis in acute lymphoblastic leukemia via regulating miR-452-5p/FOXN3 pathway
Objective(s): MAGI2-AS3 is a cancer suppressor gene of multiple malignancies. Acute lymphoblastic leukemia (ALL) is an important type of leukemia that especially occurs in children. Our work evaluated the modulation of MAGI2-AS3 in ALL.Materials and Methods: qPCR and Western blotting were adopted for detection of target molecular expression. Growth and apoptosis were determined by CCK8 assay and Annexin V/PI staining. Glycolysis was detected by commercial kits. The direct binding between miR-452-5p and MAGI2-AS3 or FOXN3 was assessed by luciferase reporter assay. Tumor growth was measured in nude mice in vivo.Results: MAGI2-AS3 was down-regulated in ALL. Enforced expression of MAGI2-AS3 inhibited growth and glycolysis while promoting apoptosis of ALL cells. Moreover, MAGI2-AS3 up-regulated FOXN3 via sponging miR-452-5p. FOXN3 depletion abrogated MAGI2-AS3-mediated anti-cancer action. More importantly, MAGI2-AS3 repressed ALL cell growth in nude mice through regulation of miR-452-5p/FOXN3. Conclusion: MAGI2-AS3 inhibits ALL development via modulating miR-452-5p/FOXN3.
https://ijbms.mums.ac.ir/article_19301_2880897d75bd5e6d764067c82942d63b.pdf
2022-01-01
46
52
10.22038/ijbms.2021.58963.13095
ALL
Apoptosis
FOXN3
Glycolysis
Growth
MAGI2-AS3
miR-452-5p
Xiao-Guang
Chen
13721419976@163.com
1
Department of Pediatrics, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, Henan Province, P.R. China
AUTHOR
Bing-Hua
Dou
15036073691@163.com
2
Department of Pediatrics, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, Henan Province, P.R. China
AUTHOR
Jin-Dou
An
anjindou@zzu.edu.cn
3
Department of Pediatrics, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, Henan Province, P.R. China
AUTHOR
Song
Feng
fs2006_fs@126.com
4
Department of Pediatrics, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, Henan Province, P.R. China
AUTHOR
Na
Liu
71201529@qq.com
5
Department of Pediatrics, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, Henan Province, P.R. China
AUTHOR
Guang-Yao
Sheng
sguangyao4251@126.com
6
Department of Pediatrics, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, Henan Province, P.R. China
LEAD_AUTHOR
1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013; 63:11-30.
1
2. Li C, Zhao T, Nie L, Zou Y, Zhang Q. MicroRNA-223 decreases cell proliferation, migration, invasion, and enhances cell apoptosis in childhood acute lymphoblastic leukemia via targeting Forkhead box O 1. Biosci Rep 2020; 40-50.
2
3. Robison LL, Bhatia S. Late-effects among survivors of leukaemia and lymphoma during childhood and adolescence. Br J Haematol 2003; 122:345-359.
3
4. Gugnoni M, Ciarrocchi A. Long Noncoding RNA and epithelial mesenchymal transition in cancer. Int J Mol Sci 2019; 20.
4
5. Hosseini ES, Meryet-Figuiere M, Sabzalipoor H, Kashani HH, Nikzad H, Asemi Z. Dysregulated expression of long noncoding RNAs in gynecologic cancers. Mol Cancer 2017; 16:107-119.
5
6. Farooqi AA, Attar R, Yulaevna IM, Berardi R. Interaction of long non-coding RNAs and circular RNAs with microRNAs for the regulation of immunological responses in human cancers. Semin Cell Dev Biol 2021.
6
7. Xu K, Zhang Z, Qian J, Wang S, Yin S, Xie H, et al. LncRNA FOXD2-AS1 plays an oncogenic role in hepatocellular carcinoma through epigenetically silencing CDKN1B(p27) via EZH2. Exp Cell Res 2019; 380:198-204.
7
8. Gu X, Chu Q, Zheng Q, Wang J, Zhu H. The dual functions of the long noncoding RNA CASC15 in malignancy. Biomed Pharmacother 2021; 135:111212.
8
9. Bahari G, Hashemi M, Naderi M, Sadeghi-Bojd S, Taheri M. Long non-coding RNA PAX8-AS1 polymorphisms increase the risk of childhood acute lymphoblastic leukemia. Biomed Rep 2018; 8:184-190.
9
10. Xue C, Li G, Lu J, Luo J, Jia J. Novel insights for lncRNA MAGI2-AS3 in solid tumors. Biomed Pharmacother 2021; 137:111429.
10
11. Garitano-Trojaola A, Jose-Eneriz ES, Ezponda T, Unfried JP, Carrasco-Leon A, Razquin N, et al. Deregulation of linc-PINT in acute lymphoblastic leukemia is implicated in abnormal proliferation of leukemic cells. Oncotarget 2018; 9:12842-12852.
11
12. Chen L, Fan X, Zhu J, Chen X, Liu Y, Zhou H. LncRNA MAGI2-AS3 inhibits the self-renewal of leukaemic stem cells by promoting TET2-dependent DNA demethylation of the LRIG1 promoter in acute myeloid leukaemia. RNA Biol 2020; 17:784-793.
12
13. Liu X, Cai H, Sheng W, Huang H, Long Z, Wang Y. microRNAs expression profile related with response to preoperative radiochemotherapy in patients with locally advanced gastric cancer. BMC Cancer 2018; 18:1048-1056.
13
14. Inoue J, Inazawa J. Cancer-associated miRNAs and their therapeutic potential. J Hum Genet 2021; 66: 937-945.
14
15. Lin X, Han L, Gu C, Lai Y, Lai Q, Li Q, et al. MiR-452-5p promotes colorectal cancer progression by regulating an ERK/MAPK positive feedback loop. Aging (Albany NY) 2021; 13:7608-7626.
15
16. Gan XN, Gan TQ, He RQ, Luo J, Tang RX, Wang HL, et al. Clinical significance of high expression of miR-452-5p in lung squamous cell carcinoma. Oncol Lett 2018; 15:6418-6430.
16
17. Zhang J, Wang Y, Mo W, Zhang R, Li Y. The clinical and prognostic significance of FOXN3 downregulation in acute myeloid leukaemia. Int J Lab Hematol 2020; 42:270-276.
17
18. Kong X, Zhai J, Yan C, Song Y, Wang J, Bai X, et al. Recent advances in understanding FOXN3 in breast cancer, and other malignancies. Front Oncol 2019; 9:1-14.
18
19. Nagel S, Pommerenke C, Meyer C, Kaufmann M, MacLeod RAF, Drexler HG. Identification of a tumor suppressor network in T-cell leukemia. Leuk Lymphoma 2017; 58:2196-2207.
19
20. Li J, Huang Q, Long X, Guo X, Sun X, Jin X, et al. Mitochondrial elongation-mediated glucose metabolism reprogramming is essential for tumour cell survival during energy stress. Oncogene 2017; 36:4901-4912.
20
21. Kai-Xin L, Cheng C, Rui L, Zheng-Wei S, Wen-Wen T, Peng X. Roles of lncRNA MAGI2-AS3 in human cancers. Biomed Pharmacother 2021; 141:111812.
21
22. Ren H, Li Z, Tang Z, Li J, Lang X. Long noncoding MAGI2-AS3 promotes colorectal cancer progression through regulating miR-3163/TMEM106B axis. J Cell Physiol 2020; 235:4824-4833.
22
23. Xu X, Yuan X, Ni J, Guo J, Gao Y, Yin W, et al. MAGI2-AS3 inhibits breast cancer by downregulating DNA methylation of MAGI2. J Cell Physiol 2021; 236:1116-1130.
23
24. Cheng W, Shi X, Lin M, Yao Q, Ma J, Li J. LncRNA MAGI2-AS3 Overexpression sensitizes esophageal cancer cells to irradiation through down-regulation of HOXB7 via EZH2. Front Cell Dev Biol 2020; 8:552822.
24
25. Pavlova NN, Thompson CB. The emerging hallmarks of cancer metabolism. Cell Metab 2016; 23:27-47.
25
26. Liberti MV, Locasale JW. Correction to: ‘The Warburg effect: How does it benefit cancer cells?’: Trends Biochem Sci 2016; 41:211-218.
26
27. Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 2009; 324:1029-1033.
27
28. Hulleman E, Kazemier KM, Holleman A, VanderWeele DJ, Rudin CM, Broekhuis MJ, et al. Inhibition of glycolysis modulates prednisolone resistance in acute lymphoblastic leukemia cells. Blood 2009; 113:2014-2021.
28
29. Tan VP, Miyamoto S. HK2/hexokinase-II integrates glycolysis and autophagy to confer cellular protection. Autophagy 2015; 11:963-964.
29
30. Luengo A, Gui DY, Vander Heiden MG. Targeting Metabolism for Cancer Therapy. Cell Chem Biol 2017; 24:1161-1180.
30
31. Kishton RJ, Barnes CE, Nichols AG, Cohen S, Gerriets VA, Siska PJ, et al. AMPK is essential to balance glycolysis and mitochondrial metabolism to control T-ALL cell stress and survival. Cell Metab 2016; 23:649-662.
31
32. Feng J, Li J, Wu L, Yu Q, Ji J, Wu J, et al. Emerging roles and the regulation of aerobic glycolysis in hepatocellular carcinoma. J Exp Clin Cancer Res 2020; 39:126-144.
32
33. Zolzer F, Basu O, Devi PU, Mohanty SP, Streffer C. Chromatin-bound PCNA as S-phase marker in mononuclear blood cells of patients with acute lymphoblastic leukaemia or multiple myeloma. Cell Prolif 2010; 43:579-583.
33
34. Lehnerdt GF, Franz P, Bankfalvi A, Grehl S, Kelava A, Nuckel H, et al. The regulatory BCL2 promoter polymorphism (-938C>A) is associated with relapse and survival of patients with oropharyngeal squamous cell carcinoma. Ann Oncol 2009; 20:1094-1099.
34
35. Rong MH, Cai KT, Lu HP, Guo YN, Huang XY, Zhu ZH, et al. Overexpression of MiR-452-5p in hepatocellular carcinoma tissues and its prospective signaling pathways. Int J Clin Exp Pathol 2019; 12:4041-4056.
35
36. Song X, Wang H, Wu J, Sun Y. Long noncoding RNA SOX2-OT knockdown inhibits proliferation and metastasis of prostate cancer cells through modulating the miR-452-5p/HMGB3 axis and inactivating wnt/beta-catenin pathway. Cancer Biother Radiopharm 2020; 35:682-695.
36
37. Zhu L, Yang N, Chen J, Zeng T, Yan S, Liu Y, et al. LINC00052 upregulates EPB41L3 to inhibit migration and invasion of hepatocellular carcinoma by binding miR-452-5p. Oncotarget 2017; 8:63724-63737.
37
38. Dai Y, Wang M, Wu H, Xiao M, Liu H, Zhang D. Loss of FOXN3 in colon cancer activates beta-catenin/TCF signaling and promotes the growth and migration of cancer cells. Oncotarget 2017; 8:9783-9793.
38
39. Zhao C, Mo L, Li C, Han S, Zhao W, Liu L. FOXN3 suppresses the growth and invasion of papillary thyroid cancer through the inactivation of Wnt/beta-catenin pathway. Mol Cell Endocrinol 2020; 515:110925.
39
ORIGINAL_ARTICLE
Neuroprotective effect of L-deprenyl on the expression level of the Mst1 gene and inhibition of apoptosis in rat-model spinal cord injury
Objective(s): After primary tissue damage as a result of spinal cord injury (SCI), there is a period of secondary damage, which includes several cellular and inflammatory biochemical cascades. As a novel pro-apoptotic kinase, Mst1 (serine/threonine kinase 4) promotes programmed cell death in an inflammatory disease model. This study aimed to evaluate Mst1 gene expression levels in rats with spinal cord injury treated with L- deprenyl. Materials and Methods: The rats were divided into control (contusion), laminectomy, sham-operated (contused rats received 1 ml normal saline intraperitoneal), and treatment (contused rats received 5 mg/kg of L-deprenyl intraperitoneal; once a day for 7 days). The BBB (Basso, Beattie, and Bresnahan) scales were performed to assess motor function following SCI. Rats were sacrificed 28 days after SCI and the spinal cord lesion area was removed. Apoptosis and cavity formation in the spinal cord were determined by H&E staining and TUNEL assay, respectively. The mRNA levels of the Mst1, Nrf2, Bcl-2, and PGC1α genes were analyzed using real-time quantitative PCR.Results: The results showed significant improvement in motor function in the L- deprenyl group compared with the untreated group. Histological analysis showed a significant reduction in the number of tunnel-positive cells after injection of L-deprenyl, as well as a decrease in the volume of the cavity. In addition, L-deprenyl treatment increased the expression of the Nrf2, Bcl-2, and PGC1α genes, while reducing the expression of the Mst1 gene in the spinal nerves. Conclusion: These results suggest that L-deprenyl is a promising treatment for spinal cord injury.
https://ijbms.mums.ac.ir/article_19480_9a5658d8ae6cc7da8904e7b6e8653419.pdf
2022-01-01
53
59
10.22038/ijbms.2022.58031.12894
Apoptosis
Bcl-2
Contusion
L-deprenyl
Mst1
Nrf2
Selegiline
Alireza
Abdanipour
abdani.anatomy@yahoo.com
1
Department of Anatomy, School of Medicine, Zanjan University of Medical Sciences, Zanjan, Iran
LEAD_AUTHOR
Ali
Nikfar
ali.nikfar7@yahoo.com
2
Department of Genetics and Molecular Medicine, Faculty of Medicine, Zanjan University of Medical Sciences, Zanjan, Iran
AUTHOR
Mahsa
Nikbakht Rad
mahsa_nikbakht90@yahoo.com
3
Department of Anatomy, School of Medicine, Zanjan University of Medical Sciences, Zanjan, Iran
AUTHOR
Iraj
Jafari Anarkooli
jafarianarkooli@gmail.com
4
Department of Anatomy, School of Medicine, Zanjan University of Medical Sciences, Zanjan, Iran
AUTHOR
Mojdeh
Mansouri
mojdeh.mansoori20@yahoo.com
5
Department of Genetics and Molecular Medicine, Faculty of Medicine, Zanjan University of Medical Sciences, Zanjan, Iran
AUTHOR
1. Shah M, Peterson C, Yilmaz E, Halalmeh DR, Moisi M. Current
1
advancements in the management of spinal cord injury: A comprehensive review of literature. Surg Neurol Int 2020; 11:2-7.
2
2. Lee JY, Chung H, Yoo YS, Oh YJ, Oh TH, Park S, et al. Inhibition of apoptotic cell death by ghrelin improves functional recovery after spinal cord injury. Endocrinology 2010; 151:3815-3826.
3
3. Cinar B, Fang PK, Lutchman M, Di Vizio D, Adam RM, Pavlova N, et al. The pro-apoptotic kinase Mst1 and its caspase cleavage products are direct inhibitors of Akt1. EMBO J 2007; 26:4523-4534.
4
4. Rawat SJ, Chernoff J. Regulation of mammalian Ste20 (Mst) kinases. Trends Biochem Sci 2015; 40:149-156.
5
5. Huot P, Fox SH, Brotchie JM. Monoamine reuptake inhibitors in Parkinson’s disease. Parkinsons Dis 2015; 2015:609428.
6
6. Naoi M, Maruyama W, Yagi K, Youdim M. Anti-apoptotic function of L-(-)deprenyl (Selegiline) and related compounds. Neurobiology (Bp) 2000; 8:69-80.
7
7. Naoi M, Maruyama W, Inaba-Hasegawa K. Revelation in the neuroprotective functions of rasagiline and selegiline: the induction of distinct genes by different mechanisms. Expert Review of Neurotherapeutics 2013; 13:671-684.
8
8. Nikfar A, Abdanipour A, Gholinejad M. Anti-apoptotic effect of selegiline as monoamine oxidase inhibitor on rat hippocampus derived neural stem cells in oxidative stress condition. J Adv Med Biomed Res 2017; 25:41-56.
9
9. David JA, Rifkin WJ, Rabbani PS, Ceradini DJ. The Nrf2/Keap1/ARE Pathway and Oxidative Stress as a Therapeutic Target in Type II Diabetes Mellitus. J Diabetes Res 2017; 2017:15.
10
10. Koundouros N, Poulogiannis G. Phosphoinositide 3-kinase/akt signaling and redox metabolism in cancer. Front Oncol 2018; 8:160-169.
11
11. Murakami S, Motohashi H. Roles of Nrf2 in cell proliferation and differentiation. Free Radic Biol Med 2015; 88:168-178.
12
12. Basso DM, Beattie MS, Bresnahan JC. Graded histological and locomotor outcomes after spinal cord contusion using the NYU weight-drop device versus transection. Exp Neurol 1996; 139:244-256.
13
13. Michel RP, Cruz-Orive LM. Application of the Cavalieri principle and vertical sections method to lung: estimation of volume and pleural surface area. J Microsc 1988; 150:117-136.
14
14. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001; 25:402-408.
15
15. Mosley YC, HogenEsch H. Selection of a suitable reference gene for quantitative gene expression in mouse lymph nodes after vaccination. BMC Res Notes 2017; 10:689-696.
16
16. Zhang N, Yin Y, Xu SJ, Wu YP, Chen WS. Inflammation & apoptosis in spinal cord injury. Indian J Med Res 2012; 135:287-296.
17
17. Zhou X, He X, Ren Y. Function of microglia and macrophages in secondary damage after spinal cord injury. Neural Regen Res 2014; 9:1787-1795.
18
18. Inaba-Hasegawa K, Shamoto-Nagai M, Maruyama W, Naoi M. Type B and A monoamine oxidase and their inhibitors regulate the gene expression of Bcl-2 and neurotrophic factors in human glioblastoma U118MG cells: different signal pathways for neuroprotection by selegiline and rasagiline. J Neural Transm (Vienna) 2017; 124:1055-1066.
19
19. Tatton WG, Wadia JS, Ju WY, Chalmers-Redman RM, Tatton NA. (-)-Deprenyl reduces neuronal apoptosis and facilitates neuronal outgrowth by altering protein synthesis without inhibiting monoamine oxidase. J Neural Transm Suppl 1996; 48:45-59.
20
20. Abdanipour A, Jafari Anarkooli I, Shokri S, Ghorbanlou M, Bayati V, Nejatbakhsh R. Neuroprotective effects of selegiline on rat neural stem cells treated with hydrogen peroxide. Biomed Rep 2018; 8:41-46.
21
21. Maruyama W, Naoi M. Neuroprotection by (-)-deprenyl and related compounds. Mech Ageing Dev 1999; 111:189-200.
22
22. Unal I, Gursoy-Ozdemir Y, Bolay H, Soylemezoglu F, Saribas O, Dalkara T. Chronic daily administration of selegiline and EGb 761 increases brain’s resistance to ischemia in mice. Brain Res 2001; 917:174-181.
23
23. Magyar K, Szende B. (-)-Deprenyl, a selective MAO-B inhibitor, with apoptotic and anti-apoptotic properties. Neurotoxicology 2004; 25:233-242.
24
24. Xu W, Chi L, Xu R, Ke Y, Luo C, Cai J, et al. Increased production of reactive oxygen species contributes to motor neuron death in a compression mouse model of spinal cord injury. Spinal Cord 2005; 43:204-213.
25
25. Zhang N, Yin Y, Xu SJ, Wu YP, Chen WS. Inflammation & apoptosis in spinal cord injury. Indian J Med Res 2012; 135:287-296.
26
26. Dulin JN, Karoly ED, Wang Y, Strobel HW, Grill RJ. Licofelone modulates neuroinflammation and attenuates mechanical hypersensitivity in the chronic phase of spinal cord injury. J Neurosci 2013; 33:652-664.
27
27. Czabotar PE, Lessene G, Strasser A, Adams JM. Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy. Nat Rev Mol Cell Biol 2014; 15:49-63.
28
28. Yuan F, Xie Q, Wu J, Bai Y, Mao B, Dong Y, et al. MST1 promotes apoptosis through regulating Sirt1-dependent p53 deacetylation. J Biol Chem 2011; 286:6940-6945.
29
29. Lee JY, Kim HS, Choi HY, Oh TH, Ju BG, Yune TY. Valproic acid attenuates blood–spinal cord barrier disruption by inhibiting matrix metalloprotease‐9 activity and improves functional recovery after spinal cord injury. J Neurochem 2012; 121:818-829.
30
30. Yuan Z, Lehtinen MK, Merlo P, Villén J, Gygi S, Bonni A. Regulation of neuronal cell death by MST1-FOXO1 signaling. J Biol Chem 2009; 284:11285-11292.
31
31. Lehtinen MK, Yuan Z, Boag PR, Yang Y, Villén J, Becker EB, et al. A conserved MST-FOXO signaling pathway mediates oxidative-stress responses and extends life span. Cell 2006; 125:987-1001.
32
32. Watabe M, Kakeya H, Onose R, Osada H. Activation of MST/Krs and c-Jun N-terminal kinases by different signaling pathways during cytotrienin A-induced apoptosis. J Biol Chem 2000; 275:8766-8771.
33
33. Cheung WL, Ajiro K, Samejima K, Kloc M, Cheung P, Mizzen CA, et al. Apoptotic phosphorylation of histone H2B is mediated by mammalian sterile twenty kinase. Cell 2003; 113:507-517.
34
34. Ardestani A, Paroni F, Azizi Z, Kaur S, Khobragade V, Yuan T, et al. MST1 is a key regulator of beta cell apoptosis and dysfunction in diabetes. Nat Med 2014; 20:385-397.
35
35. Zhang M, Tao W, Yuan Z, Liu Y. Mst-1 deficiency promotes post-traumatic spinal motor neuron survival via enhancement of autophagy flux. J Neurochem 2017; 143:244-256.
36
36. Zhang M, Tao W, Yuan Z, Liu Y. Mst‐1 deficiency promotes post‐traumatic spinal motor neuron survival via enhancement of autophagy flux. J Neurochem 2017; 143:244-256.
37
37. Lee JK, Shin JH, Hwang SG, Gwag BJ, McKee AC, Lee J, et al. MST1 functions as a key modulator of neurodegeneration in a mouse model of ALS. Proceedings of the National Academy of Sciences 2013; 110:12066-12071.
38
38. Xiao L, Chen D, Hu P, Wu J, Liu W, Zhao Y, et al. The c-Abl-MST1 signaling pathway mediates oxidative stress-induced neuronal cell death. J Neurosci 2011; 31:9611-9619.
39
39. Shang Y, Yan Y, Chen B, Zhang J, Zhang T. Over‐expressed MST1 impaired spatial memory via disturbing neural oscillation patterns in mice. Genes, Brain and Behavior 2020:e12678.
40
40. Anilkumar U, Prehn JH. Anti-apoptotic BCL-2 family proteins in acute neural injury. Front Cell Neurosci 2014; 8:281-286.
41
41. Zhang W, Cheng L, Hou Y, Si M, Zhao YP, Nie L. Plumbagin Protects Against Spinal Cord Injury-induced Oxidative Stress and Inflammation in Wistar Rats through Nrf-2 Upregulation. Drug Res (Stuttg) 2015; 65:495-499.
42
42. McBride HM, Neuspiel M, Wasiak S. Mitochondria: more than just a powerhouse. Current biology 2006; 16:R551-R560.
43
43. Lin J, Handschin C, Spiegelman BM. Metabolic control through the PGC-1 family of transcription coactivators. Cell metabolism 2005; 1:361-370.
44
44. Scarpulla RC. Nuclear control of respiratory chain expression by nuclear respiratory factors and PGC-1-related coactivator. Annals of the New York Academy of Sciences 2008; 1147:321-334.
45
45. Tummala KS, Kottakis F, Bardeesy N. NRF2: Translating the Redox Code. Trends Mol Med 2016; 22:829-831.
46
46. Kobayashi A, Kang MI, Okawa H, Ohtsuji M, Zenke Y, Chiba T, et al. Oxidative stress sensor Keap1 functions as an adaptor for Cul3-based E3 ligase to regulate proteasomal degradation of Nrf2. Mol Cell Biol 2004; 24:7130-7139.
47
47. Nakaso K, Nakamura C, Sato H, Imamura K, Takeshima T, Nakashima K. Novel cytoprotective mechanism of anti-parkinsonian drug deprenyl: PI3K and Nrf2-derived induction of antioxidative proteins. Biochem Biophys Res Commun 2006; 339:915-922.
48
48. Xiao H, Lv F, Xu W, Zhang L, Jing P, Cao X. Deprenyl prevents MPP(+)-induced oxidative damage in PC12 cells by the upregulation of Nrf2-mediated NQO1 expression through the activation of PI3K/Akt and Erk. Toxicology 2011; 290:286-294.
49
49. Wahdan SA, Tadros MG, Khalifa AE. Antioxidant and antiapoptotic actions of selegiline protect against 3-NP-induced neurotoxicity in rats. Naunyn Schmiedebergs Arch Pharmacol 2017; 390:905-917.
50
50. Inaba-Hasegawa K, Akao Y, Maruyama W, Naoi M. Type A monoamine oxidase is associated with induction of neuroprotective Bcl-2 by rasagiline, an inhibitor of type B monoamine oxidase. J Neural Transm (Vienna) 2012; 119:405-414.
51
51. Lin HI, Lee YJ, Chen BF, Tsai MC, Lu JL, Chou CJ, et al. Involvement of Bcl-2 family, cytochrome c and caspase 3 in induction of apoptosis by beauvericin in human non-small cell lung cancer cells. Cancer Lett 2005; 230:248-259.
52
52. Chiou SH, Ku HH, Tsai TH, Lin HL, Chen LH, Chien CS, et al. Moclobemide upregulated Bcl-2 expression and induced neural stem cell differentiation into serotoninergic neuron via extracellular-regulated kinase pathway. Br J Pharmacol 2006; 148:587-598.
53
53. Abdanipour A, Tiraihi T, Noori-Zadeh A, Majdi A, Gosaili R. Evaluation of lovastatin effects on expression of anti-apoptotic Nrf2 and PGC-1alpha genes in neural stem cells treated with hydrogen peroxide. Mol Neurobiol 2014; 49:1364-1372.
54
ORIGINAL_ARTICLE
Carvedilol attenuates acrylamide-induced brain damage through inhibition of oxidative, inflammatory, and apoptotic mediators
Objective(s): Acrylamide is a potent neurotoxic compound and has harmful effects on brain cells. Acrylamide promotes oxidative, inflammatory, and apoptotic mediators in the CNS leading to neurological disorders. The goal of the current study was to examine the potential protective effect of carvedilol and its underlying mechanisms in a mouse model of acrylamide-induced brain injury. Materials and Methods: Mice were treated with acrylamide (50 mg/kg/day, IP) and carvedilol (5 and 10 mg/kg/day, oral) for 11 continuous days. At the end of the experiment, mice were subjected to gait assessment. They were sacrificed and brain tissues were collected for histological and biochemical analysis. Results: The results showed that treatment of mice with carvedilol decreased acrylamide-induced bodyweight loss, abnormal gait, and histopathological damage in the brain tissue. Carvedilol treatment significantly reduced the levels of malondialdehyde (MDA) and carbonyl protein and increased the levels of glutathione (GSH), catalase, superoxide dismutase (SOD), nuclear factor erythroid 2-related factor 2 (Nrf2), and heme oxygenase-1 (HO-1). Carvedilol treatment also decreased myeloperoxidase (MPO) activity, expression of nuclear factor kappa B (NF-κB), inducible nitric oxide synthase (iNOS), overproduction of nitric oxide (NO) and proinflammatory cytokines tumor necrosis factor (TNF)-α, interleukin (IL)-1β, and IL-6 in the brain of mice exposed to acrylamide. Furthermore, administration of carvedilol significantly decreased the levels of bax, cytochrome-c, and caspase-3 as markers of apoptosis in acrylamide-treated mice. Conclusion: These findings indicate that carvedilol is able to attenuate acrylamide-induced damage to the CNS by inhibition of oxidative stress, inflammation, and apoptosis.
https://ijbms.mums.ac.ir/article_19400_6fc5aef955bed352f40f28b5f35a166c.pdf
2022-01-01
60
67
10.22038/ijbms.2021.58808.13063
Acrylamide
Apoptosis
Brain damage
Carvedilol
Inflammation
Oxidative stress
Keyvan
Amirshahrokhi
amirshahrokhi@gmail.com
1
Department of Pharmacology, School of Pharmacy, Ardabil University of Medical Sciences, Ardabil, Iran
LEAD_AUTHOR
Arezoo
Abzirakan
arezooabzirakan@gmail.com
2
Department of Pharmacology, School of Pharmacy, Ardabil University of Medical Sciences, Ardabil, Iran
AUTHOR
1. Amirshahrokhi K. Acrylamide exposure aggravates the development of ulcerative colitis in mice by the activation of proinflammatory cytokines, NF-κB, iNOS and oxidative stress. Iran J Basic Med Sci 2021; 24:312-321.
1
2. Foroutanfar A, Mehri S, Kamyar M, Tandisehpanah Z, Hosseinzadeh H. Protective effect of punicalagin, the main polyphenol compound of pomegranate, against acrylamide-induced neurotoxicity and hepatotoxicity in rats. Phytother Res 2020; 34:3262-3272.
2
3. Matoso V, Bargi-Souza P, Ivanski F, Romano MA, Romano RM. Acrylamide: A review about its toxic effects in the light of Developmental Origin of Health and Disease (DOHaD) concept. Food Chem 2019; 15;283:422-430.
3
4. Elhelaly AE, AlBasher G, Alfarraj S, Almeer R, Bahbah EI, Fouda MMA, et al. Protective effects of hesperidin and diosmin against acrylamide-induced liver, kidney, and brain oxidative damage in rats. Environ Sci Pollut Res Int 2019; 26:35151-35162.
4
5. Sui X, Yang J, Zhang G, Yuan X, Li W, Long J, et al. NLRP3 inflammasome inhibition attenuates subacute neurotoxicity induced by acrylamide in vitro and in vivo. Toxicology 2020; 28:432:152392.
5
6. Elblehi SS, El Euony OI, El-Sayed YS. Apoptosis and astrogliosis perturbations and expression of regulatory inflammatory factors and neurotransmitters in acrylamide-induced neurotoxicity under ω3 fatty acids protection in rats. Neurotoxicology 2020; 76:44-57.
6
7. Tabeshpour J, Mehri S, Abnous K, Hosseinzadeh H. Role of oxidative stress, MAPKinase and apoptosis pathways in the protective effects of thymoquinone against acrylamide-induced central nervous system toxicity in rat. Neurochem Res 2020; 45:254–267.
7
8. Thabet NM, Moustafa EM. Protective effect of rutin against brain injury induced by acrylamide or gamma radiation: role of PI3K/AKT/GSK-3b/NRF-2 signalling pathway. Arch Physiol Biochem 2018; 124:185-193.
8
9. Zhao M, Lewis Wang FS, Hu X, Chen F, Chan HM. Acrylamide-induced neurotoxicity in primary astrocytes and microglia: Roles of the Nrf2-ARE and NF-κB pathways. Food Chem Toxicol 2017; 106(Pt A):25-35.
9
10. Hamdy N, El-Demerdash E. New therapeutic aspect for carvedilol: antifibrotic effects of carvedilol in chronic carbon tetrachloride-induced liver damage. Toxicol Appl Pharmacol 2012; 15;261:292-299.
10
11. Amirshahrokhi K, Khalili AR. Carvedilol attenuates paraquat-induced lung injury by inhibition of proinflammatory cytokines, chemokine MCP-1, NF-κB activation and oxidative stress mediators. Cytokine 2016; 88:144-153.
11
12. Amirshahrokhi K, Zohouri A. Carvedilol prevents pancreatic β-cell damage and the development of type 1 diabetes in mice by the inhibition of proinflammatory cytokines, NF-κB, COX-2, iNOS and oxidative stress. Cytokine 202; 138:155394.
12
13. Wang J, Ono K, Dickstein DL, Arrieta-Cruz I, Zhao W, Qian X, et al. Carvedilol as a potential novel agent for the treatment of Alzheimer’s disease. Neurobiol Aging 2011; 32:2321.
13
14. Naidu PS, Singh A, Kulkarni SK. Carvedilol attenuates neuroleptic-induced orofacial dyskinesia: possible anti-oxidant mechanisms. Br J Pharmacol 2002; 136:193-200.
14
15. Areti A, Komirishetty P, Kumar A. Carvedilol prevents functional deficits in peripheral nerve mitochondria of rats with oxaliplatin-evoked painful peripheral neuropathy. Toxicol Appl Pharmacol 2017; 322:97-103.
15
16. Savitz SI, Erhardt JA, Anthony JV, Gupta G, Li X, Barone FC, et al. The novel beta-blocker, carvedilol, provides neuroprotection in transient focal stroke. J Cereb Blood Flow Metab 2000; 20:1197-1204.
16
17. Yue TL, Lysko PG, Barone FC, Gu JL, Ruffolo RR Jr, Feuerstein GZ. Carvedilol, a new antihypertensive drug with unique antioxidant activity: potential role in cerebroprotection. Ann N Y Acad Sci 1994; 738:230-242.
17
18. Tasset I, Espínola C, Medina FJ, Feijóo M, Ruiz C, Moreno E, et al. Neuroprotective effect of carvedilol and melatonin on 3-nitropropionic acid-induced neurotoxicity in neuroblastoma. J Physiol Biochem 2009; 65:291-296.
18
19. Gao X, Wu B, Fu Z, Zhang Z, Xu G. Carvedilol abrogates hypoxia-induced oxidative stress and neuroinflammation in microglial BV2 cells. Eur J Pharmacol. 2017; 814:144-150.
19
20. LoPachin RM. Acrylamide Neurotoxicity: Neurological, morhological and molecular endpoints in animal models. Adv Exp Med Biol 2005; 561:21-37.
20
21. Zhang L, Gavin T, Barber DS, LoPachin RM. Role of the Nrf2-ARE pathway in acrylamide neurotoxicity. Toxicol Lett 2011; 205:1– 7.
21
22. Amirshahrokhi K. Thalidomide reduces glycerol-induced acute kidney injury by inhibition of NF-κB, NLRP3 inflammasome, COX-2 and inflammatory cytokines. Cytokine 2021; 144:155574.
22
23. Amirshahrokhi K, Khalili AR. Methylsulfonylmethane is effective against gastric mucosal injury. Eur J Pharmacol 2017; 811:240-248.
23
24. Yao X, Yan L, Yao L, Guan W, Zeng F, Cao F, et al. Acrylamide exposure impairs blood-cerebrospinal fluid barrier function. Neural Regen Res 2014; 9:555-560.
24
25. Triningsih D, Yang J-H, Sim KH, Lee C, Lee YJ. Acrylamide and its metabolite induce neurotoxicity via modulation of protein kinase C and AMP-activated protein kinase pathways. Toxicol in Vitro 2021;72:105105.
25
26. Farouk SM, Gad FA, Almeer R, Abdel-Daim MM, Emam MA. Exploring the possible neuroprotective and anti-oxidant potency of lycopene against acrylamide-induced neurotoxicity in rats’ brain. Biomed and Pharmacother 2021; 138:111458.
26
27. Acaroz U, Ince S, Arslan-Acaroz D, Gurler Z, Kucukkurt I, Demirel HH, et al. The ameliorative effects of boron against acrylamide-induced oxidative stress, inflammatory response, and metabolic changes in rats. Food Chem Toxicol 2018; 118:745-752.
27
28. Song G, Liu Z, Liu Q, Liu X. Lipoic acid prevents acrylamide-induced neurotoxicity in CD-1 mice and BV2 microglial cells via maintaining redox homeostasis. J Funct Foods 2017; 35:363–375.
28
29. Kabel AM, Salama SA, Alghorabi AA, Estfanous RS. Amelioration of cyclosporine-induced testicular toxicity by carvedilol and/or alpha-lipoic acid: Role of TGF-β1, the proinflammatory cytokines, Nrf2/HO-1 pathway and apoptosis. Clin Exp Pharmacol Physiol 2020:47:1169-1181.
29
30. Refaie MMM, El-Hussieny M, Bayoumi AMA, Shehata S. Mechanisms mediating the cardioprotective effect of carvedilol in cadmium induced cardiotoxicity. Role of eNOS and HO1/Nrf2 pathway. Environ Toxicol Pharmacol 2019; 70:103198.
30
31. Ouyang Y, Chen Z, Tan M, Liu A, Chen M, Liu J, et al. Carvedilol, a third-generation β-blocker prevents oxidative stress-induced neuronal death and activates Nrf2/ARE pathway in HT22 cells. Biochem Biophys Res Commun 2013; 441; 917-922.
31
32. Wang L, Wang R, Jin M, Huang Y, Liu A, Qin J, et al. Carvedilol attenuates 6-hydroxydopamine-induced cell death in PC12 cells: Involvement of Akt and Nrf2/ARE pathways. Neurochem Res 2014; 39:1733-1740.
32
33. Santhanasabapathy R, Vasudevan S, Anupriya K, Pabitha R, Sudhandiran G. Farnesol quells oxidative stress, reactive gliosis and inflammation during acrylamide-induced neurotoxicity: Behavioral and biochemical evidence. Neuroscience 2015; 308:212-227.
33
34. Sharma C, Kang SC. Garcinol pacifies acrylamide induced cognitive impairments, neuroinflammation and neuronal apoptosis by modulating GSK signaling and activation of pCREB by regulating cathepsin B in the brain of zebrafish larvae. Food Chem Toxicol 2020; 138:111246.
34
35. Chen S, Chen H, Du Q, Shen J. Targeting myeloperoxidase (MPO) mediated oxidative stress and inflammation for reducing brain ischemia injury: Potential application of natural compounds. Front Physiol 2020; 11:433.
35
36. Maki RA, Holzer M, Motamedchaboki K, Malle E, Masliah E, et al. Human myeloperoxidase (hMPO) is expressed in neurons in the substantia nigra in Parkinson’s disease and in the hMPO-α-synuclein-A53T mouse model, correlating with increased nitration and aggregation of α-synuclein and exacerbation of motor impairment. Free Radic Biol Med 2019; 141:115-140.
36
37. Alturfan AA, Tozan-Beceren A, Sehirli AO, Demiralp E, Sener G, Omurtag GZ. Resveratrol ameliorates oxidative DNA damage and protects against acrylamide-induced oxidative stress in rats. Mol Biol Rep 2012; 39:4589-4596.
37
38. Zhang L, Wang E, Chen F, Yan H, Yuan Y. Potential protective effects of oral administration of allicin on acrylamide-induced toxicity in male mice. Food and Funct 2013; 4;1229-1236.
38
39. Pan X, Wu X, Yan D, Peng C, Rao C, Yan H. Acrylamide-induced oxidative stress and inflammatory response are alleviated by N-acetylcysteine in PC12 cells: Involvement of the crosstalk between Nrf2 and NF-κB pathways regulated by MAPKs. Toxicol Lett 2018; 288:55-64.
39
40. Yan D, Pan X, Yao J, Wang D, Wu X, Chen X, et al. MAPKs and NF-κB-mediated acrylamide-induced neuropathy in rat striatum and human neuroblastoma cells SY5Y. J Cell Biochem 2019; 120:3898-3910.
40
41. Clemens JA. Cerebral ischemia: gene activation, neuronal injury, and the protective role of anti-oxidants. Free Radic Biol Med 2000; 28:1526-1531.
41
42. Kucukler S, Caglayan C, Darendelioğlu E, Kandemir FM. Morin attenuates acrylamide-induced testicular toxicity in rats by regulating the NF-κB, Bax/Bcl-2 and PI3K/Akt/mTOR signaling pathways. Life Sci 2020; 261,118301.
42
43. Pozniak PD, White MK, Khalili K. TNF-α/NF-κB signaling in the CNS: possible connection to EPHB2. J Neuroimmune Pharmacol 2014; 9:133-141.
43
44. Chen JH, Yang CH, Wang YS, Lee JG, Cheng CH, Chou CC. Acrylamide-induced mitochondria collapse and apoptosis in human astrocytoma cells. Food Chem Toxicol 2013; 51:446-452
44
45. Kianfar M, Nezami A, Mehri S, Hosseinzadeh H, Hayes AW, Karimi G. The protective effect of fasudil against acrylamide-induced cytotoxicity in PC12 cells. Drug Chem Toxicol 2018; 43:595-601.
45
46. Li SX, Cui N, Zhang CL, Zhao XL, Yu SF, Xie KQ. Effect of subchronic exposure to acrylamide induced on the expression of bcl-2, bax and caspase-3 in the rat nervous system. Toxicology 2006; 217;46-53
46
47. Pan X, Yan D, Wang D, Wu X, Zhao W, Lu Q, et al. Mitochondrion-mediated apoptosis induced by acrylamide is regulated by a balance between Nrf2 anti-oxidant and MAPK signaling pathways in PC12 cells. Mol Neurobiol 2017; 54:4781-4794.
47
48. Liu J, Wang M. Carvedilol protection against endogenous Aβ-induced neurotoxicity in N2a cells. Cell Stress Chaperones 2018; 23:695-702.
48
49. Chen YL, Chung SY, Chai HT, Chen CH, Liu CF, Chen YL, et al. Early administration of carvedilol protected against doxorubicin-induced cardiomyopathy. J Pharmacol Exp Ther 2015; 355:516-527.
49
50. Dandona P, Ghanim H, Brooks DP. Anti-oxidant activity of carvedilol in cardiovascular disease. J Hypertens. 2007; 25:731-741.
50
51. Sahu BD, Koneru M, Bijargi SR, Kota A, Sistla R. Chromium-induced nephrotoxicity and ameliorative effect of carvedilol in rats: Involvement of oxidative stress, apoptosis and inflammation. Chem Biol Interact 2014; 223:69-79.
51
ORIGINAL_ARTICLE
Theaflavin promoted apoptosis in nasopharyngeal carcinoma unexpectedly via inducing autophagy in vitro
Objective(s): This study aimed to investigate the mechanism of the anticancer effect of theaflavin (TF) in nasopharyngeal carcinoma.Materials and Methods: CNE2 cells were used to study the anticancer effect of TF. This study used Cell Counting Kit-8 (CCK8) assay on proliferation and used flow cytometry to detect apoptosis. The protein expression of Bcl-2, Bax, caspase 3, and caspase 9 was detected by Western blot, and autophagy-related proteins were also detected.Results: TF inhibited proliferation of CNE2 cells, promoted apoptosis, and up-regulated the expression of caspase 3, caspase 9, and Bax, and decreased the level of Bcl-2. Unexpectedly, TF induced autophagy rather than inhibiting autophagy through up-regulating the levels of the autophagy marker light chain 3 (LC3) and Lysosomal-associated membrane protein 1 (LAMP1) and reducing levels of the autophagosome cargo protein p62, and the effect was via the mTOR pathway. Besides, autophagy inhibitor Chloroquine (CQ) suppressed the effect of TF on Bax, Bcl-2 and activation of caspase 3 and caspase 9.Conclusion: TF promoted apoptosis of nasopharyngeal carcinoma cells, the mechanism was unexpectedly involved in inducing autophagy.
https://ijbms.mums.ac.ir/article_19399_5f49498cdcb359725be7ce581f3b90f8.pdf
2022-01-01
68
74
10.22038/ijbms.2021.59190.13143
Apoptosis
Autophagy
Nasopharyngeal carcinoma
Proliferation
Theaflavin
Jing
Xu
science616@163.com
1
Department of Radiotherapy, The Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, Henan province, China
AUTHOR
Shujuan
Wang
wangsj0702@163.com
2
Department of Radiotherapy, The Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, Henan province, China
AUTHOR
Shanshan
Bu
bushaner@aliyun.com
3
Department of Radiotherapy, The Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, Henan province, China
AUTHOR
Xiaoqi
Guo
guoxiaoqi7788@126.com
4
Department of Radiotherapy, The Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, Henan province, China
AUTHOR
Hong
Ge
zlyygehong0199@zzu.edu.cn
5
Department of Radiotherapy, The Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, Henan province, China
LEAD_AUTHOR
1. Almomani MH, Zulfiqar H, Nagalli S. Nasopharyngeal Carcinoma (NPC, Lymphoepithelioma). StatPearls [Internet] 2020.
1
2. Xiao Z, Chen Z. Deciphering nasopharyngeal carcinoma pathogenesis via proteomics. Expert review of proteomics 2019; 16:475-485.
2
3. Lin Y-T, Lin C-C, Wang H-C, Hsu Y-C. Induction of mitotic delay in pharyngeal and nasopharyngeal carcinoma cells using an aqueous extract of Ajuga bracteosa. International journal of medical sciences 2017; 14:462.
3
4. Xu T, Tang J, Gu M, Liu L, Wei W, Yang H. Recurrent nasopharyngeal carcinoma: a clinical dilemma and challenge. Current oncology 2013; 20:e406.
4
5. Lin C-L, Huang H-C, Lin J-K. Theaflavins attenuate hepatic lipid accumulation through activating AMPK in human HepG2 cells. Journal of lipid research 2007; 48:2334-2343.
5
6. Zhang J, Cai S, Li J, Xiong L, Tian L, Liu J, et al. Neuroprotective effects of theaflavins against oxidative stress-induced apoptosis in PC12 cells. Neurochemical research 2016; 41:3364-3372.
6
7. Way T-D, Lee H-H, Kao M-C, Lin J-K. Black tea polyphenol theaflavins inhibit aromatase activity and attenuate tamoxifen resistance in HER2/neu-transfected human breast cancer cells through tyrosine kinase suppression. European Journal of Cancer 2004; 40:2165-2174.
7
8. Maity R, Chatterjee M, Banerjee A, Das A, Mishra R, Mazumder S, et al. Gold nanoparticle-assisted enhancement in the anti-cancer properties of theaflavin against human ovarian cancer cells. Materials Science and Engineering: C 2019; 104:109909.
8
9. O’Neill EJ, Termini D, Albano A, Tsiani E. Anti-Cancer Properties of Theaflavins. Molecules 2021; 26:987.
9
10. Adhikary A, Mohanty S, Lahiry L, Hossain DMS, Chakraborty S, Das T. Theaflavins retard human breast cancer cell migration by inhibiting NF-κB via p53-ROS cross-talk. FEBS letters 2010; 584:7-14.
10
11. Ou L, Lin S, Song B, Liu J, Lai R, Shao L. The mechanisms of graphene-based materials-induced programmed cell death: a review of apoptosis, autophagy, and programmed necrosis. International journal of nanomedicine 2017; 12:6633.
11
12. Li J, Liu G, Li L, Yao Z, Huang J. Research progress on the effect of autophagy-lysosomal pathway on tumor drug resistance. Experimental cell research 2020; 389:111925.
12
13. Liu L, Liao J-Z, He X-X, Li P-Y. The role of autophagy in hepatocellular carcinoma: friend or foe. Oncotarget 2017; 8:57707.
13
14. Marino G, Niso-Santano M, Baehrecke EH, Kroemer G. Self-consumption: the interplay of autophagy and apoptosis. Nature reviews Molecular cell biology 2014; 15:81-94.
14
15. Yun CW, Lee SH. The roles of autophagy in cancer. International journal of molecular sciences 2018; 19:3466.
15
16. Nazio F, Bordi M, Cianfanelli V, Locatelli F, Cecconi F. Autophagy and cancer stem cells: molecular mechanisms and therapeutic applications. Cell Death & Differentiation 2019; 26:690-702.
16
17. Aryal P, Kim K, Park PH, Ham S, Cho J, Song K. Baicalein induces autophagic cell death through AMPK/ULK1 activation and downregulation of m TORC 1 complex components in human cancer cells. The FEBS journal 2014; 281:4644-4658.
17
18. Yang ZJ, Chee CE, Huang S, Sinicrope FA. The role of autophagy in cancer: therapeutic implications. Molecular cancer therapeutics 2011; 10:1533-1541.
18
19. White E, DiPaola RS. The double-edged sword of autophagy modulation in cancer. Clinical cancer research 2009; 15:5308-5316.
19
20. Kondo Y, Kondo S. Autophagy and cancer therapy. Autophagy 2006; 2:85-90.
20
21. Sekiyama K, Nakai M, Fujita M, Takenouchi T, Waragai M, Wei J, et al. Theaflavins stimulate autophagic degradation of a-synuclein in neuronal cells. Open Journal of Neuroscience 2012; 2.
21
22. Liu G, Zou H, Luo T, Long M, Bian J, Liu X, et al. Caspase-dependent and caspase-independent pathways are involved in cadmium-induced apoptosis in primary rat proximal tubular cell culture. PloS one 2016; 11:e0166823.
22
23. Tabuchi K, Nakayama M, Nishimura B, Hayashi K, Hara A. Early detection of nasopharyngeal carcinoma. International journal of otolaryngology 2011; 2011.
23
24. Cho WC-s. Nasopharyngeal carcinoma: molecular biomarker discovery and progress. Molecular cancer 2007; 6:1-9.
24
25. Cao S-M, Simons MJ, Qian C-N. The prevalence and prevention of nasopharyngeal carcinoma in China. Chinese journal of cancer 2011; 30:114.
25
26. Hibasami H, Komiya T, Achiwa Y, Ohnishi K, Kojima T, Nakanishi K, et al. Black tea theaflavins induce programmed cell death in cultured human stomach cancer cells. International journal of molecular medicine 1998; 1:725-732.
26
27. Lawen A. Apoptosis—an introduction. Bioessays 2003; 25:888-896.
27
28. Reed JC. Mechanisms of apoptosis. The American journal of pathology 2000; 157:1415-1430.
28
29. Bagci E, Vodovotz Y, Billiar T, Ermentrout G, Bahar I. Bistability in apoptosis: roles of bax, bcl-2, and mitochondrial permeability transition pores. Biophysical journal 2006; 90:1546-1559.
29
30. Fletcher JI, Meusburger S, Hawkins CJ, Riglar DT, Lee EF, Fairlie WD, et al. Apoptosis is triggered when prosurvival Bcl-2 proteins cannot restrain Bax. Proceedings of the National Academy of Sciences 2008; 105:18081-18087.
30
31. Czabotar PE, Lessene G, Strasser A, Adams JM. Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy. Nature reviews Molecular cell biology 2014; 15:49-63.
31
32. Hoshyar R, Bathaie SZ, Sadeghizadeh M. Crocin triggers the apoptosis through increasing the Bax/Bcl-2 ratio and caspase activation in human gastric adenocarcinoma, AGS, cells. DNA and cell biology 2013; 32:50-57.
32
33. Li J, Liu F, Jiang S, Liu J, Chen X, Zhang S, et al. Berberine hydrochloride inhibits cell proliferation and promotes apoptosis of non-small cell lung cancer via the suppression of the MMP2 and Bcl-2/Bax signaling pathways. Oncology letters 2018; 15:7409-7414.
33
34. Wei L, Chen Q, Guo A, Fan J, Wang R, Zhang H. Asiatic acid attenuates CCl4-induced liver fibrosis in rats by regulating the PI3K/AKT/mTOR and Bcl-2/Bax signaling pathways. International immunopharmacology 2018; 60:1-8.
34
35. Porter AG, Jänicke RU. Emerging roles of caspase-3 in apoptosis. Cell death & differentiation 1999; 6:99-104.
35
36. Kuida K. Caspase-9. The international journal of biochemistry & cell biology 2000; 32:121-124.
36
37. Bai D-P, Zhang X-F, Zhang G-L, Huang Y-F, Gurunathan S. Zinc oxide nanoparticles induce apoptosis and autophagy in human ovarian cancer cells. International journal of nanomedicine 2017; 12:6521.
37
38. Montani MSG, Granato M, Santoni C, Del Porto P, Merendino N, D’Orazi G, et al. Histone deacetylase inhibitors VPA and TSA induce apoptosis and autophagy in pancreatic cancer cells. Cellular Oncology 2017; 40:167-180.
38
39. Zhang H-W, Hu J-J, Fu R-Q, Liu X, Zhang Y-H, Li J, et al. Flavonoids inhibit cell proliferation and induce apoptosis and autophagy through downregulation of PI3Kγ mediated PI3K/AKT/mTOR/p70S6K/ULK signaling pathway in human breast cancer cells. Scientific Reports 2018; 8:1-13.
39
40. Pang M-j, Yang Z, Zhang X-l, Liu Z-f, Fan J, Zhang H-y. Physcion, a naturally occurring anthraquinone derivative, induces apoptosis and autophagy in human nasopharyngeal carcinoma. Acta Pharmacologica Sinica 2016; 37:1623-1640.
40
41.Klionsky DJ, Abdel-Aziz AK, Abdelfatah S, Abdellatif M, Abdoli A, Abel S, et al. Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy 2021:1-382.
41
42. Kaizuka T, Morishita H, Hama Y, Tsukamoto S, Matsui T, Toyota Y, et al. An autophagic flux probe that releases an internal control. Molecular Cell 2016; 64:835-849.
42
43. Jung CH, Ro S-H, Cao J, Otto NM, Kim D-H. mTOR regulation of autophagy. FEBS letters 2010; 584:1287-1295.
43
44. Klionsky DJ, Meijer AJ, Codogno P, Neufeld TP, Scott RC. Autophagy and p70S6 kinase. Autophagy 2005; 1:59-61.
44
ORIGINAL_ARTICLE
Metabotropic glutamate receptor: A new possible therapeutic target for cochlear synaptopathy
Objective(s): Cochlear synaptopathy is a common cause of auditory disorders in which glutamate over-activation occurs. Modulating glutamatergic pathways has been proposed to down-regulate post-synaptic excitation.Materials and Methods: 12-guinea pigs as sham and test groups were exposed to a 4-kHz noise at 104 dB SPL, for 2 hr. Pre-exposure intra-tympanic injection with LY354740 and normal saline 9% was applied in the test and sham groups. The amplitude growth of ABR-wave-I and wave-III latency shift with noise were considered in pre- and post-exposure times. The synapses were observed by transmission electron-microscopy.Results: ABR thresholds recovered 1-week post-exposure in both groups. The reduction of wave-I amplitude at 4, 6, and 8 kHz were statistically different between pre- and 1- day post-exposure and recovered mostly in the sham group. The amount of latency shift in masked ABR was different between pre- and all post-exposure, and the response could not be detected at higher than 50 dB SL noise. However, the response detectability increased to 60 dB SL noise, and the significance of differences between pre- and post-exposure persisted only at the high level of noise in the test group. In electron-microscopy of sham samples, the size of the ribbon was larger, spherical with an irregularity, and hollow. The post-synaptic density was thicker and missed its flat orientation.Conclusion: The higher slope of the ABR-wave I amplitude, the more tolerance of noise in masked ABR, concomitant with the histological finding that revealed less synaptic damage, confirmed the therapeutic effect of LY354740 in cochlear synaptopathy.
https://ijbms.mums.ac.ir/article_19350_4b07c8a037577d45573db88c22180aa3.pdf
2022-01-01
75
83
10.22038/ijbms.2021.59970.13296
Cochlear synaptopathy
Excitotoxicity
Glutamate
Hidden hearing loss
Noise-induced hearing loss
Parvane
Mahdi
parvanemahdi@yahoo.com
1
Department of Audiology, School of Rehabilitation Sciences, Iran University of Medical Sciences. Tehran, Iran
LEAD_AUTHOR
Akram
Pourbakht
pourbakht.a@iums.ac.ir
2
Department of Audiology, School of Rehabilitation Sciences, Iran University of Medical Sciences. Tehran, Iran
AUTHOR
Alireza
Yazdi
karimya@sina.tums.ac.ir
3
Department of Otorhinolaryngology-Head and Neck Surgery, Imam Khomeini Educational Hospital Complex, Tehran University of Medical Sciences. Tehran, Iran
AUTHOR
Mahtab
Anari
mahtab_rabbani@yahoo.com
4
Otorhinolaryngology Research Center, Amir-Alam Educational Complex, Tehran University of Medical Sciences. Tehran, Iran
AUTHOR
Vahid
Mahabadi
vpirhajati.1@gmail.com
5
Department of Neurosciences, School of Medicine. Iran University of Medical Sciences. Tehran, Iran
AUTHOR
Mohammad
Kamali
kamali@mkamali.com
6
Department of Rehabilitation Management, School of Rehabilitation Sciences, Iran University of Medical Sciences. Tehran, Iran
AUTHOR
1. Lu Y. Metabotropic glutamate receptors in auditory processing. Neurosci 2014; 22: 429-445.
1
2. Kim KX, Payne Sh, Yang-Hood A, Li SZ, Davis B, Carlquist J, et al. Vesicular glutamatergic transmission in noise-induced loss and repair of cochlear ribbon synapses. J Neurosci 2019; 39: 4434-4447.
2
3. Sun Q, Sun JH, Shan XZ, Li XQ. Effect of glutamate on distortion product otoacoustic emission and auditory brainstem response in guinea pigs. Chinese J Otolaryng Head Neck 2005; 40: 435-439.
3
4. Liu T, Petrof I, Sherman SM. Modulatory effects of activation of metabotropic glutamate receptors on GABAergic circuits in the mouse cortex. J Neurophysiol 2014; 111: 2287–2297.
4
5. Chaki S. Group II metabotropic glutamate receptor agonists as a potential drug for schizophrenia. Eur J Pharmacol 2010; 639: 59- 66.
5
6. O’Brien DE, Conn J. Neurobiological insights from mGlu receptor allosteric modulation. Int J Neuropsychoph 2016; 19: 1–10.
6
7. Ngomba RT, Luijtelaar GV. Metabotropic glutamate receptors as drug targets for the treatment of absence epilepsy. Curr Opin Pharmacol 2018; 38: 43-50.
7
8. Popik P, Kozela E, Pilc A. Selective agonist of group II glutamate metabotropic receptors, LY354740, inhibits tolerance to analgesic effects of morphine in mice. Br J Pharmacol 2000; 130:1425-1431.
8
9. Boemer T, Bygrave AM, Chen J, Fernando A, Jackson S, et al. The group II metabotropic glutamate receptor agonist LY354740 and the D2 receptor antagonist haloperidol reduce locomotor hyperactivity but fail to rescue spatial working memory in GluA1 knockout mice. Eur J Neorosci 2017; 45: 912-921.
9
10. Lu H, Wang X, Sun W, Hu Y, Gong S. New insights into glutamate ototoxicity in cochlear hair cells and spiral ganglion neurons. Acta Oto Laryngol 2010; 130: 1316–1323.
10
11. Liberman MC, Kujawa SG. Cochlear synaptopathy in acquired sensorineural hearing loss: manifestations and mechanisms. Hearing Res 2017; 349: 138-147.
11
12. Swanson CJ, Bures M, Johnson MP, Linden AM, Monn JA, Schoepp DD. Metabotropic glutamate receptors as novel targets for anxiety and stress disorders. Nat Rev Drug Discov 2005; 4:131-144.
12
13. Hickman TT, Hashimoto K, Liberman LD, Liberman MC. Cochlear synaptic degeneration and regeneration after noise: effects of age and neuronal subgroup. Front Cell Neurosci 2021; 15:684706.
13
14. Ohinata Y, Miller JM, Schacht J. Protection from noise-induced lipid peroxidation and hair cell loss in the cochlea. Brain Res. 2003; 966: 265-273.
14
15. Yao H, Feng YB, Pang YJ, Yu BX, Liu XP. Inhibitory effect of group II mGluR agonist 2R, 4R-APDC on cell proliferation in dentate gyrus in rats with epileptic seizure. Eur Rev Med Pharmacol Sci. 2015; 19: 2922-2927.
15
16. Duan M, Agerman K, Ernfors P, Canlon B. Complementary roles of neurotrophin 3 and a N-methyl-D-aspartate antagonist in the protection of noise and aminoglycoside induced ototoxicity. PNAS 2000; 97: 7597-7602.
16
17. Chaki S. Group II metabotropic glutamate receptor agonists as a potential drug for schizophrenia. Eur J Pharmacol 2010; 639: 59- 66.
17
18. Chandrasekaran K, Muraqundla A, Demarest TG, Choi J, Saqi AR, Najimi N, et al. mGluR2/3 activation of the SIRT1 axis preserves mitochondrial function in diabetic neuropathy. Ann Clin Transl Neurol 2017; 4: 844-858.
18
19. Bratek E, Zeimbowicz A, Bronisz A, Salinska E. The activation of group II metabotropic glutamate receptors protects neonatal rat brains from oxidative stress injury after hypoxia-ischemia. Plos one 2018; 13: 1-19.
19
20. https://ethics.research.ac.ir/AnimalLabs.php
20
21. https://www.sigmaaldrich.cn/CN/zh/product/sigma/l1045
21
22. Sadreev II, Burwood GW, Flaherty SM, Kim J, Russell IJ, et al. Drug diffusion along an intact mammalian cochlea. Front Cell Neurosci 2019; 13: 1-11.
22
23. Salt AN, Plotke SK. Principles of local drug delivery to the inner ear. Audiol Neurootol 2009; 14: 350-360.
23
24. Viberg A. Canlon B. The guide to plotting a cochleogram. Hear Res 2004; 197: 1–10.
24
25. Kobel M, Le Prell CG, Liu J, Hawks Jw and Bao J. Noise-induced cochlear synaptopathy: Past findings and future studies. Hear Res 2017; 349:148-154.
25
26. Lobarinas E, Spankovich CH, Le Prell CG. Evidence of “hidden hearing loss” following noise exposures that produce robust TTS and ABR wave-I amplitude reductions. Hear Res 2017; 349: 155-163.
26
27. Shi L, Chang Y, Li X, Aiken S, Liu L, Wang J. Cochlear synaptopathy and noise-induced hidden hearing loss. Neural Plast 2016; 2016: 1-9.
27
28. Kujawa SG, Liberma MC. Adding insult to injury: cochlear nerve degeneration after ‘temporary’ noise-induced hearing loss. J Neurosci 2009; 29, 14077-14085.
28
29. Lin HW, Furman AC, Kujawa SG, Liberman MC. Primary neural degeneration in the Guinea pig cochlea after reversible noise-induced threshold shift. J Assoc Res Otolaryngol, 2011; 12, 605-616.
29
30. Valero MD, Burton JA, Hauser SN, Hackett TA, Ramachandran R, Libermn MC. Noise-induced cochlear synaptopathy in rhesus monkeys (Macaca mulatta). Hear Res 2017; 353: 213-223.
30
31. Paquette AT, Gilels F and White PM. Noise exposure modulates cochlear inner hair cell ribbon volumes, correlating with changes in auditory measures in the FVB/nJ mouse. Sci Rep 2016; 6: 25056. 32. Hickox AE, Larsen E, Heinz MG, Shinobu L, Whitton JP. Translational issues in cochlear synaptopathy. Hear Res 2017; 349: 164-171.
31
33. Bramhall NF, Konrad-Martin D, McMillan GP and Griest SE. Auditory brainstem response altered in humans with noise exposure despite normal outer hair cell function. Ear Hear 2017; 38: e1–e12. 34. Mehraei X. Hickox AX. Bharadwaj HM. Goldberg H. Verhulst S. Liberman MC, et al. Auditory brainstem response latency in noise as a marker of cochlear synaptopathy. J Neurosci 2016; 36: 3755–3764.
32
35. Burkard R, Hecox K. The effect of broadband noise on the human brainstem auditory evoked response. I. Rate and intensity effects. J Acoust Soc Am 1983; 74:1204-1213.
33
36. Song Q, Shen P, Li X, Shi L, Liu L, Wang J, et al. Coding deficits in hidden hearing loss induced by noise: the nature and impacts. Sci Rep 2016; 6: 25200.
34
37. Byrnes KR, Loane DJ, Faden AL. Metabotropic glutamate receptors as targets for multipotential treatment of neurological disorders. Neurother 2009; 6: 94-107.
35
38. Schoepp DD, Monn JA, Marek GJ, Aghajanian G, Moghadam B. LY354740: A Systemically active mGlu2/mGlu3 receptor agonist. CNS Drug Rev 1999; 5: 1-12.
36
ORIGINAL_ARTICLE
Therapeutic effect of acute and chronic use of different doses of vitamin D3 on seizure responses and cognitive impairments induced by pentylenetetrazole in immature male rats
Objective(s): This study aimed to evaluate the effects of acute and chronic intake of different doses of vitamin D3 on seizure responses and cognitive impairment induced by pentylenetetrazole (PTZ) in immature male rats.Materials and Methods: Sixty-six immature male NMRI rats were divided into control (10), epileptic (10), and treatment groups (46). The stage 5 latency (S5L) and stage 5 duration (S5D) were assessed along with the shuttle box test. Levels of antioxidant enzymes and inflammatory factors along with genes involved in inflammation, oxidative damage, apoptosis, and mTORc1 were measured in the hippocampus tissue of the brain of controlled and treated rats. Serum levels of parathyroid hormone (PTH), vitamin D, calcium, and phosphorus were also assessed.Results: The results showed that the ability to learn, memory consolidation, and memory retention in epileptic rats were reduced. In addition, S5D increased and S5L decreased in epileptic rats, while being effectively ameliorated by chronic and acute vitamin D intake. The results showed that vitamin D in different doses acutely and chronically decreased the levels of oxidative and inflammatory biomarkers in hippocampus tissue and inhibited the expression of genes involved in inflammation, oxidative damage, apoptosis, and mTORc1 in the hippocampus tissue of epileptic rats. Conclusion: The results showed that vitamin D in different doses acutely and chronically could improve cognitive impairments and convulsive responses in epileptic rats by improving neurotransmission, inflammation, apoptosis, and oxidative damage.
https://ijbms.mums.ac.ir/article_19398_4fb8aa02f48237265c5f5125bd12cb11.pdf
2022-01-01
84
95
10.22038/ijbms.2021.60123.13328
Apoptosis
Epilepsy
GABA receptor
Inflammation
NMDA receptor
Vitamin D3
Hong
Jiang
jianghongfuyou@sina.com
1
Department of Pediatric, Weinan Maternal and Child Health Hospital, Weinan, 714000, China
AUTHOR
Suying
Zhang
applezhsyy@sina.com
2
Department of Child Health, Weinan Central Hospital, Weinan, 714000, China
LEAD_AUTHOR
1. Cebeci AN, Ekici B. Epilepsy treatment by sacrificing vitamin D. Expert Review Neurother 2014; 14:481-491.
1
2. WHO. WHO global report on epilepsy. World Health Organization. 2019.
2
3. Amza A, editor Global health: epilepsy. In Seminars in neurology; 2018 2018: Thieme Medical Publishers.
3
4. Operto FF, Pastorino GMG, Mazza R, Carotenuto M, Roccella M, Marotta R, et al. Effects on executive functions of antiepileptic monotherapy in pediatric age. Epilepsy Behav 2020; 102:106648-106654.
4
5. Stafstrom CE, Carmant L. Seizures and epilepsy: an overview for neuroscientists. Cold Spring Harb Perspect Med 2015; 5:22426-22444.
5
6. Sudha K, Rao AV, Rao A. Oxidative stress and antioxidants in epilepsy. Clin Chim Acta 2001; 303:19-24.
6
7. Ambrogini P, Torquato P, Bartolini D, Albertini MC, Lattanzi D, Di Palma M, et al. Excitotoxicity, neuroinflammation and oxidant stress as molecular bases of epileptogenesis and epilepsy-derived neurodegeneration: the role of vitamin E. Biochim Biophy Acta Mol Basis Dis 2019; 1865:1098-1112.
7
8. Bagla S, Dombkowski AA. Neuroinflammatory nexus of pediatric epilepsy. J Pediatr epilepsy 2018; 7:32-39.
8
9. Méndez-Armenta M, Nava-Ruíz C, Juárez-Rebollar D, Rodríguez-Martínez E, Yescas Gómez P. Oxidative stress associated with neuronal apoptosis in experimental models of epilepsy. Oxid Medicine Cell Longev 2014; :293689-293701.
9
10. Rojas A, Chen D, Ganesh T, Varvel NH, Dingledine R. The COX-2/prostanoid signaling cascades in seizure disorders. Expert opinion on therapeutic targets 2019;23(1):1-13.
10
11. Xiao Z, Peng J, Gan N, Arafat A, Yin F. Interleukin- 1β plays a pivotal role via the PI3K/Akt/mTOR signaling pathway in the chronicity of mesial temporal lobe epilepsy. Neuroimmunomodulation 2016; 23:332-344.
11
12. Sultan S, Taimuri U, Basnan SA, Ai-Orabi WK, Awadallah A, Almowald F, et al. Low vitamin D and its association with cognitive impairment and dementia. J Aging Res 2020; :6097820-6097830.
12
13. Teagarden DL, Meador KJ, Loring DW. Low vitamin D levels are common in patients with epilepsy. Epilepsy Res 2014; 108:1352-1356.
13
14. Clemens Z, Holló A, Kelemen A, Rásonyi G, Fabó D, Halász P, et al. Seasonality in epileptic seizures. J Neurol Transl Neurosci 2013; 1:1016-1019.
14
15. Roth DE, Abrams SA, Aloia J, Bergeron G, Bourassa MW, Brown KH, et al. Global prevalence and disease burden of vitamin D deficiency: a roadmap for action in low- and middle-income countries. Ann N Y Acad Sci 2018; 1430:44-79.
15
16. Lenck-Santini P-P, Scott RC. Mechanisms responsible for cognitive impairment in epilepsy. Cold Spring Harb Perspect Med 2015; 5:22772-22787.
16
17. Junges C, Machado TD, Nunes PRS, Riesgo R, Mello EDd. Vitamin D deficiency in pediatric patients using antiepileptic drugs: systematic review with meta-analysis. J Pediatr 2020; 96:559-568.
17
18. Yazdi SAM, Abbasi M, Yazdi SMM. Epilepsy and vitamin D: a comprehensive review of current knowledge. Rev Neurosci 2017; 28:185-201.
18
19. Groves NJ, Burne THJ. The impact of vitamin D deficiency on neurogenesis in the adult brain. Neural Regen Res 2017; 12:393- 394.
19
20. Breitling LP, Perna L, Müller H, Raum E, Kliegel M, Brenner H. Vitamin D and cognitive functioning in the elderly population in Germany. Exp Gerontol 2012; 47:122-127.
20
21. Holló A, Clemens Z, Kamondi A, Lakatos P, Szűcs A. Correction of vitamin D deficiency improves seizure control in epilepsy: a pilot study. Epilepsy Behav 2012; 24:131-133.
21
22. Lauer AA, Janitschke D, Hartmann T, Grimm HS, Grimm MOW. The effects of vitamin D deficiency on neurodegenerative diseases. In: Vitam D Deficiency. IntechOpen. 3th ed. Homburg/Saar, Germany: Saarland University; 2019:125-150.
22
23. Pendo K, DeGiorgio CM. Vitamin D3 for the treatment of epilepsy: basic mechanisms, animal models, and clinical trials. Front Neurol 2016; 7:218-224.
23
24. Kalueff AV, Minasyan A, Tuohimaa P. Anticonvulsant effects of 1, 25-dihydroxyvitamin D in chemically induced seizures in mice. Brain Res Bull 2005; 67:156-160.
24
25. Palizvan MR, Fathollahi Y, Semnanian S, Hajezadeh S, Mirnajafizadh J. Differential effects of pentylenetetrazol-kindling on long-term potentiation of population excitatory postsynaptic potentials and population spikes in the CA1 region of rat hippocampus. Brain Res 2001; 898:82-90.
25
26. Rauca C, Pohle W, Grunenberg K, Franze S. Hypothermia inhibits pentylenetetrazol kindling and prevents kindling-induced deficit in shuttle-box avoidance. Pharmacol Biochem Behav 2000; 65:23-30.
26
27. Esterbauer H, Cheeseman KH. Determination of aldehydic lipid peroxidation products: malonaldehyde and 4-hydroxynonenal. Methods Enzymol 1990; 186:407-421.
27
28. Fukuzawa K, Tokumurai A. Glutathione peroxidase activity in tissues of vitamin E-deficient mice. J Nutr Sci Vitaminol 1976; 22:405-407.
28
29. Genet S, Kale RK, Baquer NZ. Alterations in antioxidant enzymes and oxidative damage in experimental diabetic rat tissues: effect of vanadate and fenugreek (Trigonella foenum graecum). Mol Cell Biochem 2002; 236:7-12.
29
30. Aebi H. Catalase. In: Methods of enzymatic analysis. Bergmeyer HU. Elsevier; 1974:673-684.
30
31. Rotruck JT, Pope AL, Ganther HE, Swanson AB, Hafeman DG, Hoekstra WG. Selenium: biochemical role as a component of glutathione peroxidase. Sci 1973; 179:588-590.
31
32. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2− ΔΔCT method. Methods 2001; 25:402-408.
32
33. Mahmoudi T, Lorigooini Z, Rafieian-Kopaei M, Arabi M, Rabiei Z, Bijad E, et al. Effect of Curcuma zedoaria hydro-alcoholic extract on learning, memory deficits and oxidative damage of brain tissue following seizures induced by pentylenetetrazole in rat. Behav Brain Funct 2020; 16:1-12.
33
34. Shimada T, Yamagata K. Pentylenetetrazole-induced kindling mouse model. J Vis Exp 2018; 136:56573-56583.
34
35. Yuan X, Fu Z, Ji P, Guo L, Al-Ghamdy AO, Alkandiri A, et al. Selenium nanoparticles pre-treatment reverse behavioral, oxidative damage, neuronal loss and neurochemical alterations in pentylenetetrazole-induced epileptic seizures in mice. Int J Nanomedicine 2020; 15:6339-6353.
35
36. Hamadi N, Sheikh A, Madjid N, Lubbad L, Amir N, Shehab SA-DS, et al. Increased pro-inflammatory cytokines, glial activation and oxidative stress in the hippocampus after short-term bilateral adrenalectomy. BMC Neurosci 2016; 17:1-18.
36
37. Engel T, Henshall DC. Apoptosis, Bcl-2 family proteins and caspases: the ABCs of seizure-damage and epileptogenesis? Int J Physiol Pathophysiol Pharmacol 2009; 1:97-115.
37
38. Shi Y, Zhang L, Teng J, Miao W. HMGB1 mediates microglia activation via the TLR4/NF-κB pathway in coriaria lactone induced epilepsy. Mol Med Rep 2018; 17:5125-5131.
38
39. Paudel YN, Shaikh M, Chakraborti A, Kumari Y, Aledo-Serrano Á, Aleksovska K, et al. HMGB1: a common biomarker and potential target for TBI, neuroinflammation, epilepsy, and cognitive dysfunction. Front Neurosci 2018; 12:628-647.
39
40. Xiao Z, Peng J, Wu L, Arafat A, Yin F. The effect of IL-1β on synaptophysin expression and electrophysiology of hippocampal neurons through the PI3K/Akt/mTOR signaling pathway in a rat model of mesial temporal lobe epilepsy. Neurol Res 2017; 39:640-648.
40
41. Streicher KL, Willmarth NE, Garcia J, Boerner JL, Dewey TG, Ethier SP. Activation of a nuclear factor κB/interleukin-1 positive feedback loop by amphiregulin in human breast cancer cells. Mol Cancer Res 2007; 5:847-861.
41
42. Vezzani A, Baram TZ. New roles for interleukin-1 Beta in the mechanisms of epilepsy. Epilepsy Curr 2007; 7:45-50.
42
43. Xiao Z, Peng J, Yang L, Kong H, Yin F. Interleukin-1β plays a role in the pathogenesis of mesial temporal lobe epilepsy through the PI3K/Akt/mTOR signaling pathway in hippocampal neurons. J Neuroimmunol 2015; 282:110-117.
43
44. Steinbrecher KA, Wilson W, 3rd, Cogswell PC, Baldwin AS. Glycogen synthase kinase 3beta functions to specify gene-specific, NF-kappaB-dependent transcription. Mol Cell Biol 2005; 25:8444-8455.
44
45. Mattson MP, Camandola S. NF-kappaB in neuronal plasticity and neurodegenerative disorders. J Clin Invest 2001; 107:247-254.
45
46. Al Khalifah R, Hudairi A, Al Homyani D, Hamad MH, Bashiri FA. Vitamin D supplementation to prevent vitamin D deficiency for children with epilepsy: randomized pragmatic trial protocol. Med 2018; 97:12734-12739.
46
47. Kalueff AV, Minasyan A, Keisala T, Kuuslahti M, Miettinen S, Tuohimaa P. Increased severity of chemically induced seizures in mice with partially deleted vitamin D receptor gene. Neurosci Lett 2006; 394:69-73.
47
48. Hii CS, Ferrante A. The non-genomic actions of vitamin D. Nutrients 2016; 8:135-149.
48
49. Norman AW. Vitamin D receptor: new assignments for an already busy receptor. Endocrinol 2006; 147:5542-5548.
49
50. Janjoppi L, Katayama MH, Scorza FA, Folgueira MAAK, Brentani M, Pansani AP, et al. Expression of vitamin D receptor mRNA in the hippocampal formation of rats submitted to a model of temporal lobe epilepsy induced by pilocarpine. Brain Res Bull 2008; 76:480-484.
50
51. Sadeghi K, Wessner B, Laggner U, Ploder M, Tamandl D, Friedl J, et al. Vitamin D3 down-regulates monocyte TLR expression and triggers hyporesponsiveness to pathogen-associated molecular patterns. Europ J Immunol 2006; 36:361-370.
51
52. Farhangi MA, Mesgari-Abbasi M, Hajiluian G, Nameni G, Shahabi P. Adipose tissue inflammation and oxidative stress: the ameliorative effects of vitamin D. Inflammation 2017; 40:1688-1697.
52
53. Zhang H, Yang N, Wang T, Dai B, Shang Y. Vitamin D reduces inflammatory response in asthmatic mice through HMGB1/TLR4/NFκB signaling pathway. Mol Med Rep 2018; 17:2915-2920.
53
54. Kim MS, Lee S, Jung N, Lee K, Choi J, Kim S-H, et al. The vitamin D analogue paricalcitol attenuates hepatic ischemia/reperfusion injury through down-regulation of toll-like receptor 4 signaling in rats. Arch Med Sci 2017; 13:459-569.
54
55. Lisse TS, Hewison M. Vitamin D. Cell Cycle 2011; 10:1888-1889.
55
56. Lisse TS, Liu T, Irmler M, Beckers J, Chen H, Adams JS, et al. Gene targeting by the vitamin D response element binding protein reveals a role for vitamin D in osteoblast mTOR signaling. FASEB J 2011; 25:937-947.
56
57. Eyles DW. Vitamin D: Brain and behavior. JBMR Plus 2020; 5:10419-10431.
57
58. Shirazi HA, Rasouli J, Ciric B, Rostami A, Zhang G-X. 1, 25-dihydroxyvitamin D3 enhances neural stem cell proliferation and oligodendrocyte differentiation. Exp Mol Pathol 2015; 98:240-245.
58
59. Araque A, Navarrete M. Glial cells in neuronal network function. Philos Trans R Soc Biol Sci 2010; 365:2375-2381.
59
60. da Silva Teixeira S, Harrison K, Uzodike M, Rajapakshe K, Coarfa C, He Y, et al. Vitamin D actions in neurons require the PI3K pathway for both enhancing insulin signaling and rapid depolarizing effects. J Steroid Biochem Mol Biol 2020; 200:105690-105709.
60
ORIGINAL_ARTICLE
C-Kit+ cells can modulate asthmatic condition via differentiation into pneumocyte-like cells and alteration of inflammatory responses via ERK/NF-ƙB pathway
Objective(s): The exact role of the progenitor cell types in the dynamic healing of asthmatic lungs is lacking. This investigation was proposed to evaluate the effect of intratracheally administered rat bone marrow-derived c-kit+ cells on ovalbumin-induced sensitized male rats.Materials and Methods: Forty rats were randomly divided into 4 groups; healthy rats received phosphate-buffered saline (PBS) (C); sensitized rats received PBS (S); PBS containing C-kitˉ cells (S+C-kit-); and PBS containing C-kit+ cells (S+C-kit+). After two weeks, circulatory CD4+/CD8+ T-cell counts and pulmonary ERK/NF-ƙB signaling pathway as well as the probability of cellular differentiation were assessed. Results: The results showed that transplanted C-Kit+ cells were engrafted into pulmonary tissue and differentiated into epithelial cells. C-Kit+ cells could increase the number of CD4+ cells in comparison with the S group (P<0.001); however, they diminished the level of CD8+ cells (P<0.01). Moreover, data demonstrated increased p-ERK/ERK ratio (P<0.001) and NF-ƙB level (P<0.05) in sensitized rats compared with the C group. The administration of C-kit+, but not C-Kit-, decreased p-ERK/ERK ratio and NF-ƙB level compared with those of the S group (P<0.05). Conclusion: The study revealed that C-Kit+ cells engrafted into pulmonary tissue reduced the NF-ƙB protein level and diminished p-ERK/ERK ratio, leading to suppression of inflammatory response in asthmatic lungs.
https://ijbms.mums.ac.ir/article_19285_23a073496c5f157c1afb8c07b2f3c76a.pdf
2022-01-01
96
102
10.22038/ijbms.2021.59946.13293
Asthma
C-kit cells
CD4+/CD8+
Differentiation
NF-ƙB
p-ERK/ERK
Fatemeh
Mirershadi
fmirershadi@yahoo.com
1
Department of Physiology, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran
AUTHOR
Mahdi
Ahmadi
mahdi59866@gmail.com
2
Tuberculosis and Lung Disease Research Center, Tabriz University of Medical Sciences, Tabriz, Iran
AUTHOR
Reza
Rahbarghazi
rezarahbardvm@gmail.com
3
Stem Cell Research Center, Tabriz University of Medical Sciences, Tabriz, Iran
AUTHOR
Hossain
Heiran
hossin.heiran@gmail.com
4
Department of Physiology, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran
AUTHOR
Rana
Keyhanmanesh
r_keyhanmanesh@yahoo.com
5
Stem Cell Research Center, Tabriz University of Medical Sciences, Tabriz, Iran
LEAD_AUTHOR
1. Pawankar R. Allergic diseases and asthma: A global public health concern and a call to action. World Allergy Organ J 2014; 7:1939-4551.
1
2. Papi A, Brightling C, Pedersen SE, Reddel HK. Asthma. Lancet 2018; 391:783-800.
2
3. Price MM, Oskeritzian CA, Falanga YT, Harikumar KB, Allegood JC, Alvarez SE, et al. A specific sphingosine kinase 1 inhibitor attenuates airway hyperresponsiveness and inflammation in a mast cell-dependent murine model of allergic asthma. J Allergy Clin Immunol 2013; 131:501-511.
3
4. Endo Y, Nakayama T. Pathogenic Th2 (Tpath2) cells in airway inflammation. Oncotarget 2015; 6:32303-32304.
4
5. Fahy JV. Type 2 inflammation in asthma--present in most, absent in many. Nat Rev Immunol 2015; 15:57-65.
5
6. Foster PS, Maltby S, Rosenberg HF, Tay HL, Hogan SP, Collison AM, et al. Modeling TH2 responses and airway inflammation to understand fundamental mechanisms regulating the pathogenesis of asthma. Immunol Rev 2017; 278:20-40.
6
7. Rogala B, Bozek A, Gluck J, Jarzab J. Prevalence of IgE-mediated allergy and evaluation of Th1/Th2 cytokine profiles in patients with severe bronchial asthma. Postepy Dermatol Alergol 2015; 32:274.
7
8. Guo C-H, Liu P-J, Hsia S, Chuang C-J, Chen P-C. Role of certain trace minerals in oxidative stress, inflammation, CD4/CD8 lymphocyte ratios and lung function in asthmatic patients. Ann Clin Biochem 2011; 48:344-351.
8
9. Miyahara N, Swanson BJ, Takeda K, Taube C, Miyahara S, Kodama T, et al. Effector CD8+ T cells mediate inflammation and airway hyper-responsiveness. Nat med 2004; 10:865-869.
9
10. Ci X, Chu X, Xu X, Li H, Deng X. Short-term roxithromycin treatment attenuates airway inflammation via MAPK/NF-κB activation in a mouse model of allergic asthma. Inflamm Res 2012; 61:749-758.
10
11. Zhang Y, Cardell L-O, Edvinsson L, Xu C-B. MAPK/NF-κB-dependent upregulation of kinin receptors mediates airway hyperreactivity: a new perspective for the treatment. Pharmacol Res 2013; 71:9-18.
11
12. Gras D, Chanez P, Vachier I, Petit A, Bourdin A. Bronchial epithelium as a target for innovative treatments in asthma. Pharmacol Ther 2013; 140:290-305.
12
13. Mishra A, Yao X, Levine SJ. From bedside to bench to clinic trials: identifying new treatments for severe asthma. Dis Model Mech 2013; 6:877-888.
13
14. Wise J. Corticosteroids for asthma may suppress growth in children in first year of treatment, researchers say. BMJ 2014; 349:g4623.
14
15. Ciriaco M, Ventrice P, Russo G, Scicchitano M, Mazzitello G, Scicchitano F, et al. Corticosteroid-related central nervous system side effects. J Pharmacol Pharmacother 2013; 4:S94.
15
16. Ogliari KS, Marinowic D, Brum DE, Loth F. Stem cells in dermatology. An bras dermatol 2014; 89:286-291.
16
17. Bogers SH. Cell-based therapies for joint disease in veterinary medicine: what we have learned and what we need to know. Front Vet Sci 2018; 5:70-86.
17
18. Arnhold S, Elashry MI, Klymiuk MC, Wenisch S. Biological macromolecules and mesenchymal stem cells: Basic research for regenerative therapies in veterinary medicine. Int J Biol Macromol 2019; 123:889.
18
19. Dias IE, Pinto PO, Barros LC, Viegas CA, Dias IR, Carvalho PP. Mesenchymal stem cells therapy in companion animals: useful for immune-mediated diseases? BMC Vet Res 2019; 15:358.
19
20. Marino F, Scalise M, Cianflone E, Mancuso T, Aquila I, Agosti V, et al. Role of c-Kit in myocardial regeneration and aging. Front Endocrinol 2019; 10.
20
21. Micheva-Viteva SN, Shou Y, Nowak-Lovato KL, Rector KD, Hong-Geller E. c-KIT signaling is targeted by pathogenic Yersinia to suppress the host immune response. BMC Microbiol 2013; 13:249.
21
22. Corti S, Nizzardo M, Nardini M, Donadoni C, Salani S, Simone C, et al. Systemic transplantation of c-kit+ cells exerts a therapeutic effect in a model of amyotrophic lateral sclerosis. Hum Mol Genet 2010; 19:3782-3796.
22
23. Moorefield EC, McKee EE, Solchaga L, Orlando G, Yoo JJ, Walker S, et al. Cloned, CD117 selected human amniotic fluid stem cells are capable of modulating the immune response. PLoS One 2011; 6-12.
23
24. Di Trapani M, Bassi G, Fontana E, Giacomello L, Pozzobon M, Guillot PV, et al. Immune regulatory properties of CD117pos amniotic fluid stem cells vary according to gestational age. Stem Cells Dev 2015; 24:132-143.
24
25. Zou T, Gao L, Zeng Y, Li Q, Li Y, Chen S, et al. Organoid-derived C-Kit+/SSEA4− human retinal progenitor cells promote a protective retinal microenvironment during transplantation in rodents. Nat commun 2019; 10:1-17.
25
26. Ellison GM, Vicinanza C, Smith AJ, Aquila I, Leone A, Waring CD, et al. Adult c-kitpos cardiac stem cells are necessary and sufficient for functional cardiac regeneration and repair. Cell 2013; 154:827-842.
26
27. Beltrami AP, Barlucchi L, Torella D, Baker M, Limana F, Chimenti S, et al. Adult cardiac stem cells are multipotent and support myocardial regeneration. Cell 2003; 114:763-776.
27
28. Smith AJ, Lewis FC, Aquila I, Waring CD, Nocera A, Agosti V, et al. Isolation and characterization of resident endogenous c-Kit+ cardiac stem cells from the adult mouse and rat heart. Nat Protoc 2014; 9:1662-1681.
28
29. Ghobadi H, Alipour MR, Keyhanmanesh R, Boskabady MH, Aslani MR. Effect of high-fat diet on tracheal responsiveness to methacholine and insulin resistance index in ovalbumin-sensitized male and female rats. Iran J Allergy Asthma Immunol 2019; 18:48-61.
29
30. Akhavanakbari G, Babapour B, Alipour MR, Keyhanmanesh R, Ahmadi M, Aslani MR. Effect of high fat diet on NF-кB microRNA146a negative feedback loop in ovalbumin-sensitized rats. BioFactors 2019; 45:75-84.
30
31. Khaksar M, Sayyari M, Rezaie J, Pouyafar A, Montazersaheb S, Rahbarghazi R. High glucose condition limited the angiogenic/cardiogenic capacity of murine cardiac progenitor cells in in vitro and in vivo milieu. Cell Biochem Func 2018; 36:346-356.
31
32. Rahbarghazi R, Keyhanmanesh R, Aslani MR, Hassanpour M, Ahmadi M. Bone marrow mesenchymal stem cells and condition media diminish inflammatory adhesion molecules of pulmonary endothelial cells in an ovalbumin-induced asthmatic rat model. Microvasc Res 2019; 121:63-70.
32
33. Dong QM, Ling C, Zhao L. Immunofluorescence analysis of cytokeratin 8/18 staining is a sensitive assay for the detection of cell apoptosis. Oncol Lett 2015; 9:1227-1230.
33
34. Lindsey J, Ganguly K, Brass D, Li Z, Potts E, Degan S, et al. c-Kit is essential for alveolar maintenance and protection from emphysema-like disease in mice. Am J Respir Crit Care Med 2011; 183:1644–1652.
34
35. Spaziano G, Cappetta D, Urbanek K, Piegari E, Esposito G, Matteis M, et al. New role of adult lung c-kit+ cells in a mouse model of airway hyperresponsiveness. Mediators Inflamm 2016; 2016.
35
36. Kajstura J, Rota M, Hall SR, Hosoda T, D’Amario D, Sanada F, et al. Evidence for human lung stem cells. N Engl J Med 2011; 364:1795-1806.
36
37. Sen N, Weprin S, Peter Y. Discrimination between lung homeostatic and injury-induced epithelial progenitor subsets by cell-density properties. Stem Cells Dev 2013; 22:2036-2046.
37
38. Suzuki T, Suzuki S, Fujino N, Ota C, Yamada M, Suzuki T, et al. c-Kit immunoexpression delineates a putative endothelial progenitor cell population in developing human lungs. Am J Physiol-Lung Cell Mol Physiol 2014; 306:L855-L865.
38
39. Liu Q, Huang X, Zhang H, Tian X, He L, Yang R, et al. c-Kit+ cells adopt vascular endothelial but not epithelial cell fates during lung maintenance and repair. Nat Med 2015; 21:866-868.
39
40. Takahashi T, Friedmacher F, Zimmer J, Puri P. Increased c-kit and stem cell factor expression in the pulmonary vasculature of nitrofen-induced congenital diaphragmatic hernia. J Pediatric Surgery 2016; 51:706-709.
40
41. Pelaia G, Vatrella A, Busceti M, Gallelli L, Calabrese C, Terracciano R, et al. Cellular mechanisms underlying eosinophilic and neutrophilic airway inflammation in asthma. Mediators Inflamm 2015; 2015:1-8.
41
42. Ahmadi M, Rahbarghazi R, Soltani S, Aslani MR, Keyhanmanesh R. Contributory anti-inflammatory effects of mesenchymal stem cells, not conditioned media, on ovalbumin-induced asthmatic changes in male rats. Inflammation 2016; 39:1960-1971.
42
43. Ahmadi M, Rahbarghazi R, Aslani MR, Shahbazfar A-A, Kazemi M, Keyhanmanesh R. Bone marrow mesenchymal stem cells and their conditioned media could potentially ameliorate ovalbumin-induced asthmatic changes. Biomed Pharmacother 2017; 85:28-40.
43
44. Li P, Li Z, Zhang G, Yang J, Chen J. CD4+ CD25+ Regulatory T Cells Decreased CD8+ IL-4+ cellsin a mouse model of allergic asthma. Iranian J Allergy Asthma Immunol 2018:1-10.
44
45. Heiran H, Ahmadi M, Rahbarghazi R, Mir-ershadi F, Delkhosh A, Khaksar M, et al. C-Kit+ progenitors restore rat asthmatic lung function by modulation of T-bet and GATA-3 expression. Exp Physiol 2020; 105:1623-1633.
45
46. Rahbarghazi R, Keyhanmanesh R, Rezaie J, Mirershadi F, Heiran H, Saghaei Bagheri H, et al. c-Kit+ cells offer hopes in ameliorating asthmatic pathologies via regulation of miRNA-133 and -126. Iran J Basic Med Sci 2021; 24:1-8.
46
47. Mirershadi F, Ahmadi M, Rezabakhsh A, Rajabi H, Rahbarghazi R, Keyhanmanesh R. Unraveling the therapeutic effects of mesenchymal stem cells in asthma. Stem Cell Res Ther 2020; 11:400-411.
47
48. Damera G, Druey KM, Cooper PR, Krymskaya VP, Soberman RJ, Amrani Y, et al. An rgs4-mediated phenotypic switch of bronchial smooth muscle cells promotes fixed airway obstruction in asthma. PLoS ONE 2012; 7:e28504.
48
49. Schuliga M. NF-kappaB Signaling in chronic inflammatory airway disease. Biomolecules 2015; 5:1266-1283.
49
50. Shimizu K, Konno S, Ozaki M, Umezawa K, Yamashita K, Todo S, et al. Dehydroxymethylepoxyquinomicin (DHMEQ), a novel NF-kappaB inhibitor, inhibits allergic inflammation and airway remodelling in murine models of asthma. Clin Exp Allergy 2012; 42:1273–1281.
50
51. Moore F, Buonocore S, Aksoy E, Ouled-Haddou N, Goriely S, Lazarova E, et al. An alternative pathway of NF-kappaB activation results in maturation and T cell priming activity of dendritic cells overexpressing a mutated IkappaBalpha. J Immunol 2007; 178:1301-1311.
51
52. Hirose K, Wakashin H, Oki m, Kagami S, Suto A, Ikeda K, et al. GS143, an IkappaB ubiquitination inhibitor, inhibits allergic airway inflammation in mice. Biochem biophys Res Commun 2008; 374:507-511.
52
53. Piao H, Choi YH, Li H, Wang C, Xian Z, Ogasawara M, et al. Recombinant pyrin domain protein attenuates allergic inflammation by suppressing NF-κB pathway in asthmatic mice. Scandinavian J Immunol 2019; 89:e12720.
53
54. Kandhare AD, Liu Z, Mukherjee AA, Bodhankar SL. Therapeutic potential of morin in ovalbumin-induced allergic asthma via modulation of SUMF2/IL-13 and BLT2/NF-kB signaling pathway. Current Mol Pharmacol 2019; 12:122-138.
54
55. Pang L, Zou S, Shi Y, Mao Q, Chen Y. Apigenin attenuates PM2. 5-induced airway hyperresponsiveness and inflammation by down-regulating NF-κB in murine model of asthma. Int J Clin Exp Pathol 2019; 12:3700-3709.
55
56. Shin N-R, Lee AY, Song J-H, Yang S, Park I, Lim J-O, et al. Scrophularia buergeriana attenuates allergic inflammation by reducing NF-κB activation. Phytomedicine 2020; 67:153159.
56
57. Liu W, Liang Q, Balzar S, Wenzel S, Gorska M, Alam R. Cell-specific activation profile of extracellular signal-regulated kinase 1/2, jun n-terminal kinase, and p38 mitogen-activated protein kinases in asthmatic airways. J Allergy Clin Immunol 2008; 121:893-902 e892.
57
58. Gaffey K, Reynolds S, Plumb J, Kaur M, Singh D. Increased phosphorylated p38 mitogen activated protein kinase in copd lungs. Eur Respir J 2013; 42:28-41.
58
59. Munoz L, Ramsay E, Manetsch M, Ge Q, Peifer C, Laufer S, et al. Novel p38 MAPK inhibitor ml3403 has potent anti-inflammatory activity in airway smooth muscle. Eur J Pharmacol 2010; 635:212–218.
59
60. Chung K. P38 mitogen-activated protein kinase pathways in asthma and COPD. Chest 2011; 139:1470–1479.
60
ORIGINAL_ARTICLE
Hepatitis B virus X mediates podocyte pyroptosis by regulating the ROS/NLRP3 signaling pathway in hepatitis B virus-associated glomerulonephritis
Objective(s): This study was designed to investigate whether HBx-induced podocyte injury is related to the nucleotide-binding oligomerization domain-like receptor protein 3 (NLRP3) inflammasome and the specific mechanism of the oxidative stress pathway in hepatitis B virus-associated glomerulonephritis (HBV-GN).Materials and Methods: The HBx gene was overexpressed in renal podocytes to mimic HBV-GN. Podocyte morphology was observed under a scanning electron microscope. Reactive oxygen species (ROS) generation was detected by dichlorodihydrofluorescein diacetate (DCFH-DA) assay. The podocytes in each group were treated with Hoechst 33342 and subjected to immunofluorescence staining. Caspase-1 activity and LDH levels were assessed with a Caspase-1 Activity Assay Kit and an LDH ELISA Kit, respectively. The expression of all pyroptosis-related proteins was examined by Western blot analysis.Results: Pyroptosis-related proteins, including NLRP3, apoptosis-associated speck-like protein containing card (ASC), caspase-1, IL-1β, and IL-18 (P<0.05), were up-regulated upon HBx overexpression, and caspase-1 enzyme activity and LDH and Desmin expression were also enhanced (P<0.05). NLRP3 knockdown attenuated the increased expression of pyroptosis-related proteins upon HBx overexpression (P<0.05), which was also achieved by the addition of an ROS inhibitor (P<0.05).Conclusion: HBx regulates podocyte pyroptosis in HBV-GN by targeting the NLRP3 inflammasome, and mitochondrial oxidative stress plays an important role in this process.
https://ijbms.mums.ac.ir/article_19488_92687f9c59c49971b7d4f4f034823b31.pdf
2022-01-01
103
109
10.22038/ijbms.2022.61105.13520
Glomerulonephritis
HBx
NLRP3
Pyroptosis
ROS
Yani
Yu
www.yaniyu1997@163.com
1
Department of Nephrology, The Affiliated Hospital of Qingdao University, Qingdao 266003, Shandong, China
AUTHOR
Hui
Dong
www.donghui19751003@163.com
2
Health Management Center, The Affiliated Hospital of Qingdao University, Qingdao 266003, Shandong, China
AUTHOR
Jingyi
Sun
www.964228125@qq.com
3
Department of Nephrology, The Affiliated Hospital of Qingdao University, Qingdao 266003, Shandong, China
AUTHOR
Baoshuang
Li
www.libaoshuang1234@163.com
4
Department of Nephrology, The Affiliated Hospital of Qingdao University, Qingdao 266003, Shandong, China
AUTHOR
Yueqi
Chen
www.1561213136@qq.com
5
Department of Nephrology, The Affiliated Hospital of Qingdao University, Qingdao 266003, Shandong, China
AUTHOR
Moxuan
Feng
www.fengmoxuan717@163.com
6
Department of Nephrology, The Affiliated Hospital of Qingdao University, Qingdao 266003, Shandong, China
AUTHOR
Xiaoqian
Yang
www.18363990768@163.com
7
Department of Nephrology, The Affiliated Hospital of Qingdao University, Qingdao 266003, Shandong, China
AUTHOR
Wei
Jiang
jwqyfy@163.com
8
Department of Nephrology, The Affiliated Hospital of Qingdao University, Qingdao 266003, Shandong, China
LEAD_AUTHOR
1. Slagle, B. L. et al. Technical standards for hepatitis B virus X protein (HBx) research[J). Hepatology 61, 1416-1424.
1
2. He, P. et al. Hepatitis B virus X protein modulates apoptosis in human renal proximal tubular epithelial cells by activating the JAK2/STAT3 signaling pathway[J]. International journal of molecular medicine 31, 1017-1029.
2
3. Schroder, K. & Tschopp, J. The inflammasomes[J]. Cell 140, 821-832.
3
4. Miller, C. M. et al. The role of the P2X(7) receptor in infectious diseases[J]. PLoS pathogens 7, e1002212
4
5. Jiang, W. et al. Activation of the NLRP3/caspase-1 inflammasome in human dental pulp tissue and human dental pulp fibroblasts[J]. Cell and tissue research 361, 541-555.
5
6. Zhang C,Boini KM,Xia M,et al.Activation of Nod-like receptor protein 3 inflammasomes turns on podocyte injury and glomerular sclerosis in hyperhomocysteinemia[J]. Hypertension,2012,60(1):154-162.
6
7. Wang W,Ding XQ,Gu TT,et al.Pterostilbene and allopurinol reduce fructose-induced podocyte oxidative stress and inflammation via microRNA-377[J]. Free Radical Bio Med,2015,83:214-226.
7
8. Singh GB,Kshirasagar N,Patibandla S,et al.Nicotine instigates podocyte injury via NLRP3 inflammasomes activation[J]. Aging (Albany NY),2019,11(24):12810-12821.
8
9. Nagata, M., Tomari, S., Kanemoto, K., Usui, J. & Lemley, K. V. Podocytes, parietal cells, and glomerular pathology: the role of cell cycle proteins[J]. Pediatric nephrology 18, 3-8.
9
10. Pavenstadt, H., Kriz, W. & Kretzler, M. Cell biology of the glomerular podocyte[J]. Physiological reviews 83, 253-307.
10
11. Lin Chun-Liang,Lee Pei-Hsien,Hsu Yung-Chien et al. MicroRNA-29a promotion of nephrin acetylation ameliorates hyperglycemia-induced podocyte dysfunction.[J] .J Am Soc Nephrol, 2014, 25: 1698-709.
11
12. Herzer, K., Sprinzl, M. F. & Galle, P. R. Hepatitis viruses: live and let die[J]. Liver international : official journal of the International Association for the Study of the Liver 27, 293-301.
12
13. Jiang Wei,Liu Tuo,Dong Hui et al. Relationship Between Serum DNA Replication, Clinicopathological Characteristics and Prognosis of Hepatitis B Virus-associated Glomerulonephritis with Severe Proteinuria by Lamivudine Plus Adefovir Dipivoxil Combination Therapy.[J] .Biomed Environ Sci, 2015, 28: 206-13.
13
14. Fu Baohui,Ji Yue,Hu Shouci et al. Efficacy and safety of anti-viral therapy for Hepatitis B virus-associated glomerulonephritis: A meta-analysis.[J] .PLoS One, 2020, 15: e0227532.
14
15. Xie Wen-Hui,Ding Jian,Xie Xiao-Xia et al. Hepatitis B virus X protein promotes liver cell pyroptosis under oxidative stress through NLRP3 inflammasome activation.[J] .Inflamm Res, 2020, 69: 683-696.
15
16. Diao Zongli,Ding Jiaxiang,Yin Chenghong et al. Purified hepatitis B virus induces human mesangial cell proliferation and extracellular matrix expression in vitro.[J] .Virol J, 2013, 10: 300.
16
17. Hui D,Yan X,Wei J et al. Significance of mutations in hepatitis B virus X gene for the pathogenesis of HB-associated glomerulonephritis.[J] .Acta Virol, 2014, 58: 278-81.
17
18. Qu Siming,Jin Li,Huang Hanfei et al. A positive-feedback loop between HBx and ALKBH5 promotes hepatocellular carcinogenesis.[J] .BMC Cancer, 2021, 21: 686.
18
19. Cho, H. K., Kim, S. Y., Yoo, S. K., Choi, Y. H. & Cheong, J. Fatty acids increase hepatitis B virus X protein stabilization and HBx-induced inflammatory gene expression[J]. The FEBS journal 281, 2228-2239.
19
20. Lee, M. O. et al. Hepatitis B virus X protein induced expression of interleukin 18 (IL-18): a potential mechanism for liver injury caused by hepatitis B virus (HBV) infection[J]. J Hepatol 37, 380-386.
20
21. He Ping,Zhang Beiru,Liu Dajun et al. Hepatitis B Virus X Protein Modulates Apoptosis in NRK-52E Cells and Activates Fas/FasL Through the MLK3-MKK7-JNK3 Signaling Pathway.[J] .Cell Physiol Biochem, 2016, 39: 1433-43.
21
22. Kim Yang Gyun,Kim Su-Mi,Kim Ki-Pyo et al. The Role of Inflammasome-Dependent and Inflammasome-Independent NLRP3 in the Kidney.[J] .Cells, 2019, 8: undefined.
22
23. Patel Seema,Inflammasomes, the cardinal pathology mediators are activated by pathogens, allergens and mutagens: A critical review with focus on NLRP3.[J] .Biomed Pharmacother, 2017, 92: 819-825.
23
24. Zhivaki Dania,Kagan Jonathan C,NLRP3 inflammasomes that induce antitumor immunity.[J] .Trends Immunol, 2021, 42: 575-589.
24
25. Wang Yao,Li Xun,Chen Qian et al. The relationship between liver pathological inflammation degree and pyroptosis in chronic hepatitis B patients.[J] .J Med Virol, 2021, undefined: undefined.
25
26. Franklin, B. S. et al. The adaptor ASC has extracellular and ‘prionoid’ activities that propagate inflammation[J]. Nature immunology 15, 727-737.
26
27. Zhang Ke-Jia,Wu Qi,Jiang Shi-Min et al. Pyroptosis: A New Frontier in Kidney Diseases.[J] .Oxid Med Cell Longev, 2021, 2021: 6686617.
27
28. Jiang Chunxia,Wang Yuping,Guo Man et al. PCB118 Induces Inflammation of Islet Beta Cells via Activating ROS-NLRP3 Inflammasome Signaling.[J] .Biomed Res Int, 2021, 2021: 5522578.
28
29. Xu Qingxue,Zhao Bo,Ye Yingze et al. Relevant mediators involved in and therapies targeting the inflammatory response induced by activation of the NLRP3 inflammasome in ischemic stroke.[J] .J Neuroinflammation, 2021, 18: 123.
29
30. Wang Yue,Zhao Yan,Wang Zhecheng et al. Peroxiredoxin 3 Inhibits Acetaminophen-Induced Liver Pyroptosis Through the Regulation of Mitochondrial ROS.[J] .Front Immunol, 2021, 12: 652782.
30
31. Zheng Tong,Tan Yuqin,Qiu Jiang et al. Alternative polyadenylation trans-factor FIP1 exacerbates UUO/IRI-induced kidney injury and contributes to AKI-CKD transition via ROS-NLRP3 axis.[J] .Cell Death Dis, 2021, 12: 512.
31
32. Abais Justine M,Zhang Chun,Xia Min et al. NADPH oxidase-mediated triggering of inflammasome activation in mouse podocytes and glomeruli during hyperhomocysteinemia.[J] .Antioxid Redox Signal, 2013, 18: 1537-48.
32
33. Conley Sabena M,Abais-Battad Justine M,Yuan Xinxu et al. Contribution of guanine nucleotide exchange factor Vav2 to NLRP3 inflammasome activation in mouse podocytes during hyperhomocysteinemia.[J] .Free Radic Biol Med, 2017, 106: 236-244.
33
34. Abais Justine M,Xia Min,Li Guangbi et al. Contribution of endogenously produced reactive oxygen species to the activation of podocyte NLRP3 inflammasomes in hyperhomocysteinemia.[J] .Free Radic Biol Med, 2014, 67: 211-20.
34
35. Fu Rong,Guo Chaohuan,Wang Shuang et al. Podocyte Activation of NLRP3 Inflammasomes Contributes to the Development of Proteinuria in Lupus Nephritis.[J] .Arthritis Rheumatol, 2017, 69: 1636-1646.
35
36. Yan J,Li Y,Yang H et al. Interleukin-17A participates in podocyte injury by inducing IL-1β secretion through ROS-NLRP3 inflammasome-caspase-1 pathway.[J] .Scand J Immunol, 2018, 87: e12645.
36
37. Li Xue,Zou Yu,Fu Yuan-Yuan et al. Ibudilast Attenuates Folic Acid-Induced Acute Kidney Injury by Blocking Pyroptosis Through TLR4-Mediated NF-κB and MAPK Signaling Pathways.[J] .Front Pharmacol, 2021, 12: 650283.
37
38. Hua Kuo-Feng,Yang Shun-Min,Kao Tzu-Yang et al. Osthole mitigates progressive IgA nephropathy by inhibiting reactive oxygen species generation and NF-κB/NLRP3 pathway.[J] .PLoS One, 2013, 8: e77794.
38
39. Ding Tao,Wang Shaofei,Zhang Xuyao et al. Kidney protection effects of dihydroquercetin on diabetic nephropathy through suppressing ROS and NLRP3 inflammasome.[J] .Phytomedicine, 2018, 41: 45-53.
39
40. Liu Xuemei,Liu Hui,Lu Xiaoxiao et al. N-acetylcysteine alleviates ocular surface damage in STZ-induced diabetic mice by inhibiting the ROS/NLRP3/Caspase-1/IL-1β signaling pathway.[J] .Exp Eye Res, 2021, undefined: 108654.
40
41. Shahzad Khurrum,Bock Fabian,Al-Dabet Moh’d Mohanad et al. Stabilization of endogenous Nrf2 by minocycline protects against Nlrp3-inflammasome induced diabetic nephropathy.[J] .Sci Rep, 2016, 6: 34228.
41
ORIGINAL_ARTICLE
Maternal aromatase inhibition via letrozole altered RFamide-related peptide-3 and gonadotropin-releasing hormone expression in pubertal female rats
Objective(s): Despite prevalence of polycystic ovary syndrome (PCOS) among childbearing women and development of many animal models for this syndrome, information on its etiology is still scarce. The intrauterine hyperandrogenic environment may underlie changes at the level of hypothalamus, pituitary, ovary organization in female offspring, and PCOS later in life. Letrozole has been shown to mimic reproductive and metabolic characteristics of PCOS in adult rodent models. Therefore, this research aimed to assess the condition in a prenatal letrozole-treated rat model. Materials and Methods: Twenty-eight female rats dams receiving letrozole at certain doses during late pregnancy were used in the trial. Pregnant Sprague-Dawley rats (n=21) received letrozole treatment on gestation days 16–18 at doses of 1.25, 1.0, 0.75, 0.5, and 0.25 mg/kg body weight (BW). Results: Prenatal letrozole treatment delayed parturition time and reduced the litter size in pregnant dams (P<0.0001). Late puberty onset, irregular ovarian cyclicity, increased anogenital distance (AGD), body weight gain, serum testosterone concentration, and reduced estradiol levels (P<0.0001) were observed in the female offspring of dams receiving 1.25 and 1 mg/kg BW letrozole. Furthermore, letrozole at 1.25 and 1 mg/kg BW showed increased RFRP and decreased GnRH mRNA expression (P<0.0001). Letrozole treatment at doses of 1 mg/kg BW and lower was not fetotoxic. Conclusion: It was concluded that 1 mg/kg BW letrozole may be suggested for prenatal PCOS induction.
https://ijbms.mums.ac.ir/article_19500_37d3362a509f1dbdd6b8d309166e8c73.pdf
2022-01-01
110
120
10.22038/ijbms.2022.60962.13499
Gonadotropin-Releasing Hormone
Hypothalamus
Letrozole
Polycystic ovary syndrome Prenatal
Rat
RFamide-related peptide-3
Zahra
Shaaban
z.shaban91@yahoo.com
1
Department of Animal Science, College of Agriculture, Shiraz University, Shiraz, Iran
AUTHOR
Amin
Tamadon
amintamaddon@yahoo.com
2
The Persian Gulf Marine Biotechnology Research Center, The Persian Gulf Biomedical Sciences Research Institute, Bushehr University of Medical Sciences, Bushehr, Iran
AUTHOR
Mohammad Reza
Jafarzadeh Shirazi
jafarzd@shirazu.ac.ir
3
Department of Animal Science, College of Agriculture, Shiraz University, Shiraz, Iran
LEAD_AUTHOR
Mohammad Javad
Zamiri
mjzamiri@yahoo.com
4
Department of Animal Science, College of Agriculture, Shiraz University, Shiraz, Iran
AUTHOR
Amin
Derakhshanfar
aderakhshanfar@yahoo.com
5
Diagnostic Laboratory Sciences and Technology Research Center, School of Paramedical Sciences, Shiraz University of Medical Sciences, Shiraz, Iran
AUTHOR
1. Escobar-Morreale HF. Polycystic ovary syndrome: definition, aetiology, diagnosis and treatment. Nat Rev Endocrinol. 2018;14:270-284.
1
2. Astapova O, Minor BMN, Hammes SR. Physiological and pathological androgen actions in the ovary. Endocrinology. 2019;160:1166-1174.
2
3. Krentowska A, Kowalska I. Metabolic syndrome and its components in different phenotypes of polycystic ovary syndrome. Diabetes Metab Res Rev. 2021:e3464.
3
4. Tamadon A, Hu W, Cui P, Ma T, Tong X, Zhang F, et al. How to choose the suitable animal model of polycystic ovary syndrome? Traditional Medicine and Modern Medicine. 2018;1:95-113.
4
5. Abruzzese GA, Heber MF, Ferreira SR, Ferrer MJ, Motta AB. Prenatal androgen exposure affects ovarian lipid metabolism and steroid biosynthesis in rats. J Endocrinol. 2020;247:239-250.
5
6. Kawwass JF, Sanders KM, Loucks TL, Rohan LC, Berga SL. Increased cerebrospinal fluid levels of GABA, testosterone and estradiol in women with polycystic ovary syndrome. Hum Reprod. 2017;32:1450-1456.
6
7. Paixão L, Ramos RB, Lavarda A, Morsh DM, Spritzer PM. Animal models of hyperandrogenism and ovarian morphology changes as features of polycystic ovary syndrome: a systematic review. Reprod Biol Endocrinol 2017;15:12-22.
7
8. Kafali H, Iriadam M, Ozardali I, Demir N. Letrozole-induced polycystic ovaries in the rat: a new model for cystic ovarian disease. Arch Med Res. 2004;35:103-108.
8
9. Mehdinejadiani S, Amidi F, Mehdizadeh M, Barati M, Safdarian L, Aflatoonian R, et al. The effects of letrozole and clomiphene citrate on ligands expression of Wnt3, Wnt7a, and Wnt8b in proliferative endometrium of women with Polycystic ovarian syndrome. Gynecol Endocrinol 2018;34:775-780.
9
10. Steiner N, Shrem G, Tannus S, Dahan SY, Balayla J, Volodarsky-Perel A, et al. Effect of GnRH agonist and letrozole treatment in women with recurrent implantation failure. Fertil Steril 2019;112:98-104.
10
11. Yun J, Choi YS, Lee I, Won YB, Lee JH, Seo SK, et al. Comparison of congenital malformations among babies born after administration of letrozole or clomiphene citrate for infertility treatment in a Korean cohort. Reprod Toxicol 2018;82:88-93.
11
12. Bizzarri C, Cappa M. Ontogeny of hypothalamus-pituitary gonadal axis and minipuberty: An ongoing debate? Front Endocrinol (Lausanne) 2020;11:187.
12
13. Patisaul HB. Endocrine disruption and reproductive disorders:impacts on sexually dimorphic neuroendocrine pathways. Reproduction 2021;1(aop).
13
14. Ibanez L, de Zegher F, Potau N. Anovulation after precocious pubarche: early markers and time course in adolescence. J Clin Endocrinol Metab. 1999;84:2691-2695.
14
15. Bakker J, Baum MJ. Role for estradiol in female-typical brain and behavioral sexual differentiation. Front Neuroendocrinol. 2008;29:1-16.
15
16. Lephart ED. A review of brain aromatase cytochrome P450. Brain Res Brain Res Rev 1996;22:1-26.
16
17. Vandenbergh JG, Huggett CL. The anogenital distance index, a predictor of the intrauterine position effects on reproduction in female house mice. Lab Anim Sci 1995;45:567-573.
17
18. Marcondes F, Bianchi F, Tanno A. Determination of the estrous cycle phases of rats: some helpful considerations. Braz J Biol 2002;62:609-614.
18
19. Chaudhari N, Dawalbhakta M, Nampoothiri L. GnRH dysregulation in polycystic ovarian syndrome (PCOS) is a manifestation of an altered neurotransmitter profile. Reprod Biol Endocrinol 2018;16:37-49.
19
20. Kauffman AS, Thackray VG, Ryan GE, Tolson KP, Glidewell-Kenney CA, Semaan SJ, et al. A novel letrozole model recapitulates both the reproductive and metabolic phenotypes of polycystic ovary syndrome in female mice. Biol Reprod 2015;93:1-12.
20
21. Feng Y, Johansson J, Shao R, Manneras L, Fernandez-Rodriguez J, Billig H, et al. Hypothalamic neuroendocrine functions in rats with dihydrotestosterone-induced polycystic ovary syndrome: effects of low-frequency electro-acupuncture. PLoS One 2009;4:e6638.
21
22. Han X, He Y, Zeng G, Wang Y, Sun W, Liu J, et al. Intracerebroventricular injection of RFRP-3 delays puberty onset and stimulates growth hormone secretion in female rats. Reprod Biol Endocrinol 2017;15:35-44.
22
23. Esparza LA, Schafer D, Ho BS, Thackray VG, Kauffman AS. Hyperactive LH pulses and elevated kisspeptin and NKB gene expression in the arcuate nucleus of a PCOS mouse model. Endocrinology. 2020;16:bqaa018.
23
24. Iwasa T, Matsuzaki T, Yano K, Mayila Y, Yanagihara R, Yamamoto Y, et al. Prenatal undernutrition affects the phenotypes of PCOS model rats. J Endocrinol. 2018;239:137-151.
24
25. Aliabadi E, Namavar MR, Mortezaee K, Toolee H, Keshtgar S, Mirkhani H, et al. Kisspeptin expression features in the arcuate and anteroventral periventricular nuclei of hypothalamus of letrozole-induced polycystic ovarian syndrome in rats. Arch Gynecol Obstet. 2017;296:957-963.
25
26. Osuka S, Iwase A, Nakahara T, Kondo M, Saito A, Nakamura T, et al. Kisspeptin in the hypothalamus of 2 rat models of polycystic ovary syndrome. Endocrinology 2017;158):367-377.
26
27. Shaaban Z, Jafarzadeh Shirazi MR, Nooranizadeh MH, Tamadon A, Rahmanifar F, Ahmadloo S, et al. Decreased expression of arginine-phenylalanine-amide-related peptide-3 gene in dorsomedial hypothalamic nucleus of constant light exposure model of polycystic ovarian syndrome. Int J Fertil Steril 2018;12:43-50.
27
28. Iwasa T, Matsuzaki T, Tungalagsuvd A, Munkhzaya M, Kuwahara A, Yasui T, et al. The advancement of the onset of vaginal opening in female rats subjected to chronic testosterone treatment occurs independently of hypothalamic Kiss1 and RFRP expression. Neuro Endocrinol Lett 2015;36:767-770.
28
29. Hafez ES, Kodituwakku GE. Postnatal development of the oviduct of intact and ovariectomized rabbits. J Morphol 1970;130:353-365.
29
30. Semaan SJ, Kauffman AS. Daily successive changes in reproductive gene expression and neuronal activation in the brains of pubertal female mice. Mol Cell Endocrinol 2015;401:84-97.
30
31. Zurvarra FM, Salvetti NR, Mason JI, Velazquez MM, Alfaro NS, Ortega HH. Disruption in the expression and immunolocalisation of steroid receptors and steroidogenic enzymes in letrozole-induced polycystic ovaries in rat. Reprod Fertil Dev 2009;21:827-839.
31
32. Baravalle C, Salvetti NR, Mira GA, Pezzone N, Ortega HH. Microscopic characterization of follicular structures in letrozole-induced polycystic ovarian syndrome in the rat. Arch Med Res. 2006;37:830-839.
32
33. Sir-Petermann T, Maliqueo M, Codner E, Echiburu B, Crisosto N, Pérez V, et al. Early metabolic derangements in daughters of women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2007;92:4637-4642.
33
34. Xu G, Zhang A, Liu J, Wang X, Feng J, Chen Y. Effects of electroacupuncture on ovarian expression of the androgen receptor and connexin 43 in rats with letrozole-induced polycystic ovaries. Evid Based Complement Alternat Med 2020;2020:3608062.
34
35. Tiboni GM, Ponzano A. Fetal safety profile of aromatase inhibitors: Animal data. Reprod Toxicol 2016;66:84-92.
35
36. Skarra DV, Hernández-Carretero A, Rivera AJ, Anvar AR, Thackray VG. Hyperandrogenemia induced by letrozole treatment of pubertal female mice results in hyperinsulinemia prior to weight gain and insulin resistance. Endocrinology 2017;158:2988-3003.
36
37. Torres PJ, Skarra DV, Ho BS, Sau L, Anvar AR, Kelley ST, et al. Letrozole treatment of adult female mice results in a similar reproductive phenotype but distinct changes in metabolism and the gut microbiome compared to pubertal mice. BMC Microbiol 2019;19:57.
37
38. Wu XY, Li ZL, Wu CY, Liu YM, Lin H, Wang SH, et al. Endocrine traits of polycystic ovary syndrome in prenatally androgenized female Sprague-Dawley rats. Endocr J 2010;57:201-209.
38
39. Tehrani FR, Noroozzadeh M, Zahediasl S, Piryaei A, Hashemi S, Azizi F. The time of prenatal androgen exposure affects development of polycystic ovary syndrome-like phenotype in adulthood in female rats. Int J Endocrinol Metab 2014;12:e16502ch.
39
40. Caldwell AS, Middleton LJ, Jimenez M, Desai R, McMahon AC, Allan CM, et al. Characterization of reproductive, metabolic, and endocrine features of polycystic ovary syndrome in female hyperandrogenic mouse models. Endocrinology 2014;155:3146-3159.
40
41. Sullivan SD, Moenter SM. Prenatal androgens alter GABAergic drive to gonadotropin-releasing hormone neurons: implications for a common fertility disorder. Proc Natl Acad Sci U S A 2004;101:7129-7134.
41
42. Tandulwadkar SR, Lodha PA, Mangeshikar NT. Obstetric complications in women with IVF conceived pregnancies and polycystic ovarian syndrome. J Hum Reprod Sci 2014;7:13-18.
42
43. Birch RA, Padmanabhan V, Foster DL, Unsworth WP, Robinson JE. Prenatal programming of reproductive neuroendocrine function: fetal androgen exposure produces progressive disruption of reproductive cycles in sheep. Endocrinology 2003;144:1426-1434.
43
44. Foecking EM, Szabo M, Schwartz NB, Levine JE. Neuroendocrine consequences of prenatal androgen exposure in the female rat: absence of luteinizing hormone surges, suppression of progesterone receptor gene expression, and acceleration of the gonadotropin-releasing hormone pulse generator. Biol Reprod. 2005;72:1475-1483.
44
45. Manneras L, Cajander S, Holmäng A, Seleskovic Z, Lystig T, Lönn M, et al. A new rat model exhibiting both ovarian and metabolic characteristics of polycystic ovary syndrome. Endocrinology 2007;148:3781-3791.
45
46. Matsuzaki T, Tungalagsuvd A, Iwasa T, Munkhzaya M, Yanagihara R, Tokui T, et al. Kisspeptin mRNA expression is increased in the posterior hypothalamus in the rat model of polycystic ovary syndrome. Endocr J 2016;64:7-14.
46
47. Arroyo P, Ho BS, Sau L, Kelley ST, Thackray VG. Letrozole treatment of pubertal female mice results in activational effects on reproduction, metabolism and the gut microbiome. PLoS One 2019;14:e0223274.
47
48. Ryan GE, Malik S, Mellon PL. Antiandrogen treatment ameliorates reproductive and metabolic phenotypes in the letrozole-induced mouse model of PCOS. Endocrinology 2018;159:1734-47.
48
49. Agoreyo F, Okeke O. Quantitative evaluation of serum oestrogen levels in the three trimesters of pregnancy in albino rat. NISEB J 2018;14:77-79.
49
50. Kafali H, Iriadam M. A novel tocolytic agent: effects of letrozole on gestational length and parturition time. Am J Perinatol 2007;24:323-326.
50
51. Tiboni G, Marotta F, Rossi C, Giampietro F. Effects of the aromatase inhibitor letrozole on in utero development in rats. Human Reproduction 2008;23:1719-1723.
51
52. Tiboni G, Marotta F, Castigliego A, Rossi C. Impact of estrogen replacement on letrozole-induced embryopathic effects. Hum Reprod. 2009;24:2688-2692.
52
53. Boomsma C, Eijkemans M, Hughes E, Visser G, Fauser B, Macklon N. A meta-analysis of pregnancy outcomes in women with polycystic ovary syndrome. Hum Reprod Update. 2006;12:673-683.
53
ORIGINAL_ARTICLE
Analysis of potential protective effects of caffeic acid phenethyl ester against gentamicin ototoxicity: An experimental study
Objective(s): In this study, it is aimed to investigate the potential protective effect of caffeic acid phenethyl ester (CAPE) on ototoxicity caused by gentamicin in a rat model.Materials and Methods: Thirty Wistar albino rats were divided into 3 groups. Group I was selected as the control group. Gentamicin was administered intraperitoneally in group II, gentamicin and CAPE in group III. Audiological assessment was performed by the distortion product otoacoustic emission (DPOAE) and auditory brainstem response (ABR) measurements before and after treatment of each group. At the end of the study all rats were decapitated, cochlea was removed and electron microscopic examination was performed. Results: In group II post-treatment DPOAE levels were found to be lower than pretreatment DPOAE levels (P<0.05). However, in group III, there is no significant difference between pre- and post-treatment DPOAE levels (P>0.05). Except for Group I, ABR thresholds increased after the procedure and this increase was statistically significant (P<0.0001). According to histological examination by transmission electron microscopy, CAPE has a cellular protective effect against gentamicin ototoxicity. Conclusion: CAPE may ameliorate hearing deterioration caused by gentamicin ototoxicity and protect the cochlear cells from apoptosis due to the strong antioxidant effect.
https://ijbms.mums.ac.ir/article_19469_3fa003175c4d144fc4a18c71c65b313e.pdf
2022-01-01
121
125
10.22038/ijbms.2022.60794.13467
Aminoglycoside
Anti-oxidant
caffeic acid phenethyl ester
Gentamicin
Ototoxicity
Fuat
Aydemir
dr_fuataydemr@yahoo.com.tr
1
Department of Otorhinolaryngology, Kulu State Hospital, Konya, Turkey
LEAD_AUTHOR
Cagatay Han
Ulku
chanulku@yahoo.com
2
Department of torhinolaryngology, Necmettin Erbakan University Meram Faculty of Medicine, Konya, Turkey
AUTHOR
Cigdem
Elmas
00cigdem@gmail.com
3
Department of Histology and Embryology, Gazi University Faculty of Medicine, Ankara, Turkey
AUTHOR
Cemile Merve
Seymen
cmerveseymen@gmail.com
4
Department of Histology and Embryology, Gazi University Faculty of Medicine, Ankara, Turkey
AUTHOR
1. Kim YJ, Tian C, Kim J, Shin B, Choo OS, Kim YS et al. Autophagic flux, a possible mechanism for delayed gentamicin-induced ototoxicity. Scientific Reports 2017; 7: 41356.
1
2. Xie J, Talaska AE, Schacht J. New developments in aminoglycoside therapy and ototoxicity. Hear Res 2011; 281: 28-37.
2
3. Dror AA, Avraham KB. Hearing impairment: a panoply of genes and functions. Neuron 2010; 68: 293-308.
3
4. Menezes da Silveira CCS, Luz DA, da Silva CCS, Prediger RDS, Martins MD, Martins MAT et al. Propolis: A useful agent on psychiatric and neurological disorders? A focus on CAPE and pinocembrin components. Med Res Rev 2021; 41: 1195-1215.
4
5. Agrı I, Erdal Agrı A, Ozdemir D, Ozgur A. CAPE and Tympanosclerosis. In: Watson RR, Preedy VR, Zibadi S, Eds. Polyphenols: Mechanisms of Action in Human Health and Disease. 2nd ed. Academic Press Elsevier; 2018. p. 421–430.
5
6. Sforcin JM, Bankova V. Propolis: is there a potential for the development of new drugs? J Ethnopharmacol 2011; 133: 253-260.
6
7. Toreti VC, Sato HH, Pastore GM, Park YK. Recent progress of propolis for its biological and chemical compositions and its botanical origin. Evid Based Complement Alternat Med 2013; 2013: 697390.
7
8. Ozen S, Akyol O, Iraz M, Sogut S, Ozugurlu F, Ozyurt H et al. Role of caffeic acid phenethyl ester, an active component of propolis, against cisplatin-induced nephrotoxicity in rats. J Appl Toxicol 2004; 24: 27-35.
8
9. Lee KJ, Choi JH, Khanal T, Hwang YP, Chung YC, Jeong HG. Protective effect of caffeic acid phenethyl ester against carbon tetrachloride-induced hepatotoxicity in mice. Toxicology 2008; 248: 18-24.
9
10. Fadillioglu E, Oztas E, Erdogan H, Yagmurca M, Sogut S, Ucar M et al. Protective effects of caffeic acid phenethyl ester on doxorubicin-induced cardiotoxicity in rats. J Appl Toxicol 2004; 24: 47-52.
10
11. Yildiz OG, Soyuer S, Saraymen R, Eroglu C. Protective effects of caffeic acid phenethyl ester on radiation induced lung injury in rats. Clin Invest Med 2008; 31: E242-247.
11
12. Uzar E, Koyuncuoglu HR, Uz E, Yilmaz HR, Kutluhan S, Kilbas S et al. The activities of anti-oxidant enzymes and the level of malondialdehyde in cerebellum of rats subjected to methotrexate: protective effect of caffeic acid phenethyl ester. Mol Cell Biochem 2006 ;291: 63-68.
12
13. Balaha M, De Filippis B, Cataldi A, di Giacomo V. CAPE and Neuroprotection: A Review. Biomolecules 2021; 11: 176.
13
14. Atik OS, Erdogan D, Seymen CM, Bozkurt HH, Take Kaplanoglu G: Is there crosstalk between subchondral bone, cartilage, and meniscus in the pathogenesis of osteoarthritis? Joint Diseases and Related Surgery 2016; 27: 62-67.
14
15. Schacht J. Aminoglycoside ototoxicity: prevention in sight? Otolaryngology Head and Neck Surgery 1998; 118: 674-677.
15
16. Fetoni AR, Eramo SL, Rolesi R, Troiani D, Paludetti G. Anti-oxidant treatment with coenzyme Q-ter in prevention of gentamycin ototoxicity in an animal model. Acta Otorhinolaryngol Ital 2012; 32: 103-110.
16
17. Somdaş MA, Korkmaz F, Gürgen SG, Sagit M, Akçadağ A. N-acetylcysteine Prevents Gentamicin Ototoxicity in a Rat Model. The Journal of International Advanced Otology 2015; 11: 12-18.
17
18. Fu X, Wan P, Li P, Wang J, Guo S, Zhang Y et al. Mechanism and Prevention of Ototoxicity Induced by Aminoglycosides. Front Cell Neurosci 2021; 15: 692762.
18
19. Nomura K, Naruse K, Watanabe K, Sokabe M. Aminoglycoside blockade of Ca2(+)-activated K+ channel from rat brain synaptosomal membranes incorporated into planar bilayers. The Journal of Membrane Biology 1990; 115: 241-251.
19
20. Marcotti W, Van Netten SM, Kros CJ. The aminoglycoside antibiotic dihydrostreptomycin rapidly enters mouse outer hair cells through the mechano-electrical transducer channels. The Journal of Physiology 2005; 567: 505-521.
20
21. Pavlidis P, Maurer J, Apostolidou E, Kekes G, Kouvelas D. Memantine’s action against aminoglycoside-induced ototoxicity. Eur Arch Otorhinolaryngol 2014; 271: 1491-1496.
21
22. Mostafa BE, Tawfik S, Hefnawi NG, Hassan MA, Ismail FA. The role of deferoxamine in the prevention of gentamicin ototoxicity: a histological and audiological study in guinea pigs. Acta Otolaryngology 2007 ;127: 234-239.
22
23. Campbell KC, Martin SM, Meech RP, Hargrove TL, Verhulst SJ, Fox DJ. D-methionine (D-met) significantly reduces kanamycin-induced ototoxicity in pigmented guinea pigs. Int J Audiol 2016; 55: 273-278.
23
24. Park SK, Choi D, Russell P, John EO, Jung TT. Protective effect of corticosteroid against the cytotoxicity of aminoglycoside otic drops on isolated cochlear outer hair cells. Laryngoscope 2004; 114: 768-771.
24
25. Dogan M, Polat H, Yasar M, Bayram A, Karatas D, Hira I et al. Protective role of misoprostol in prevention of gentamicin ototoxicity. International Journal of Pediatric Otorhinolaryngology 2017; 96: 140-144.
25
26. Akyol S, Isik B, Altuntas A, Erden G, Cakmak O, Kurşunlu SF et al. Future opportunities in preventing ototoxicity: Caffeic acid phenethyl ester may be a candidate (Review). Mol Med Rep 2015; 12: 3231-3235.
26
27. Park MK, Im GJ, Chang J, Chae SW, Yoo J, Han WG et al. Protective effects of caffeic acid phenethyl ester (CAPE) against neomycin-induced hair cell damage in zebrafish. International journal of pediatric otorhinolaryngology 2014; 78: 1311–1315.
27
28. Kizilay A, Kalcioglu MT, Ozerol E, Iraz M, Gulec M, Akyol O et al. Caffeic acid phenethyl ester ameliorated ototoxicity induced by cisplatin in rats. Journal of Chemotherapy 2004; 16: 381-387.
28
29. Bakir S, Ozbay M, Gun R, Yorgancilar E, Kinis V, Keles A et al. The protective role of caffeic acid phenethyl ester against streptomycin ototoxicity. American Journal of Otolaryngology 2013; 34: 16-21.
29
30. Sud’ina GF, Mirzoeva OK, Pushkareva MA, Korshunova GA, Sumbatyan NV, Varfolomeev SD. Caffeic acid phenethyl ester as a lipoxygenase inhibitor with anti-oxidant properties. FEBS Letters 1993; 329: 21-24.
30
ORIGINAL_ARTICLE
Biliary cirrhosis-induced cardiac abnormality in rats: Interaction between Farnesoid-X-activated receptors and the cardiac uncoupling proteins 2 and 3
Objective(s): This study aimed to evaluate the relationship between Farnesoid-X-activated receptors (FXR) as nuclear regulators of the antioxidant defense system as well as cardiac mitochondrial carrier proteins of UCP2 and UCP3 in cardiac damage induced by cirrhosis. Materials and Methods: Twenty-two male Wistar rats (200–250 g) were randomly divided into 3 experimental groups, including a control group (n=6), a sham-operated group (n=8), and a bile duct ligated (BDL) group (n=8). Four weeks after surgical intervention, biochemical assessment (AST, ALT, GGT, LDH, and ALP), histological observation, and molecular evaluation (FXR, UCP2, UCP3, BNP, Caspase3, and GAPDH) using real-time RT-PCR were performed. Results: Compared with the sham-operation group, the BDL group showed a significant rise in liver enzymes of AST, ALT, GGT, LDH, and ALP. Defined fibrotic and necrotic bundles and thick reticulin fibers were also found in BDL liver tissue. Besides liver morphological alterations, left ventricles of BDL ones were also associated with defined cardiomyocyte hypertrophy, myofiber vacuolization, and clear pigmentation. Findings showed a significant up-regulation of cardiac Brain Natriuretic Peptide (BNP) along with marked down-regulation in hepatic FXR, cardiac FXR, and cardiac UCP2 and UCP3. However, the expression of caspase 3 in the cardiac tissue was not affected by BDL operation during 4 weeks. Conclusion: Expression of FXR as an upstream regulator of cellular redox status, besides the non-enzymatic ROS buffering defense system of cardiac UCPs, has a pivotal role in the pathogenesis of cirrhotic-induced cardiac abnormality in rats.
https://ijbms.mums.ac.ir/article_19499_c68621b1f16a2e3808af654c208eb07b.pdf
2022-01-01
126
133
10.22038/ijbms.2022.60888.13485
Cardiomyopathy
cholestasis
Farnesoid-X-receptor
Liver Cirrhosis
Mitochondrial uncoupling proteins
Gholamreza
Bayat
g.bayat@abzums.ac.ir
1
Department of Physiology-Pharmacology-Medical Physic, School of Medicine, Alborz University of Medical Sciences, Karaj, Iran
AUTHOR
Seyed Ali
Hashemi
alihashemi48@yahoo.com
2
Department of Pathology, School of Medicine, Alborz University of Medical Sciences, Karaj, Iran
AUTHOR
Hosein
Karim
h.karim@abzums.ac.ir
3
Cardiovascular Research Center, Alborz University of Medical Sciences, Karaj, Iran
AUTHOR
Parviz
Fallah
parvizfallah@gmail.com
4
Department of Medical Laboratory Sciences, Faculty of Para-Medicine, Alborz University of Medical Sciences, Karaj, Iran
AUTHOR
Keshvad
Hedayatyanfard
keshvad_tam@yahoo.com
5
Department of Physiology-Pharmacology-Medical Physic, School of Medicine, Alborz University of Medical Sciences, Karaj, Iran
AUTHOR
Mahnaz
Bayat
ma_bayat@sums.ac.ir
6
Clinical Neurology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran
AUTHOR
Azadeh
Khalili
az.khalili@abzums.ac.ir
7
Department of Physiology-Pharmacology-Medical Physic, School of Medicine, Alborz University of Medical Sciences, Karaj, Iran
LEAD_AUTHOR
1. Caramelo C Fau - Fernandez-Muñoz D, Fernandez-Muñoz D Fau - Santos JC, Santos Jc Fau - Blanchart A, Blanchart A Fau - Rodriguez-Puyol D, Rodriguez-Puyol D Fau - López-Novoa JM, López-Novoa Jm Fau - Hernando L, et al. Effect of volume expansion on hemodynamics, capillary permeability and renal function in conscious, cirrhotic rats. Hepatology 1986; 6:129-134.
1
2. Cazzaniga M, Salerno F, Pagnozzi G, Dionigi E, Visentin S, Cirello I, et al. Diastolic dysfunction is associated with poor survival in patients with cirrhosis with transjugular intrahepatic portosystemic shunt. Gut 2007; 56:869-875.
2
3. Carvalho MVH, Kroll PC, Kroll RTM, Carvalho VN. Cirrhotic cardiomyopathy: the liver affects the heart. Braz J Med Biol Res 2019; 52:e7809.
3
4. Cichoż-Lach H, Michalak A. Oxidative stress as a crucial factor in liver diseases. World J Gastroenterol 2014; 20:8082-8091.
4
5. Orr AL, Ashok D, Sarantos MR, Shi T, Hughes RE, Brand MD. Inhibitors of ROS production by the ubiquinone-binding site of mitochondrial complex I identified by chemical screening. Free Radic Biol Med 2013; 65:1047-1059.
5
6. Meany DL, Poe BG, Navratil M, Moraes CT, Arriaga EA. Superoxide released into the mitochondrial matrix. Free Radic Biol Med 2006; 41:950-959.
6
7. Mousavi K, Niknahad H, Ghalamfarsa A, Mohammadi H, Azarpira N, Ommati MM, et al. Taurine mitigates cirrhosis-associated heart injury through mitochondrial-dependent and antioxidative mechanisms. Clin Exp Hepatol 2020; 6:207-219.
7
8. Safari F, Anvari Z, Moshtaghioun S, Javan M, Bayat G, Forosh SS, et al. Differential expression of cardiac uncoupling proteins 2 and 3 in response to myocardial ischemia-reperfusion in rats. Life Sci 2014; 98:68-74.
8
9. Chen GG, Yan JB, Wang XM, Zheng MZ, Jiang JP, Zhou XM, et al. Mechanism of uncoupling protein 2‑mediated myocardial injury in hypothermic preserved rat hearts. Mol Med Rep 2016; 14:1857-1864.
9
10. Bugger H, Guzman C, Zechner C, Palmeri M, Russell KS, Russell RR, 3rd. Uncoupling protein down-regulation in doxorubicin-induced heart failure improves mitochondrial coupling but increases reactive oxygen species generation. Cancer Chemother Pharmacol 2011; 67:1381-1388.
10
11. Hoerter J, Gonzalez-Barroso MD, Couplan E, Mateo P, Gelly C, Cassard-Doulcier AM, et al. Mitochondrial uncoupling protein 1 expressed in the heart of transgenic mice protects against ischemic-reperfusion damage. Circulation 2004; 110:528-533.
11
12. Teshima Y, Akao M, Jones Steven P, Marbán E. Uncoupling Protein-2 Overexpression Inhibits Mitochondrial Death Pathway in Cardiomyocytes. Circ Res 2003; 93:192-200.
12
13. Gai Z, Chu L, Xu Z, Song X, Sun D, Kullak-Ublick GA. Farnesoid X receptor activation protects the kidney from ischemia-reperfusion damage. Sci Rep 2017; 7:9815.
13
14. Haga S, Yimin, Ozaki M. Relevance of FXR-p62/SQSTM1 pathway for survival and protection of mouse hepatocytes and liver, especially with steatosis. BMC Gastroenterol 2017; 17:9-21.
14
15. Zhang Y, Xu Y, Qi Y, Xu L, Song S, Yin L, et al. Protective effects of dioscin against doxorubicin-induced nephrotoxicity via adjusting FXR-mediated oxidative stress and inflammation. Toxicology 2017; 378:53-64.
15
16. Gai Z, Gui T, Hiller C, Kullak-Ublick GA. Farnesoid X Receptor Protects against Kidney Injury in Uninephrectomized Obese Mice. J Biol Chem 2016; 291:2397-2411.
16
17. Lu C, Zhang F, Xu W, Wu X, Lian N, Jin H, et al. Curcumin attenuates ethanol-induced hepatic steatosis through modulating Nrf2/FXR signaling in hepatocytes. IUBMB Life 2015; 67:645-658.
17
18. Xia Y, Zhang F, Zhao S, Li Y, Chen X, Gao E, et al. Adiponectin determines farnesoid X receptor agonism-mediated cardioprotection against post-infarction remodelling and dysfunction. Cardiovasc Res 2018; 114:1335-1349.
18
19. Wu H, Liu G, He Y, Da J, Xie B. Obeticholic acid protects against diabetic cardiomyopathy by activation of FXR/Nrf2 signaling in db/db mice. Eur J Pharmaco 2019; 858:172393.
19
20. Gao J, Liu X, Wang B, Xu H, Xia Q, Lu T, et al. Farnesoid X receptor deletion improves cardiac function, structure and remodeling following myocardial infarction in mice. Mol Med Rep 2017; 16:673-679.
20
21. Han CY, Kim TH, Koo JH, Kim SG. Farnesoid X receptor as a regulator of fuel consumption and mitochondrial function. Arch Pharm Res 2016; 39:1062-1074.
21
22. Yang Y, Chen B, Chen Y, Zu B, Yi B, Lu K. A comparison of two common bile duct ligation methods to establish hepatopulmonary syndrome animal models. Lab Anim 2015; 49:71-79.
22
23. Khalili A, Fallah P, Hashemi SA, Ahmadian-Attari MM, Jamshidi V, Mazloom R, et al. New mechanistic insights into hepatoprotective activity of milk thistle and chicory quantified extract: The role of hepatic Farnesoid-X activated receptors. Avicenna J Phytomed 2021; 11:367-379.
23
24. Safari F, Hajiadeh S, Moshtaghion SH, Forouzandeh Moghadam M, Shekarforoush S, Bayat G, et al. Effect of losartan on NOX2 transcription following acute myocardial ischemia-reperfusion. Physiol-Pharmacol 2012; 16:44-53.
24
25. Desai MS, Mathur B, Eblimit Z, Vasquez H, Taegtmeyer H, Karpen SJ, et al. Bile acid excess induces cardiomyopathy and metabolic dysfunctions in the heart. Hepatology 2017; 65:189-201.
25
26. Jazaeri F, Afsharmoghaddam R, Abdollahi A, Ghamami G, Dehpour AR. Evaluation of chronic losartan treatment effect on cardiac chronotropic dysfunction in biliary cirrhotic rats. Acta Med Iran 2018; 56:4-13.
26
27. Cruz A, Tasset I, Ramírez LM, Arjona A, Segura J, Túnez I, et al. Effect of melatonin on myocardial oxidative stress induced by experimental obstructive jaundice. Rev Esp Enferm Dig 2009; 101:460-463.
27
28. Matyas C, Erdelyi K, Trojnar E, Zhao S, Varga ZV, Paloczi J, et al. Interplay of Liver–Heart Inflammatory Axis and Cannabinoid 2 Receptor Signaling in an Experimental Model of Hepatic Cardiomyopathy. Hepatology 2020; 71:1391-1407.
28
29. Kemp R, Castro-e-Silva O, Santos JS, Sankarankutty AK, Correa RB, Baldo CF, et al. Evaluation of the mitochondrial respiration of cardiac myocytes in rats submitted to mechanical bile duct obstruction. Acta Cir Bras 2008; 23:66-71.
29
30. Lunseth JH, Olmstead EG, Abboud F. A study of heart disease in one hundred eight hospitalized patients dying with portal cirrhosis. AMA Arch Intern Med 1958; 102:405-413.
30
31. Chayanupatkul M, Liangpunsakul S. Cirrhotic cardiomyopathy: review of pathophysiology and treatment. Hepatol Int 2014; 8:308-315.
31
32. Sergeeva IA, Christoffels VM. Regulation of expression of atrial and brain natriuretic peptide, biomarkers for heart development and disease. Biochim Biophys Acta 2013; 1832:2403-2413.
32
33. Nunes S, Soares E, Fernandes J, Viana S, Carvalho E, Pereira FC, et al. Early cardiac changes in a rat model of prediabetes: brain natriuretic peptide overexpression seems to be the best marker. Cardiovasc Diabetol 2013; 12:44-54.
33
34. Januzzi JL, Jr. Natriuretic peptides as biomarkers in heart failure. J Investig Med 2013; 61:950-955.
34
35. Duran J, Martinez A, Adler E. Cardiovascular Manifestations of Mitochondrial Disease. Biology (Basel) 2019; 8:34-60.
35
36. Hilse KE, Rupprecht A, Egerbacher M, Bardakji S, Zimmermann L, Wulczyn AEMS, et al. The expression of uncoupling protein 3 coincides with the fatty acid oxidation type of metabolism in adult murine heart. Front Physiol 2018; 9:747.
36
37. Duncan JG. Mitochondrial dysfunction in diabetic cardiomyopathy. Biochim Biophys Acta 2011; 1813:1351-1359.
37
38. Ramachandra CJA, Hernandez-Resendiz S, Crespo-Avilan GE, Lin Y-H, Hausenloy DJ. Mitochondria in acute myocardial infarction and cardioprotection. EBioMedicine 2020; 57:102884.
38
39. Bugger H, Abel ED. Mitochondria in the diabetic heart. Cardiovasc Res 2010; 88:229-240.
39
40. Hassanein T. Mitochondrial dysfunction in liver disease and organ transplantation. Mitochondrion 2004; 4:609-620.
40
41. Viengchareun S, Penfornis P, Zennaro M-C, Lombès M. Mineralocorticoid and glucocorticoid receptors inhibit UCP expression and function in brown adipocytes. Am J Physiol Endocrinol Metab 2001; 280:E640-E649.
41
42. Perrino C, Schiattarella GG, Sannino A, Pironti G, Petretta MP, Cannavo A, et al. Genetic deletion of uncoupling protein 3 exaggerates apoptotic cell death in the ischemic heart leading to heart failure. J Am Heart Assoc 2013; 2:e000086.
42
43. Harmancey R, Vasquez HG, Guthrie PH, Taegtmeyer H. Decreased long-chain fatty acid oxidation impairs postischemic recovery of the insulin-resistant rat heart. FASEB J 2013; 27:3966-3978.
43
44. Verbeke L, Mannaerts I, Schierwagen R, Govaere O, Klein S, Vander Elst I, et al. FXR agonist obeticholic acid reduces hepatic inflammation and fibrosis in a rat model of toxic cirrhosis. Sci Rep 2016; 6-Last page.
44
45. Wu W, Zhu B, Peng X, Zhou M, Jia D, Gu J. Activation of farnesoid X receptor attenuates hepatic injury in a murine model of alcoholic liver disease. Biochem Biophys Res Commun 2014; 443:68-73.
45
46. Lívero FA, Stolf AM, Dreifuss AA, Bastos-Pereira AL, Chicorski R, de Oliveira LG, et al. The FXR agonist 6ECDCA reduces hepatic steatosis and oxidative stress induced by ethanol and low-protein diet in mice. Chem Biol Interact 2014; 217:19-27.
46
47. Wang B, Zhang H, Luan Z, Xu H, Wei Y, Zhao X, et al. Farnesoid X receptor (FXR) activation induces the antioxidant protein metallothionein 1 expression in mouse liver. Exp Cell Res 2020; 390:111949.
47
48. Qiang S, Tao L, Zhou J, Wang Q, Wang K, Lu M, et al. Knockout of farnesoid X receptor aggravates process of diabetic cardiomyopathy. Diabetes Res Clin Pract 2020; 161:108033.
48
49. Pu J, Yuan A, Shan P, Gao E, Wang X, Wang Y, et al. Cardiomyocyte-expressed farnesoid-X-receptor is a novel apoptosis mediator and contributes to myocardial ischaemia/reperfusion injury. Eur Heart J 2013; 34:1834-1845.
49
50. Tsoporis James N, Izhar S, Desjardins Jean F, Salpeas V, Rizos Ioannis C, Parker Thomas G. Abstract 16846: Activation of farnesoid x receptor signaling mediates atrial myocyte apoptosis in patients undergoing on-pump coronary artery bypass grafting and ventricular remodeling after experimental myocardial infarction. Circulation 2017; 136:A16846-A16846.
50